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ABSTRACT 
Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which is produced by the 
cleavage of the inactive precursor, big ET-1 at the Trp21-Val 22 bond by endothelin 
converting enzyme (ECE). ECE has been found to be expressed by a variety of cell 
types and tissues. 
Using the human endothelial cell line, EA. hy926, ECE has been demonstrated, by 
analogy to the related protein, E-24.11 to be an integral transmembrane protein which 
is not anchored by a G-PI moiety. The relationship between E-24.11 and ECE was 
further investigated by screening of antibodies raised to E-24.11 for cross-reactivity 
with the ECE protein. Immobilised GK4A9, a monoclonal antibody to E-24.11 was 
found to immunoprecipitate >80 % of the total E-24.11 and ECE activity from Triton 
X-100 solubilised membrane preparations of EA. hy926 cells. The 
immunoprecipitation was reproduced using a transfected cell line which expressed high 
levels of ECE activity but was shown not to express E-24.11. Immunoprecipitation of 
ECE from transfected cells was confirmed by enzyme assay and immunoblotting. The 
immunoreactivity of GK4A9 was shown to be specific for ECE and E-24.11 
suggesting a shared epitope between the two proteins. These data were consistent 
with the hypothesis that E-24.11 and ECE originated from the same protein family, 
sharing significant structural and sequence homology. 
The cell specific expression of ECE was demonstrated by radioimmunoassay in the 
neuroblastoma cell line, SH-SY5Y, and the Bu17, C6 and D384 glioma lines. The 
identity of the activity was confirmed by immunoblotting which revealed a polypeptide 
of approximately 120 kDa in each of these cell lines. 
Pre-treatment of EA. hy926, Bu17 and SH-SYSY cells with the zinc metalloprotease 
inhibitor phosphoramidon (PR) resulted in an accumulation of the ECE protein. This 
increase was reproduced by treatment of cells with thiorphan and suggests the possible 
involvement of a novel PR and thiorphan-sensitive metalloprotease in the turnover of 
ECE. 
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Other possible regulatory mechanisms involved in ECE production were investigated. 
The protein tyrosine phosphatase inhibitor vanadate was found to cause a 2-3-fold up- 
regulation of ECE in EA. hy926 and Bu17 cells and appeared to induce ECE 
expression in rat pheochromocytoma PC12 cells which had been stimulated to 
differentiate to a neuronal phenotype in response to vanadate treatment. 
The identification of two distinct human isoforms of ECE-1, a and ß (Schmidt et al., 
1994; Shimada et al., 1995) which were found to differ only in N-terminal amino acid 
sequence, allowed the generation of antibodies specific for each isoform. Peptides 
corresponding to immunogenic regions of the N-terminal sequence in each isoform 
were synthesised, attached to a carrier protein and used to raise anti-peptide 
antibodies. The immunoreactivity of the antiserum was monitored using an E. L. I. S. A. 
with the peptide as the antigen. The most immunoreactive antiserum was affinity 
purified and the antibody characterised by detection of each ECE-1 isoform using 
transfected cell lines expressing high levels of each isoform. One antibody (ECE1a I 
was successfully raised to ECE-1 a and found to be specific for this isoform. 
iv 
CONTENTS 
Abstract 
Contents 
List of tables 
List of figures 
Abbreviations 
Acknowledgements 
Publications 
CHAPTER ONE 
Introduction 
1.1 Location, function and diversity of peptidases 
1.2 Nomenclature of peptidases 
1.3 The mechanisms of peptidase association with membranes 
1.3.1 Peripheral membrane proteins 
1.3.2 Integral membrane proteins 
1.4 Peptidases localised at the cell surface 
1.4.1 Cell surface endopeptidases 
1.5 The biology of endothelial cells (EC) 
1.6 The endothelin isopeptides 
1.6.1 The physiological and pathophysiological roles of 
endothelin 
1.6.2 Endothelin biosynthesis 
1.6.3 Endothelin receptors and signal transduction 
1.6.4 Synthesis of endothelin in brain cells 
1.7 Endothelin converting enzymes 
1.7.1 Endopeptidase-24.11 as a model for the characteristion 
of ECE 
1.7.2 Purification of ECE 
11 
iv 
xi 
xu 
xiv 
xvi 
XVII 
2 
2 
3 
3 
3 
4 
7 
9 
9 
12 
15 
16 
18 
20 
24 
25 
V 
1.7.3 Molecular cloning of ECE 25 
1.7.4 Tissue distribution of ECE-1 27 
1.7.5 Cloning and expression of ECE-2 28 
1.7.6 The sub-cellular location of ECE 28 
1.8 The existence of a metalloprotease sub-family 30 
1.9 Aims of the project 31 
1.9.1 The use of cell culture as a basis for the investigation of ECE 32 
1.9.2 The use of EA. hy926 as a model system for the study of ECE 33 
1.9.3 The selection and use of other cell lines 35 
CHAPTER TWO 
Materials and methods 
2.1 Materials 
2.1.1 Peptidase inhibitors 
2.1.2 Peptides 
2.1.3 Antibiotics 
2.1.4 Enzymes 
2.1.5 Antibody production 
2.1.6 Electrophoresis and western blotting 
2.1.7 Cell culture 
2.1.8 Detergents 
2.2 Protein assays 
2.2.1 BCA protein assay 
2.3 Enzyme assays 
2.3.1 Endopeptidase-24.11 (EC 3.4.24.11) 
2.3.2 Dipeptidyl peptidase-IV (EC 3.4.15.5) and aminopeptidase-N 
(EC 3.4.11.2) 
2.3.3 Angiotensin converting enzyme (EC 3.4.15.1) 
2.3.4 Alkaline phosphatase (EC 3.1.3.1) 
2.3.5 Lactate dehydrogenase (EC 1.1.1.27) and 5'-nucleotidase 
2.3.6 Endothelin converting enzyme 
37 
37 
37 
38 
38 
38 
39 
39 
39 
40 
40 
40 
40 
41 
41 
41 
41 
42 
-17 
2.3.7 Radioimmunoassays for ET-1 
2.3.7.1 Radioimmunoassay procedure 
2.3.8 Reverse phase HPLC protocols 
2.4 Cell culture 
2.4.1 EA. hy926 cell culture 
2.4.2 Culture of other cell lines 
2.4.3 Preparation of EAhy926 membranes 
2.4.4 Porcine lung membrane preparation 
2.4.5 Preparation of kidney brush border membranes 
2.4.6 Preparation of reagents used for regulation studies 
2.4.6.1 Application of reagents used for expression regulation 
studies 
2.5 Solubilisation of cell membranes 
2.5.1 Detergent solubilisation 
2.5.2 Precondensation of Triton X-114 
2.5.3 Temperature-induced phase separation of proteins 
2.5.4 Detergent solubilisation profiling 
2.5.5 Solubilisation of membrane proteins with phospholipase C 
2.6 Separation and detection of proteins by PAGE 
2.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
2.6.2 Staining of acrylamide gels 
2.6.3 Immunoelectrophoretic (Western) blotting 
2.7 Production of anti-peptide antibodies 
2.7.1 Coupling of peptides to Keyhole Limpet Haemocyanin (KLH) 
2.7.2 Antiserum production 
2.7.3 Coupling of peptide to resin 
2.7.4 Affinity purification of antisera 
2.7.5 E. L. I. S. A. (Enzyme-linked immunosorbent assay) 
2.7.6 Western blotting of transfected cell lines 
2.8 Immunoadsorption of peptidase activities 
42 
42 
43 
43 
43 
45 
45 
45 
46 
46 
46 
47 
47 
47 
48 
48 
48 
49 
49 
49 
50 
50 
50 
51 
51 
52 
53 
53 
54 
2.8.1 Coupling of antibody to cyanogen-bromide activated sepharose 4B 54 
-v11 
2.8.2 Immunoadsorption of membrane peptidase activities 54 
CHAPTER THREE 
The biochemistry of ECE 
3.1 Aims 
3.2 Introduction 
3.3 Membrane peptidase expression in EA. hy926 
3.3.1 Expression of E-24.11 by EA. hy926 cells 
3.3.2 Profile of membrane peptidase activities 
3.4 Identification of the ECE membrane anchor 
56 
57 
58 
58 
58 
60 
3.4.1 Temperature-induced phase separation of membrane proteins 60 
3.4.2 Detergent solubilisation profiles of membrane peptidases in 
EA. hy926 cells 63 
3.4.3 Bacterial phospholipase C solubilisation of EA. hy926 membrane 
proteins 63 
3.5 Recognition of ECE by antibodies raised to E-24.11 66 
3.5.1 Immunoprecipitation of ECE and E-24.11 by GK4A9 66 
3.5.2 Immunodepletion of ECE from transfected CHO cells using 
GK4A9 67 
3.5.3 Assessment of the effectiveness of thiorphan and PR inhibition of 
E-24.11 activity 68 
3.5.4 Immunoprecipitation of peptidase activities by 3C7 monoclonal 
antibody to E-24.11 68 
3.5.5 Immunoprecipitation of peptidase activities by GK4A9 from pig 
lung membranes 73 
3.6 Immunodetection of ECE-1 using the monoclonal AEC32-236 antibody 73 
3.7 Effect of tunicamycin on ECE expression 76 
3.8 Discussion 78 
3.8.1 The biochemical characteristics of the ECE protein 78 
3.8.2 Glycosylation of ECE protein 79 
3.8.3 Co-precipitation of E-24.11 and ECE using monoclonal antibodies 80 
viii 
CHAPTER FOUR 
The identification of ECE in neuronal and glial cell lines 
4.1 Aims 83 
4.2 Introduction 84 
4.2.1 Tissue specific expression of ECE 84 
4.2.2 Regulation of ECE by control of protein degradation 84 
4.2.2.1 Regulation of ECE in response to phosphoramidon (PR) 85 
4.2.2.2 Regulation of ECE in response to thiorphan 86 
4.3 Results 87 
4.3.1 Expression of ECE and E-24.11 in endothelial, glial, 
neuroblastoma cells and in a pheochromocytoma cell line 87 
4.3.2 Immunoblotting of selected cell types to confirm ECE expression 88 
4.4 The effects of PR on levels of membrane peptidase expression 90 
4.4.1 The effects of PR on levels of membrane peptidase expression in 
EA. hy926 cells 
4.4.2 Immunoblotting of membranes prepared from PR treated 
SH-SYSY and Bu17 cells 
4.5 The effects of thiorphan on membrane peptidase expression in EA. hy926 
cells 
4.6 Discussion 
4.6.1 The identification of ECE in brain cell types 
4.6.2 The regulation of ECE expression 
4.6.2.1 The effect of PR and thiorphan on ECE expression 
90 
90 
93 
95 
95 
95 
96 
CHAPTER FIVE 
Investigation of the role of tyrosine phosphorylation in the regulation of 
ECE 
5.1 Aims 98 
99 5.2 Introduction 
LX 
5.2.1 Cellular effects of protein tyrosine phosphorylation 99 
5.2.2 Effects of vanadate on tyrosine phosphorylation 100 
5.2.3 The investigation of tyrosine phosphorylation effects in ECE 
regulation 100 
5.3 Results 101 
5.3.1 The response of EA. hy926 cells to vanadate treatment 101 
5.3.1.1 The time-dependent response of EA. hy926 cells to 
vanadate 101 
5.3.1.2 Dose-response of membrane peptidase expression in 
EA. hy926 cells to vanadate treatment 101 
5.3.2 Dose-response of membrane peptidase expression in Bu17 cells 
to vanadate treatment 104 
5.3.3 Dose-response of membrane peptidase expression in PC 12 cells 
to vanadate treatment 107 
5.3.4 Protein tyrosine phosphatase inhibition by phenylarsine oxide 112 
5.4 Discussion 113 
CHAPTER SIX 
The identification of ECE-1 isoforms using anti-peptide antibodies 
6.1 Aims 
6.2 Introduction 
6.3 Selection of peptides 
6.3.1 Selection of peptides for synthesis 
6.4 Computer analysis of potential peptide sequences 
6.4.1 Prediction of hydrophilicity/hydrophobicity 
6.4.2 Surface probability 
6.4.3 Flexibility 
6.4.4 Prediction of secondary structure 
6.4.4.1 Chou & Fasman method 
6.4.4.2 Robson Garner method 
6.4.5 Glycosylation sites 
116 
117 
120 
120 
121 
122 
122 
122 
122 
123 
123 
126 
a 
6.4.6 Cross-reactivity of candidate peptides with other proteins 
6.5 Peptides selected for synthesis 
6.5.1 Peptide purity 
6.5.2 Peptide coupling to the carrier protein 
6.5.3 Injection protocol 
6.6 Analysis of antisera following final injection 
6.6.1 Assessment of immunoreactivity of antisera 
6.6.2 Affinity purification of anti-peptide antibodies 
6.7 The characterisation and use of anti peptide antibodies 
6.7.1 The specificity of immunorecognition by the ECEIa 1 antibody 
6.7.2 Immunoblotting of cultured cells and pig lung membranes using 
the ECE1a I antibody 
6.7.3 Immunoblotting of PR treated EA. hy926 cell membranes using 
the ECEIa 1 antibody 
6.7.4 Immunoblotting of PR treated Bu17 cell membranes using 
the ECE 1a1 antibody 
6.8 Discussion 
CHAPTER SEVEN 
126 
126 
128 
128 
128 
129 
129 
133 
133 
136 
136 
138 
138 
142 
General discussion 144 
REFERENCES 152 
xi 
LIST OF TABLES 
1.1 Disease models in which ET production has been implicated as a possible 
causative factor 14 
1.2 Comparison of E-24.11, ECE-1 and ECE-2 29 
3.1 Profile of specific activities of membrane peptidases expressed in 
EA. hy926 endothelial cells 61 
3.2 Temperature-induced phase separation of E-24.11, ECE and lactate 
dehydrogenase (LDH) 62 
3.3 Solubilisation of membrane proteins using bacterial phosphatidylinositol- 
specific phospholipase C 65 
4.1 Summary of ECE and E-24.11 specific activities in a variety of cell types 88 
4.2 Dose-response of membrane peptidase expression in EA. hy926 cells 
following PR treatment 91 
4.3 Assays of thiorphan treated EA. hy926 cells 94 
5.1 Time-related effect of vanadate on peptidase expression in EA. hy926 cells 102 
5.2 Dose-response of membrane peptidase expression in EA. hy926 cells to 
vanadate treatment 105 
5.3 Dose-response of E-24.11 and ECE activity in Bu17 cells following 
vanadate treatment 108 
5.4 Dose-response of E-24.11 and ECE activity in PC12 cells following 
vanadate treatment 110 
6.1 Peptides selected for synthesis 127 
xii 
LIST OF FIGURES 
1.1 Membrane anchorage of cell surface hydrolases 5 
1.2 The endothelin isopeptides and sarafatoxin b 10 
1.3 Endothelium-derived factors involved in the regulation of smooth muscle 
tone 11 
2.1 Radioimmunoassay standard curve for ET-1 44 
3.1 Detection of the E-24.11 protein expressed by EA. hy926 cells by western 
blotting of membrane preparations using the polyclonal antibody RP161 59 
3.2 Detergent solubilisation profile of E-24.11, ECE and 5'-Nucleotidase 64 
3.3 Immunodepletion of EA. hy926 cell membranes using GK4A9 labelled 
Sepharose beads 69 
3.4 Immunoprecipitation of E-24.11 from EA. hy926 cells detected by the 
polyclonal antibody to E-24.1 1, RP 161 70 
3.5 Immunoprecipitation of ECE activity from CHO cells transfected with 
ECE detected by the monoclonal antibody AEC32-236 71 
3.6 Immunoadsorption of solubilised EA. hy926 cell membranes using 3C7 
labelled and unlabelled Sepharose beads 72 
3.7 Immunodepletion of solubilised pig lung membranes by GK4A9 74 
3.8 Western blot of EA. hy926 cell membrane preparations under reducing and 
non-reducing conditions using the monoclonal antibody AEC32-236 75 
3.9 Investigation of the effect of glycosylation on ECE expression and activity 77 
4.1 Immunoblot analysis of ECE expression in selected cell types using the 
monoclonal antibody AEC32-236 89 
4.2 Dose-response of ECE expression in SH-SY5Y and Bu17 cells following 
PR treatment 92 
5.1 Time-related effect of vanadate on ECE expression in EA. hy926 cells 
revealed by immunoblotting 103 
5.2 Dose-response of ECE expression in EA. hy926 cells to vanadate 
treatment revealed by immunoblotting 106 
5.3 Dose-response of ECE expression in Bu17 cells following treatment with 
vanadate detected by immunoblotting 109 
Xill 
5.4 Dose-response of ECE expression in PC 12 cells to vanadate treatment 
detected by immunoblotting 111 
6.1 Sequence alignment of ECE-1 a and ß isoforms 118 
6.2 Analysis of ECE-1 a peptide sequence features 124 
6.3 Analysis of ECE-1 ß peptide sequence features 125 
6.4 Structure of the peptide conjugate linkage 130 
6.5 E. L. I. S. A. analysis of immunoreactivity of ECEIa I and ECEIa 2 
antisera 131 
6.6 E. L. I. S. A. analysis of immunoreactivity of ECEIb 1 and ECE1b 2 
antisera 132 
6.7 Elution profile of ECE 1a1 antibody from ECE-1 a peptide affinity 
column 134 
6.8 SDS-PAGE of affinity purified ECEIa 1 antibody 135 
6.9 Immunorecognition of ECE-1 a expressed by transfected and 
non-transfected cell lines using ECEIa I and AEC32-236 137 
6.10 Immunoblotting of membranes prepared from cells and tissues with 
the ECEIa 1 antibody to ECE-1 a 139 
6.11 Immunoblotting of PR treated EA. hy926 cell membranes using the 
ECEIa Ipolyclonal antibody to ECE-1 a 140 
6.12 Immunoblotting of PR treated Bu17 cells using the ECEIa 1 polyclonal 
antibody to ECE-1 a 141 
Yit' 
ABBREVIATIONS 
The abbreviations used are as defined in Biochem. J. (1996) 313,1-15. 
Other abbreviations are as follows: 
ACE 
AP-N 
BCA 
CAPS 
CMC 
CTF 
DCI 
Dip-F 
DMSO 
DPP-IV 
DTT 
E-24.11 
E64 
ECE 
ECL 
EDCF 
EDRF 
EDTA 
E. L. I. S. A. 
ET 
FBHE 
G-PI 
HPLC 
HUVEC 
kDa 
KLH 
LDH 
- Angiotensin converting enzyme 
- Aminopeptidase-N 
- Bicinchoninic acid 
- 3-[Cyclohexylamino]-1-propanesulphonic acid 
- Critical micellar concentration 
- C-terminal fragment 
- 3,4-dichloroisocoumarin 
- Di-isopropylfluorophosphate 
- Dimethylsulfoxide 
- Dipeptidyl-peptidase-IV 
- Dithiothreitol 
- Endopeptidase-24.11 
- L-trans-epoxysuccinyl-leucylamido-[4-guanido]-butane 
- Endothelin converting enzyme 
- Enhanced Chemiluminescence 
- Endothelial derived constrictor factor 
- Endothelial derived relaxing factor 
- Ethylenediamine tetraacetic acid 
- Enzyme-linked immunosorbent assay 
- Endothelin 
- Foetal bovine heart endothelial cells 
- Glycosyl-phosphatidylinositol 
- High performance liquid chromatography 
- Human umbilical vein endothelial cell 
- kiloDalton 
- Keyhole limpet haemocyanin 
- Lactate dehydrogenase 
aV 
NMS 
NEM 
PBS 
PEG 
PLC 
PKC 
PR 
PVDF 
RIA 
SDS 
TBST 
TEMED 
TRLEC-03 
- 3-maleimidobenzoic acid N-hydroxysuccinimide ester 
- N-ethylmaleimide 
- Phosphate Buffered Saline 
- Polyethylene glycol 
- Phospholipase C 
- Protein kinase C 
- Phosphoramidon 
- Polyvinylidene difluoride 
- Radioimmunoassay 
- Sodium dodecyl sulphate 
- Tris buffered saline containing 0.1 % (v/v) Tween-20 
- N, N, NN'-tetramethylethylene diamine 
- Simian virus 40-transformed rat lung vascular endothelial cells 
Any remaining abbreviations used in this thesis have been clearly defined in the text. 
atii 
ACKNOWLEDGEMENTS 
I would like to express my gratitude to my academic supervisor, Professor A. J. Turner 
for his advice, guidance and encouragement throughout my research. I would like to 
thank the Medical Research Council for their financial support of this work. 
I would also like to thank Mr. J. Hryszko, Mrs. J. Ingram and Ms. H. McLaren for 
technical advice, Ralph Hyde for his help with the peptide analysis, and also my other 
colleagues involved in ECE research, particularly M. V. Hoang. In addition, I would 
like to thank all the members of the membrane peptidase research group in Leeds for 
providing a varied and friendly environment in which to work. 
Thanks also to all my close friends here in Leeds, particularly Jim Mayock, Peter 
Garner, Steve Mayhew and Martin Moore for such an enjoyable sporting and social 
life, and to my brother and Maria for sharing some great times and helping me through 
the bad ones. 
Finally, I would like to thank my parents for all their love, support and encouragement. 
I could not have asked for more. 
xvii 
PUBLICATIONS 
Extracts of this work have been reported in the following publications: 
Barnes, K., Walkden, B., Wilkinson, T. & Turner, A. J. (1997) J. Neurochem. 23,100- 
109 
Walkden, B. and Turner, A. J. (1995) J. Cardiovasc. PharmacoL 23, S47-S49 
Greenhough, K., Walkden, B., Murphy, L., McLaren, H., Barnes, K. & Turner, A. J. 
(1994) Biochem. Soc. Trans 22,454S 
CHAPTER ONE 
INTRODUCTION 
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1.1 Location, function and diversity of peptidases 
This work has investigated the expression of a range of membrane bound peptidases in 
a number of mammalian cell lines. Recent research into the biochemistry of peptidases 
focusing primarily on the identification of specific inhibitors of these has resulted in the 
possibility of new treatments for a number of conditions including hypertension 
(Burris, 1995), cancer and metastasis (DeClerck & Imren, 1994; Mikulewicz et al., 
1993); Alzheimer's disease (Ichai et al., 1994) and inflammation (Jochuni et al., 1993). 
Inhibitors of angiotensin converting enzyme (EC 3.4.15.1; ACE; dipeptidyl peptidase 
A) have proved highly successful in the treatment and control of hypertension and 
congestive heart failure (for review see Remme, 1995). It is this potential for the 
treatment of human pathophysiological conditions that has established peptidase 
research as a rapidly growing branch of biochemistry. 
Due to the limited sophistication of the techniques available at the time, the first 
peptidases to be isolated and characterised were those involved in the digestion of 
dietary proteins since these were relatively abundant and extracellular in location. 
These included examples such as the serine peptidases found in leukocytes and mast 
cells and peptidases of renal and brush border membranes including serine and 
metalloproteases. The physiological roles played by peptidases are both many and 
diverse including the processing of peptide hormones and enzyme precursors and also 
the deactivation of many biologically active peptides. 
1.2 Nomenclature of peptidases 
The Nomenclature Committee of the International Union of Biochemistry and 
Molecular Biology has defined peptidases as hydrolases (class 3) which cleave peptide 
bonds (subclass 3.4). Within this classification there are 2 general definitions referring 
to the type of cleavage shown by the enzyme. Exopeptidases cleave peptide bonds 
close to a free N or C terminus whilst in contrast endopeptidases preferentially 
hydrolyse internal peptide bonds since the active site of these proteins cannot 
accommodate a free N or C terminus. 
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Peptidases are classified according to one of four catalytic mechanisms (Hartley, 1960) 
based on the major catalytic amino acid residues involved: serine, cysteine and aspartic 
peptidases or the presence of an important metal ion (metalloproteases). The 
classification system of identification of catalytic mechanisms has been used to expand 
the carboxypeptidase class of peptidases into 3 sub-subclasses and endopeptidases into 
4 sub-subclasses and endopeptidases of unknown catalytic mechanism into a fifth sub- 
subclass (EC. 3.4.99). 
1.3 The mechanisms of peptidase association with membranes 
1.3.1 Peripheral membrane proteins 
Peripheral membrane proteins do not interact structurally with cellular membranes but 
associate with them by way of non-covalent interactions. They are often hydrophilic 
and can generally be dissociated from membranes by washing with buffers containing 
high salt concentrations or with sodium carbonate, pH 10.0. 
1.3.2 Integral membrane proteins 
An integral membrane protein is, by nature, an amphipathic molecule consisting of a 
hydrophilic, globular glycoprotein domain and, usually, a sequence of hydrophobic 
membrane spanning residues. Release of the protein can only result from the removal 
of the hydrophobic anchor or by shielding the anchor in a detergent micelle. Integral 
proteins are classified according to their orientation and the number of membrane 
spanning sequences. Type I integral membrane proteins are synthesised with an N- 
terminal signal sequence which is removed in the early stages of biosynthesis. The 
protein is retained in the membrane by the presence of a hydrophobic sequence of 
amino acids close to the C-terminus. In contrast, type II integral membrane proteins 
such as endopeptidase E-24.11 (neprilysin; EC 3.4.24.11) (Malfroy et al., 1987; 
Devault et al., 1987) have a signal peptide which remains intact throughout the 
process of biosynthesis eventually forming the hydrophobic membrane anchor. These 
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proteins have a short hydrophilic, cytoplasmic N-terminal domain and an extracellular 
C-terminal domain. Proteins with multiple membrane spanning regions of hydrophobic 
amino acid residues are termed type III integral membrane proteins. The number of 
these sequences has been found to vary from 2 in subunit c of the F0, -ATPase complex 
up to 24 in the case of neuronal sodium channels. 
1.4 Peptidases localised at the cell surface 
Many mammalian enzymes are found bound to intracellular membranes where they 
serve a diverse range of functions. In addition, a second group of enzymes are found 
associated with the plasma membrane of the cell. To date, most of these enzymes have 
been characterised as ectoenzymes as defined by their orientation, with the bulk of the 
protein, including the catalytic site exposed at the extracellular surface. 
The cell-surface peptidases identified to date associate with the membrane in one of 
two ways. This occurs either by way of a hydrophobic transmembrane anchor or by 
attachment to a glycosyl-phosphatidylinositol (G-PI) moiety. G-PI anchored proteins 
are attached to the G-PI structure at their C-termini and it is the G-PI structure which 
associates with the upper lipid leaflet of the membrane surface through fatty acids of 
the phospholipid component. Examples of G-PI anchored proteins include membrane 
dipeptidase (EC 3.4.13.19) (Hooper and Turner, 1988 a) and aminopeptidase P (EC 
3.4.11.9) (Hooper et al., 1987). 
Peptidases which are G-PI anchored are generally identified by their release through 
the action of bacterial phospholipase C. A phospholipase C has been reported in rat 
liver membranes (Fox et al., 1987) and a phospholipase D has been found in plasma 
(Davitz et al., 1987; 1989). However, as yet the physiological significance of the 
endogenous release of G-PI anchored proteins by the action of phospholipases remains 
unclear. 
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Fig. 1.1 Membrane anchorage of cell surface hydrolases (see opposite) 
Schematic representation of the mode of membrane attachment of cell surface 
hydrolases. (a) N-terminal transmembrane polypeptide anchor (uncleaved signal 
peptide) (e. g., endopeptidase-24.11, aminopeptidase-N and dipeptidyl peptidase-IV), 
(b) C-terminal transmembrane polypeptide anchor (e. g., angiotensin converting 
enzyme) and (c) C-terminal G-PI anchor (e. g., alkaline phosphatase, aminopeptidase 
P). 
Predicted glycosylation sites are represented by 
°O° 
symbols. 
(Modified from Kenny & Hooper, 1991). 
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Cell surface peptidases are found in abundance in the brush border membranes of renal 
and intestinal tissues (Kenny et al., 1987). The majority of these were first isolated 
from kidney microvillar membranes and have since been found to be metalloproteases 
though one significant exception is the serine protease dipeptidyl peptidase IV (DPP- 
IV). Cell-surface peptidases have been found in a wide range of tissues hydrolysing a 
vast array of substrates. The majority are not substrate specific but act together to 
metabolise a wide range of peptide substrates. The action of such cell-surface 
peptidases is crucial for hydrolysis of dietary constituents, hormones, nucleotides and 
neurotransmitters. The substrates are often oligopeptides with little secondary or 
tertiary structure. One such example is the identification of E-24.11 as the synaptic 
peptidase involved in hydrolysis of the opioid peptides (Relton et al, 1983; Matsas et 
al., 1983) acting effectively as an "off" switch (Turner et al., 1985). 
1.4.1 Cell surface endopeptidases 
The majority of cell surface peptidases identified to date have been shown to be 
exopeptidases however, one such cell-surface peptidase which has been thoroughly 
characterised and shown to be an endopeptidase is E-24.11. 
E-24.11 was first purified and characterised from rabbit kidney microvillar membranes 
(Kerr and Kenny, 1974 a, b). Subsequently, E-24.11 was found to be located on the 
surfaces of cells throughout the mammalian body including intestine, lung and brain 
(Gee et al., 1985). Whilst E-24.11 has a broad tissue distribution the enzyme is not 
ubiquitous and levels of tissue-specific expression vary substantially (Howell et at., 
1991; Gee et al., 1985). It is has been found to be constitutively expressed in tissues 
such as brain and kidney but is developmentally regulated in other cell types (e. g. 
lymphocytes). Isolation of E-24.11 from different source tissues has shown the 
molecular weight to vary from 85 kDa to 100 kDa, the variations being attributable to 
differences in glycosylation (Relton et at., 1983; Malfroy et al., 1987). Molecular 
cloning of E-24.11 and subsequent sequencing of the cDNAs revealed rabbit (Devault 
et at., 1987) and rat (Malfroy et al., 1987) to consist of 750 and 742 amino acids 
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respectively. A year later, Malfroy et al., (1988) revealed human E-24.11 to have 742 
amino acids, in common with the rat enzyme. Further differences in glycosylation 
were identified, the rabbit enzyme having 5 N-linked glycosylation sites compared with 
6 in rat and human forms. 
Structural characterisation of E-24.11 by biochemical analysis and study of the cDNA 
sequence revealed the enzyme to have a short N-terminal cytoplasmic domain (27 
residues in rabbit; 20 in human and rat), a single hydrophobic membrane spanning 
sequence of 23 residues and a major extracellular C-terminal domain (Devault et al., 
1987; Malfroy et al., 1987; Malfroy et al., 1988). The topology of E-24.11 has been 
shown to be typical of a type II transmembrane anchored ectoenzyme which exists in 
its native form in rat and human as a non-covalently attached dimer (Kerr and Kenny, 
1974 b; Fulcher & Kenny, 1983). Of the 12 cysteine residues found in the whole 
protein, 4 are found clustered within a 32 amino acid sequence on the C-terminal side 
immediately following the transmembrane anchor. Examination of the C-terminal 
sequence revealed an HExxH motif consistent with many zinc binding proteins, and 
accordingly E-24.11 is inhibited by metal chelating agents such as EDTA and 1,10- 
phenanthroline. E-24.11 is also inhibitable by phosphoramidon (PR), originally 
described as a potent inhibitor of bacterial thermolysin (Suda et al., 1973) and 
subsequently found to be an equally potent (Ki =2 nM) inhibitor of E-24.11 (Kenny, 
1977). PR is not however a general inhibitor of zinc peptidases and has been shown to 
be ineffective against ACE or meprin. 
E-24.11 was found to hydrolyse a broad range of substrates on the N-terminal side of 
hydrophobic residues. In this respect, peptides considered to be possible physiological 
substrates for E-24.11 are thought to include natriuretic peptides, tachykinins including 
substance P and chemotactic peptides such as fMet-Leu-Phe (for review see Turner & 
Tanzawa, 1997). The sensitivity of E-24.11 to PR was to prove crucial in the 
identification of E-24.11 as the synaptic peptidase involved in cleavage of the opioid 
peptides at the membranes of the synaptic cleft (Relton et al., 1983; Matsas et al., 
1983) and further research has shown E-24.11 to play a variety of physiological roles 
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cleaving other neuropeptides and regulatory peptides involved in inflammation and 
cardiovascular regulation. 
1.5 The biology of endothelial cells (EC) 
The endothelial cell monolayer lines the inner surface of all blood vessels and forms a 
structurally and functionally heterogeneous population of cells occupying a surface 
area of > 1000 m2 in a 70 kg adult (Jaffe, 1987). The endothelium was originally 
thought to be a passive, blood-compatible lining functioning as a diffusion barrier but is 
now regarded as crucial to maintaining vascular homeostasis (Vane et al., 1990). 
Amongst the functions served by the endothelium are coagulation, thrombolysis, 
antigen presentation and control of vasotone, accomplished by locally acting 
endothelium-derived hormones. EC dysfunction is now recognised as a major 
causative event in the pathophysiology of cardiovascular disease (Luscher, 1992). The 
first indication that the endothelium played a role in the control of vasotone was the 
discovery of prostaglandin (PGI2) (Moncada et al., 1976) which was first described as 
an inhibitor of platelet aggregation but later was shown to act as a potent vasodilator. 
The endothelium was later shown to mediate vascular smooth muscle relaxation in 
response to acetylcholine (Furchgott & Zawadzki, 1980) and shown to produce other 
vasoactive agents including endothelium-derived constricting factors (EDCF) (De Mey 
& Vanhoutte, 1983; Hickey et al., 1985; Gillespie et al., 1986; O'Brien eta!., 1987) 
and nitric oxide which was found to be a potent vasodilator (Ignarro et al., 1987; 
Palmer et al., 1987). The discovery of these vasoactive factors, apparently crucial to 
cardiovascular regulation gave hope that EC, which are advantageously situated to 
communicate chemical signals in the blood to the vascular smooth muscle cells, could 
be targeted for the development of novel therapeutic compounds with the aim of 
treating pathophysiological conditions. Fig. 1.3 
1.6 The endothelin isopeptides 
In 1988, Yanagisawa et at, working on the supernatant of porcine aortic endothelial 
cells, isolated, cloned and sequenced one EDCF as a 21 amino acid bicyclic peptide 
with 2 intramolecular disulphide bonds. The peptide was named endothelin and had an 
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Fig. 1.2 The endothelin isopeptides and sarafatoxin b 
Three distinct endothelin isopeptides have been discovered, each the product of a 
separate gene (Inoue et al., 1989). The ET isopeptide sequences and structure 
revealed significant homology to sarafatoxin b, the snake venom toxin produced by A. 
engaddensis. All of these peptides are bicyclic with 2 disulphide peptide bonds (Cys' - 
Cys15 and Cys3 - Cys"), a cluster of polar, charged side-chains within the hairpin loop 
and a predominantly hydrophobic C-terminus. The shaded residues in the figure 
highlight the amino acids which differ from the corresponding amino acid in the ET- I 
sequence. 
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Fig. 1.3 Endothelium-derived factors involved in the regulation of smooth 
muscle tone 
Cleavage of big ET-1 at the Trp21-Va122 bond by ECE forms the vasoconstrictive 
peptide, ET-1. This peptide has been found to promote both constriction and 
proliferation of the underlying smooth muscle cells through signals mediated by both 
ETA and ETB receptor subtypes. Nitric oxide (NO) derived from L-arginine and 
prostacyclin (PGI2) derived from arachidonic acid (AA) cause relaxation through cyclic 
GMP (cGMP) and cyclic AMP (cAMP) respectively and also inhibit the 
vasoconstrictive and proliferative properties of ET-1. ET-1 can initiate relaxation 
through these pathways via stimulation of ETB-type receptors located on the vascular 
endothelium. 
(Modified from Gray & Webb, 1996). 
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development, Kurihara et al., (1994) found ET-1 +" heterozygotes which, due to their 
impaired production of endothelin, would be expected to have lower blood pressure, 
were actually found to have a transient increase compared with the ET-1 +i+ wild type, 
challenging the long held view that endothelin functioned only as a vasoconstrictor in 
the physiological state. Another approach involving targeted and natural (piebald- 
lethal) mutations of the endothelin-B receptor gene. Hosoda et al. (1994) and 
Puffenberger et al. (1994) revealed homozygous mutants deficient in endothelin-B 
receptors exhibited a phenotype reminiscent of that found in patients with 
Hirschprung's disease. In addition to exhibiting megacolon development, typical of 
Hirschprung's disease, these mice exhibited coat colour abnormalities of both 
myenteric ganglion neurones and epidermal melanocytes; two tissue types derived from 
the neural crest. Targeted mutations of the endothelin-3 gene resulted in a similar, 
though milder phenotype suggesting endothelin-3 is the natural ligand for the 
endothelin-B receptor during development (Baynash et al., 1994). Two naturally 
occurring recessive mutant mice (piebald-lethal and lethal spotting) were found to 
display the same phenotype to that exhibited by mice deficient in endothelin-3 and 
endothelin-B receptor. Genetic analysis of the two naturally occurring mutants 
revealed piebald-lethal mutants to have a deletion of the entire endothelin-B receptor 
gene whilst the lethal spotting mice had a point mutation in the endothelin-3 gene 
sequence. The physiological significance of these findings was shown by genetic 
analysis of the Mennonite religious sect in the U. S. A., a highly inbred population with 
a relatively high occurrence of hereditary Hirschprung's disease. The analysis revealed 
this population to express a mis-sense mutation in the endothelin-B gene and in 
addition, defects in pigmentation were often found in the Mennonites, a feature found 
consistently in the mice mutants. This evidence for a role in tissue development added 
to a growing list of disease models in which endothelin and its biosynthesis was 
thought to play a major role (see Table 1.1). 
Since the production of endothelin is regulated at the mRNA level and secreted 
through the constitutive pathway, no further regulation is thought to occur during 
exocytosis. It is therefore essential that the production of this potent vasoactive 
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Table 1.1 Disease models in which ET production has been implicated as a 
possible causative factor 
Disease References 
Systemic hypertension Clozel et al., 1993 
Stein et al., 1994 
Ohlstein et al., 1994 
Ischaemic neuronal cell death Ohistein et al., 1994 
Hirschprung's disease Puffenberger et at, 1994 
Hosoda et al., 1994 
Human endometrial cancer Pekonen et al., 1995 
Acute myocardial infarction Grover et al., 1993 
Progressive proliferative Benigni et al., 1993 
glomerulonephropathy 
Cerebrovascular spasm Clozel et al., 1993 
Itoh et al., 1993 
Craniofacial development abnormalities Kurihara et al., 1994 
Prostate Cancer Nelson et al., 1995 
Human coronary atherosclerosis Bacon et al., 1996 
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peptide be tightly regulated and it is the mode by which this process is controlled that 
has become a major focus for research. 
1.6.2 Endothelin biosynthesis 
Endothelins are synthesised constitutively by smooth muscle or vascular endothelial 
cells and function in the manner of a locally acting hormone secreted in a paracrine 
fashion (Kennedy et al., 1993). Like many other biologically active peptides, 
endothelin is initially synthesised in the form of a much larger, inactive precursor 
molecule, termed pre-pro endothelin which is approximately 200 amino acids long 
(Yanagisawa et al., 1988). Big ET was proposed to be a 38 or 39 residue processing 
intermediate resulting from cleavage of the prepro-peptide + early in the biosynthetic 
pathway. The resultant pro-peptide is then cleaved at pairs of basic amino acids by a 
dibasic-pair specific endopeptidase to liberate big ET-1. The vasoconstrictive potency 
of big ET-1 is 100-fold less than that of correctly processed mature endothelin 
(Kashiwabara et al., 1989, Kimura et al., 1989), indicating processing of big ET-1 is 
necessary to induce the potent vasoactive effects of this system. The activation of 
many biologically active proteins and almost all peptide hormones occurs following 
endoproteolysis which is catalysed by cleavage at the carboxyl side of an evolutionary 
conserved site, typically a doublet or cluster of basic amino acids (usually Arg-Arg or 
Lys-Arg) (see Sossin et al., 1989 for review). In the case of ET production, current 
opinion suggests that the cleavage of the pro-peptide is carried out by furin, a 
prohormone convertase of the constitutive secretory pathway (Denault et al., 1995; 
Kido et al., 1997) followed by trimming by exopeptidases. The processing step which 
processes big ET-1 to ET-1 and the C-terminal fragment (CTF) occurs by what is 
thought to be a unique step in peptide hormone processing involving cleavage of the 
Trp21-Val22 bond by what is now termed endothelin converting enzyme (processing of 
big ET-2 to ET-2 involves cleavage of the Trp21-Val' bond whilst cleavage of big ET- 
3 occurs at the Trp21-Ile bond). This hypothesis concerning endothelin production 
gained support when the substrate and end products of the reaction (big ET-1; ET-1 
and CTF) were all detected in the culture supernatant of porcine and bovine 
endothelial cells (Emori et al., 1989, Sawamura et al., 1989 and Matsumura et al., 
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1990 a). A further clue as to the nature of the putative ECE activity was found when 
it was shown that phosphoramidon, an inhibitor of certain metalloproteases, 
suppressed secretion of ET-1 and CTF from cultured endothelial cells (Ikegawa et al., 
1990 a). At this point in time it was still undetermined if the processing of big ET-1 
occurred at the cell surface or was processed intracellularly. However, exogenously 
applied big ET-1 was rapidly converted to ET-1 and CTF consistent with a cell 
surface location for the processing step. 
1.6.3 Endothelin receptors and signal transduction 
Following the discovery of three distinct ET gene products it was suggested that each 
of these may exert their physiological effects through multiple receptor subtypes. The 
first indications that more than one receptor type existed came from the results of 
studies of the potency and activities of the three naturally occurring ET peptides 
(Inoue et al., 1989; Warner et al., 1989 a, b). This was supported by receptor binding 
assays suggested the expression of receptor subtypes in a variety of tissues (Watanabe 
et al., 1989; Masuda et al., 1989). Identification of these receptor subtypes was 
established with the cloning and expression of two different receptors designated ETA 
(Arai et al., 1990) and ETB (Sakurai et al., 1990). Both were found to be G-protein 
coupled receptors with 7 transmembrane domains belonging to the rhodopsin type 
superfamily of receptors. ETA was found to have much greater affinity for ET-1 
exhibiting an affinity profile of ET-1 >_ ET-2 >ET-3 (Arai et al., 1990). In contrast the 
ETB receptor was found to have equal affinity for all 3 ET peptides (Sakurai et al., 
1990). The development of novel receptor agonists and antagonists provided further 
understanding as to the role of each receptor subtype and was also instrumental in 
providing evidence for the existence of yet further ET receptor subtypes. Initial 
studies suggested ET-1 preferring receptors were located on vascular smooth muscle 
and responsible for the vasoconstrictive effects whilst ET isoform non-selective 
receptors were located in endothelial cells. Further work showed this concept to be 
flawed, for example ET-3 proved to be a less potent vasoconstrictive agent in guinea 
pig pulmonary artery whilst studies using the trachea revealed all 3 isopeptides were 
equipotent in promoting constriction (Cardell et al., 1992). These data suggested 
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different ET receptors were responsible for the mediation of the contractile activity of 
ET peptides in these tissues. It has now been shown that both ETA and ETB receptors 
mediate smooth muscle contraction whilst only ETB receptors localised on endothelial 
cells mediate nitric oxide release resulting in endothelium-derived vasodilation (Sumner 
et al., 1992; Clozel et al., 1992; Warner et al., 1993 a). 
More recent work has suggested receptor differences within the ETB receptor 
classification (Warner et al., 1993 a; Gray & Clozel, 1994). The ETB receptor which is 
present on the endothelium mediating vasodilation through NO production has been 
found to be functionally different from the ETB receptor of vascular and non-vascular 
smooth muscle which mediates vasoconstriction (Warner et al., 1993 b). Tentative 
nomenclature of these ETB subtypes has been proposed as ETBI present on 
endothelium and ETB2 present on smooth muscle. 
Further evidence supporting the existence of ETD receptor subtypes has been reported 
by Elshourbagy et al. (1996) who reported the molecular characterisation of a novel 
human endothelin receptor splice variant (ETB-SVR) which northern blotting revealed 
to be expressed in placenta, lung, kidney and skeletal muscle. Examination of the 
effects of ligand binding resulted in accumulation of inositol phosphate in COS cells 
transfected with ETB receptor whereas no increase in inositol phosphates was observed 
in cells transfected with ETD-SVR The receptors were found to have 91 % sequence 
identity suggesting ETB-SVR to be functionally distinct from the ETB-receptor with 
the amino acid sequence differences determining functional coupling. 
Evidence for a receptor selective for ET-3 over ET-1 would suggest at least one more 
receptor subtype. A receptor which has greater affinity for ET-3>ET-1 was discovered 
in bovine endothelial cells and tentatively designated an ETc receptor (Sakurai et al., 
1992). Confirmation of this has not yet been possible since it has not yet been cloned. 
Further ET-3 receptors have been identified in rat brain and atria (Nambi et al., 1990; 
Sokolovsky et al., 1992) and anterior pituitary cells (Samson et al., 1990). 
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The signal transduction mechanism whereby the interaction of an ET peptide with its 
receptor causes a physiological change is not yet understood in detail. The best 
characterised effect is that of vasoconstriction triggered by the binding of ET-1 to ETA 
receptors in vascular smooth muscle cells. Initially several possible signal transduction 
mechanisms were suggested to be involved with the contractile mechanism mediated 
by ET-1. It is now known that the binding of ET-1 to the receptor leads to the 
formation of an activated receptor agonist complex. This initiates the stimulation of 
two different signal transduction cascades. These are the activation of the 
dihydropyridine-sensitive, voltage dependent Ca2+ channel causing an increase in 
intracellular free Ca2+ levels (Goto et al., 1989; Kasuya et al., 1989) and secondly, the 
G-protein mediated activation of phospholipase C leading to phosphatidylinositol 
hydrolysis and rapid formation of IP3 and sustained diacylglycerol accumulation 
(Resink et al., 1988; Takuwa et al., 1990; Gardner et al., 1992). Both pathways are 
G-protein dependent and the outcome is a biphasic increase in intracellular free Ca2+ 
ion concentration which then reduces to a lower level which is still significantly higher 
than baseline concentration. The initial transient increase in Ca2+, in contrast to the 
sustained elevation of Ca2+, is not sensitive to the removal of extracellular calcium 
(Danthuluri & Brock, 1990; Kai et al., 1989; Takuwa et al., 1991) but can be reduced 
by treatment of cells with caffeine in the absence of extracellular calcium (Kai et al., 
1989; Wagner-Mann & Sturek, 1991) or by ryanodine, a specific inhibitor of Ca2+ 
release from the sarcoplasmic reticulum (Wagner-Mann et al., 1991). It is now 
accepted that the rapid, transient elevation of free Ca2+is the result of Ca2+ release from 
the sarcoplasmic reticulum in response to stimulation by inositol phosphate. The 
sustained latter part of the elevation of calcium is thought to be due to the influx of 
extracellular calcium. 
1.6.4 Synthesis of endothelin in brain cells 
Until recently there was conflicting information about the possible expression of ECE 
in brain although a wealth of evidence for ET production and receptor expression had 
been acquired. RNA blot hybridisation had revealed ET gene expression in a variety of 
regions in the human brain (Lee et al., 1990) and spinal cord (Giaid et al., 1991). 
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Prepro-ET-1 mRNA was detected at the highest density in cells of the hypothalamus 
and striatum (Lee et al., 1990) and ET-3 was shown to be produced in magnocellular 
neurons of the hypothalamoneurohypophyseal system (Samson et al., 1991 a, b, c). 
Further evidence came from the examination of the location of ET binding sites which 
showed receptors for ET present in a variety of cell types in human brain (Jones et 
al., 1989; Kurihara et al., 1990) and ET-1 and ET-3 binding sites to have a similar 
distribution profile in rat brain (Nambi, 1990). High affinity ET-1 binding was 
observed in cerebellar granule cells and astrocytes (MacCumber et al., 1990) whilst 
subsequent research revealed the presence of ET-1 and ET-3 in glial and neuronal cells 
(MacCumber et al., 1990 ; Ehrenreich et al., 1991 ; Fuxe et al., 1991; Giaid et al., 
1991). 
Recent studies of astrocytoma cell lines have further characterised the expression of 
the ET receptors in this cell type. Wu-Wong et al., (1995) working on human 
astrocytoma U373 MG cells concluded that the ET receptor predominantly expressed 
by this cell line was ETC, with a molecular mass of 45 kDa whilst a later report (Wu- 
Wong et al., 1996) demonstrated that a different astrocytoma cell line (U138 MG) 
expressed predominantly the ETA receptor. They concluded that the major function of 
ETC receptors was to remove ET from the neuronal environment though in response to 
certain pathological conditions, ETA may become the dominant form resulting in 
impaired ability to clear ET. 
These findings were supported by Lazarini et al., (1996) who demonstrated that rat 
astrocytes preferentially expressed the ETB receptor which is coupled to several 
intracellular signal transduction pathways via pertussis toxin-sensitive and insensitive 
G-proteins. These pathways were found to include inhibition of adenylyl cyclase / 
cAMP-dependent protein kinase and stimulation of the mitogen-activated protein 
kinase and DNA synthesis, suggesting the ETB receptor may mediate several biological 
effects of ET in astrocytes in vivo, including proliferation during brain development 
and tissue repair. In view of this evidence suggesting ET production in brain it has 
been proposed that the ET peptides may play important roles in the regulation of 
cerebral blood flow and astrocytic function (Barone et al., 1995). 
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It is possible that the effects of the ET peptides in brain may extend beyond those 
involving the control of vascular tone. Natural or induced disruption of the ET gene 
resulting in impaired ET production has shown ET to act as a morphogen involved in 
development of tissues derived from the neural crest (Baynash et al., 1994; Kurihara et 
al., 1994 ; Puffenberger et al., 1994). The presence of ET and ET receptors in brain 
has led to interest in the expression of ECE by some brain cell types but, until recently, 
little was known about production of ECE in brain and much of the evidence was 
conflicting. Warner et al., (1992 a) first detected a phosphoramidon inhibitable ECE 
activity in rat brain then subsequently in human brain (Warner et al., 1992 b). More 
recent work by Deschepper et al., (1995) has revealed ECE expression in highly 
purified cultures of rat brain astrocytes. During the course of this work, several 
cultured brain cell types were examined by western blotting and enzyme assay to 
determine possible ECE expression in brain. 
1.7 Endothelin converting enzymes 
Following the discovery of endothelin in 1988 by Yanagisawa et al, there was an 
explosion of interest in the biosynthetic mechanism that resulted in the production of 
this potent vasoactive peptide in the belief that this may provide a useful tool in the 
treatment of some human pathophysiological conditions. Initially a variety of enzyme 
activities were proposed as possible candidates for the physiological ECE activity. It 
was first thought that the primary specificity of ECE was due to a tryptophanyl residue 
in the Pl position which would have implicated a chymotrypsin-like cleavage in the 
processing mechanism (Yanagisawa et al., 1988). McMahon et al. (1989) 
demonstrated that the serine proteinase chymotrypsin was able to metabolise big ET to 
form a product which elicited similar responses as mature ET both in vitro and in vivo. 
However chymotrypsin was discounted as the physiological ECE since it was 
discovered that in addition to cleaving the Trp21-Va122 bond, big ET was initially 
degraded at the Tyr31-G1y32 bond therefore producing a truncated CTF (Takaoka et al., 
1990 a). In addition Wypij et al., (1992) identified a chymostatin-sensitive serine 
protease from rat lung able to process extracellular big ET-1 to ET-1. The activity 
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was identified as mast cell chymase I which significantly increased big ET-1 in perfused 
rat lung preparations by inducing degranulation of mast cells. However this has now 
been discounted as the activity responsible for physiological ET processing. 
For a period, aspartic proteases were considered candidate ECE activities. Takaoka et 
al., (1990 b) reported that the aspartic peptidase pepsin degraded big ET producing a 
product which was demonstrated to have potent vasoconstrictive activity in isolated rat 
aorta. Reverse-phase HPLC separation of the products confirmed that big ET was 
degraded at the Trp21-Val22 bond to produce ET and CTF. The first reported big ET 
converting activity isolated from endothelial cells was reported by Matsumura et al., 
(1990 a). They found an ET immunoreactive product was formed when an extract 
from cultured porcine aortic endothelial cells was incubated with porcine big ET. The 
degradation was found to be optimal at pH 4.0 and potently inhibited by the aspartic 
peptidase inhibitor, pepstatin A. This was soon followed by several reports describing 
both membrane and cytosolic aspartic protease converting activities in bovine and 
porcine endothelial cells, adrenal medulla and rat lung (Sawamura et al., 1990 ab; 
Ikegawa et al., 1990 b; Wu-Wong et al., 1990). Two of these reports (Sawamura et 
al., 1990 ab) implicated a cathepsin D-like enzyme. Bovine cathepsin D itself was 
shown to cleave big ET in the Trp21-Val22 position but was also found to cleave at the 
Asp's-Ile19 position forming a truncated inactive form of ET (Sawamura et al., 1990 c; 
Takaoka et al., 1990 c; Lees et al., 1990). However, work by Wu-Wong et al., 1991) 
reported an ECE-like activity from rat lung which was inhibitable by pepstatin A but 
appeared to be distinct from cathepsin D. 
This led to investigation of cathepsin E which was shown to cleave big ET exclusively 
at the Trp21-Val22 bond to form mature ET and CTF (Robinson et al., 1992). Kinetic 
studies of this activity revealed cathepsin E was able to bind the three ET precursors 
efficiently and generate the mature products of hydrolysis, ET-1, ET-2 and ET-3. The 
relevance of this enzyme in terms of physiological big ET breakdown was investigated 
in vivo by the use of specific inhibitors of cathepsin E which failed to provide evidence 
to support cathepsin E as the activity responsible for the physiological ECE (Bird et 
al., 1992). Further evidence to discount cathepsin E as the true ECE activity was 
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provided by Shields et al. (1991) who showed that the incubation of vascular 
endothelial cells with pepstatin A did not alter the ratio of big ET-1 to ET-1 nor the 
secretion of either peptide. 
Ohnaka et al., (1990) reported an ECE with an activity optimal at neutral pH. They 
identified two ECE-like activities in the homogenate of cultured bovine endothelial 
cells with pH optima of 3.0 and 7.0. Immunoreactive ET-1 was exclusively detected at 
pH 7.0 but several ET-like immunoreactive species were detected at pH 3.0. Pepstatin 
A was capable of complete inhibition of the activity at pH 3.0 whilst in contrast, the 
activity found at pH 7.0 was found to be insensitive to a wide range of inhibitors 
although it was found to be inhibited by the metal chelating agents EDTA and EGTA, 
suggestive of a metal-dependent neutral endopeptidase. Further evidence supporting 
this as the physiological ECE activity was reported by Okada et al. (1990) who found 
that bovine carotid artery endothelial cells converted human big ET-1 to ET-1 by a 
cleavage which was inhibitable by the metal chelating agents EDTA and o- 
phenanthroline and also by phosphoramidon. The activity was found to be insensitive 
to thiorphan and the ACE inhibitor captopril. The breakdown of big ET-1 was optimal 
between pH 6.6 and 7.6 suggesting the putative ECE to be a membrane bound neutral 
metallo-endopeptidase. 
Activities matching the apparent criteria for the physiological ECE (optimal at neutral 
pH, insensitive to thiorphan, sensitive to metal chelators and phosphoramidon) derived 
from endothelial cells were reported by several groups (Matsumura et al, 1990 b, 
1991 a; Takada et al., 1991; Devine et al., 1991; Hioki et al., 1991). Neutral ECE- 
like activities were isolated from cytosolic fractions of cultured endothelial cells 
(Okada et al., 1990; Matsumura et al., 1990 b, 1991 ab; Takada et al., 1991) and in 
vascular smooth muscle cells (Hioki et al., 1991; Matsumura et al., 1991 b). Whilst 
these were championed as possible candidate ECE enzymes these neutral pH activities 
were not identical. Matsumura et al., (1990 b; 1991 a) discovered both membrane 
associated and cytosolic ECE-like activities in cultured endothelial cells originally 
isolated from fresh porcine thoracic aortas. Both activities were found to be inhibited 
by metal chelating agents though only the membranous form was found to be sensitive 
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to phosphoramidon. Further differentiation of the two enzyme forms revealed that the 
sulphydryl blocking agent N-ethylmaleimide (NEM) markedly enhanced the apparent 
converting activity of the membrane fraction by inhibiting the degradation of ET-1. In 
contrast NEM completely inhibited the activity of the cytosolic fraction. These results 
were reproduced using porcine vascular smooth muscle cells (Matsumura, 1991 b). 
Further claims to have identified ECE were made by Deng et al. (1992) who found 
that a soluble extract of primary porcine endothelial cells contained an apparent ECE 
with a sharp pH optimum of 7.0-7.5 that was inhibitable by thiol peptidase inhibitors 
including Z-Phe-Phe-CHN2 and p-hydroxymercuribenzoate but was found to be 
insensitive to serine or metallopeptidase inhibitors. No activity was detectable at pH 
4.0. Takada et al. (1991) found a cytosolic ECE activity in bovine endothelial cells 
which was found to be phosphoramidon sensitive. However, the purified enzyme had 
an apparent molecular mass of 540 kDa, approximately five times greater than that 
previously recorded for solubilised ECE activity from membrane fractions. 
Several characteristics of the physiological ECE activity had now been established and 
it is possible that many of the reports published claiming to describe ECE might have 
been avoided with more thorough investigation regarding their cell biology and 
assessment of their sensitivity to key inhibitor compounds. It was now apparent that 
the physiological ECE must be located in the correct sub-cellular location with the 
correct topology in order to hydrolyse big ET-1 efficiently. 
The key to identification of a metalloprotease ECE was phosphoramidon. The co- 
inhibition of ECE and E-24.11 by this compound was indicative that ECE was related 
to the well characterised E-24.11 enzyme. Several key studies using phosphoramidon 
suggested a neutral PR-sensitive metalloprotease ECE activity was responsible for 
production of mature ET. Addition of micromolar concentrations of PR to cell culture 
media prevented the release of ET-1 from endothelial cells and was found to alter the 
ratio of ET-1 and big ET-1 in a manner consistent with the inhibition of hydrolysis of 
big ET-1 by the putative ECE ( Ikegawa et al., 1990 b; Shields et al., 1991; Budzik et 
al., 1991). In addition, effects consistent with PR inhibition of ECE were seen in vivo 
which showed inhibition of big ET-1 hydrolysis and the big ET-1 pressor response 
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whilst the pressor response of mature ET-1 remained unaffected (Matsumura et at, 
1990 c; Shinyama et al., 1991; McMahon et al., 1991; Bird et al., 1992; ). Other 
inhibitors of E-24.11, including thiorphan appeared to show no effect on big ET 
conversion in vivo or in vitro (Bird et al., 1992; Pollock & Opgenorth, 1991). 
McMahon et al. (1991) did report big ET-1 pressor inhibition by thiorphan though 
these apparent discrepancies in response were probably a reflection of dosage 
differences. All of these observations prompted many research groups to focus their 
search on an ECE activity distinct from, though structurally and catalytically related to 
E-24.11 by virtue of ECE being less sensitive to phosphoramidon and insensitive to 
thiorphan. The sensitivity of ECE to PR gave a further insight into the probable 
location of ECE. Since PR is a phosphorylated sugar derivative and would not be 
expected to enter cells at any appreciable rate, it implied that big ET-1 hydrolysis 
occurred on the extracellular face of the plasma membrane suggesting ECE to be a 
membrane bound or secreted protein. The different sensitivities of ECE and E-24.11 
to PR and thiorphan were eventually to prove crucial in identification and assay of the 
true physiological ECE. 
1.7.1 Endopeptidase 24.11 as a model for the characterisation of ECE 
As described in section 1.4.1, E-24.11 is known to hydrolyse peptide bonds on the 
amino side of hydrophobic residues -and therefore has many potential substrates including 
the Trp21-Va122 bond of big ET-1. In this respect E-24.11 was thought to be a possible 
ECE and the sensitivity of big ET-1 breakdown to PR both in vivo and in vitro 
suggested at least catalytic similarities between E-24.11 and ECE. Further 
investigation of E-24.11 suggested this activity was capable of converting big ET-1 to 
ET-1 efficiently (Murphy et al., 1994). However previous reports had revealed E- 
24.11 further degraded mature ET (Sokolovsky et al., 1990; Vijayaraghavan et al., 
1990) and so E-24.11 was discounted as the true ECE. Nevertheless significant steady 
state levels of ET remain, implying that any PR-sensitive ECE activity could be due, at 
least in part, to big ET-1 hydrolysis by E-24.11. For this reason the ECE assay system 
used during this work, outlined in section 2.3.7 includes, amongst a range of inhibitors, 
the compound thiorphan which selectively inhibits E-24.11 ensuring any big ET-1 
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hydrolysis is due exclusively to physiological ECE activity. ECE has been successfully 
separated from E-24.11 by isoelectric focusing (Corder et al., 1995). 
1.7.2 Purification of ECE 
Following the initial reports characterising ECE as a membrane bound PR sensitive/ 
thiorphan insensitive metalloprotease distinct from E-24.11 (Okada et al., (1990), it 
was a further 3 years before the first published reports of purification of ECE to 
homogeneity. This delay was a consequence of several factors including the low 
specific activity of ECE in endothelial cells and other cell lines and tissue preparations 
and the lack of a suitably sensitive and reproducible assay system. The first reports of 
successful ECE purification came from the use of rat lung (Takahashi et al., 1993) and 
porcine aortic endothelium (Ohnaka et al., 1993) as source material. 
The rat enzyme was purified a reported 6300-fold from a lung microsomal preparation 
following solubilisation with Triton X-100 (Takahashi et al., 1993) and utilised the 
relatively high degree of glycosylation of the ECE protein to aid purification using a 
column of lectin (wheat germ agglutinin). The purification was enhanced further by 
using zinc-chelating Sepharose and Blue-B agarose. SDS-PAGE showed the protein 
to have an apparent monomeric weight of 130 kDa under reducing conditions. 
Purification of ECE from porcine aortic endothelium was achieved some 12,000 fold 
to homogeneity (Ohnaka et al., 1993). In this case the apparent monomeric weight of 
ECE was found to be 120 kDa by SDS-PAGE. 
1.7.3 Molecular cloning of ECE 
Following the purification of ECE by several groups in 1993 the ECE cDNA was 
subsequently cloned and sequenced. Partial amino acid sequence data for the rat lung 
enzyme was used to synthesise probes for the screening of a vascular endothelial cell 
cDNA library (Shimada et al., 1994). This strategy was also adopted for the cloning 
of the bovine ECE cDNA following the purification of this from adrenal cortex (Xu et 
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at., 1994). Subsequently ECE was cloned from bovine aortic endothelial cells (Ikura 
et al., 1994; Schmidt et al., 1994) and human placental cells (Schmidt et al., 1994). 
The 5 predicted amino acid sequences reveal a high degree of homology with some 
differences in the N-terminal region in 2 of the 3 bovine sequences (Ikura et al., 1994; 
Schmidt et al., 1994). From the experiments outlined in chapter 3 and the 
subsequent publishing of the sequence data for ECE-1, the ECE protein was 
determined to be an integral membrane protein with a single hydrophobic 
transmembrane sequence and a large catalytic domain containing the characteristic 
motif HExxH found in many zinc peptidases. It was also apparent that ECE was a 
highly glycosylated protein with 10 putative N-linked glycosylation sites compared 
with 5 or 6 found in E-24.11. Comparison of the predicted amino acid sequence with 
that of E-24.11 and Kell blood group protein revealed a high degree of sequence 
homology, particularly in the C-terminal region. In addition to sequence homology 
there were also similarities in predicted protein structure. All three proteins were 
found to have a cluster of 4 conserved cysteine residues within a 32 amino acid residue 
sequence immediately following the transmembrane hydrophobic anchor on the C- 
terminal side, a feature also found in brush border membrane hydrolases, sucrase 
isomaltase and y-glutamyl transpepiidase (Hunziker et al., 1986; Laperche et al., 
1986). A comparison of the major features of E-24.11 and ECE-1 can be found in 
Table 1.2. 
All the ECE sequences cloned to date show > 95% homology in the C-terminal 
extracellular domain, however there are notable differences in the N-terminal regions. 
The bovine sequences cloned by Xu et al., (1994) and Ikura et al, (1994) were seen to 
be different from the bovine ECE sequence cloned by Schmidt et al., (1994) in the N- 
terminal 28 amino acid residues. The bovine ECE-1 cDNA sequence cloned by 
Schmidt et al., (1994) had a greater degree of homology in comparison with the rat 
ECE-1 sequence than the other cloned bovine sequences. In addition the cloned, 
sequenced human ECE-1 cDNAs (Schmidt et al., 1994; Yorimitsu et al., 1995) were 
also found to have a higher degree of homology to the rat sequence. The human 
cDNA sequence cloned by Shimada et al. (1994) was different to that cloned by 
Schmidt et al. (1994) at the 5' terminus. It was suggested by Turner & Murphy, 
27 
(1996) that the short form (cytoplasmic N-terminal domain of 51-52 residues) reported 
by Shimada et al., (1994) and later by Schmidt et al., (1994) be designated the a form 
and the longer form (cytoplasmic N-terminal domain of 56 residues) reported by Xu et 
al., (1994); Ikura et al., (1994); Shimada et al., (1995) be designated the ß form. This 
is the nomenclature adhered to throughout this work. To date no reason for the 
production of these isoforms has been identified though current opinion is that they are 
products of alternative splicing (Valdenaire et al., 1995). An alternative system of 
nomenclature has been described by Valdenaire et al. (1995). 
The tissue distribution of ECE mRNA has been examined by Northern blot analysis 
which has revealed abundant expression in lung, pancreas, placenta, adrenal gland, 
ovary and testis (Shimada et al., 1994,1995; Xu et al., 1994; Ikura et al., 1994; 
Schmidt et al., 1994). Shimada et al. (1995) examined the relative tissue distribution of 
ECE-1 a and ß isoform mRNAs in a variety of cells and tissues and found the a form 
to be between 5 and 10 fold more abundant in every case. These data suggested ECE- 
1a to be the physiologically relevant form of the enzyme under normal conditions. 
1.7.4 Tissue distribution of ECE-1 
In situ hybridisation analysis confirmed the expression of ECE-1 mRNA in vascular 
endothelial cells derived from tissues including heart, lung, liver, brain, pancreas, 
adrenal cortex (Xu et al., 1994). This represents a comparatively wide tissue 
distribution and is consistent with the wide distribution of prepro-endothelin and 
endothelin but contrasts with the distribution of E-24.11 which has been found to be 
expressed in renal and intestinal brush border membranes and is constitutively 
expressed by neutrophils (Connelly et al., 1985) and is also expressed in the majority 
of acute lymphoblastic leukaemias where it is referred to as common acute 
lymphoblastic leukaemia antigen (CALLA) or CD 10 (Letarte, 1988; Shipp et at, 
1989). However E-24.11 is expressed at much lower levels in other tissues (Howell et 
al., 1991). 
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1.7.5 Cloning and expression of ECE-2 
In 1995 Emoto and Yanagisawa reported the molecular cloning and expression of a 
novel big ET-1 converting activity, ECE-2 which was shown to cleave big ET-1 at the 
Trp21-Val22bond to produce mature ET-1 both in vitro and in transfected Chinese 
Hamster Ovary (CHO) cells. The cDNA sequence predicted bovine ECE-2 to be a 
metalloprotease structurally related to ECE-1. ECE-2 had 59 % sequence homology 
to ECE-1 and was shown to be potently inhibited by phosphoramidon having 
apparently 250-fold greater degree of sensitivity compared with ECE-1. ECE-2 was 
found to have an acidic pH optimum of 5.5 and was also found to be virtually inactive 
at neutral pH. The same researchers predicted ECE-2 to act as an intracellular enzyme 
since CHO cells which lack detectable levels of endogenous ECE activity were found 
to secrete mature ET-1 into the culture medium following double transfection with 
ECE-2 and pre-pro endothelin cDNAs. In addition it was reported that ECE-2 
transfected CHO cells do not efficiently produce mature ET-1 when cells were 
cultured in media supplemented with big ET-1 through coculture with prepro ET-1 
transfected CHO cells. This evidence was consistent with the endogenous synthesis of 
big ET-1 at the trans-Golgi network where the vesicular fluid would be acidified 
providing optimal conditions for the activity of ECE-2. Since the work by Emoto and 
Yanagisawa (1995) showed ECE-2 to have virtually no activity at neutral pH it has 
been assumed through the course of this work that ECE-2 does not contribute to any 
significant big ET-1 breakdown in the assay system used and therefore all quoted ECE 
activities relate to ECE-1 a and/or ECE-10 and not ECE-2. 
1.7.6 The sub-cellular location of ECE 
Until recently, ECE-1 has been regarded exclusively as an ectoenzyme converting big 
ET-1 to ET-1 at the extracellular face of the plasma membrane. This has been 
supported by a number of studies including immunohistochemical staining of ECE-1 in 
endothelial cells (Takahashi et al., 1995) and the ability of PR to inhibit the formation 
of ET-1 from exogenous big ET-1 (McMahon et al., 1991; Auguet et al., 1992) 
consistent with the localisation of ECE-I at an accessible plasma membrane site. 
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Table 1.2 Comparison of E-24.11, ECE-1 and ECE-2 
Total amino acids 
Molecular weight 
(kDa) 
N-linked 
glycosylation sites 
Zn binding motif 
Cleavage site 
pH optimum 
Localisation 
Phosphoramidon 
sensitivity (Ki) 
E-24.11 ECE-1 
742 or 750 754 or 758 
90-100 120 
5/6 
ECE-2 
787 
120 
10 10 
H-E-I-T-H H-E-L-T-H H-E-L-T-H 
Broad range Trp21-Vain bond of Trp21-Vain bond of 
N-terminal side of big ET big ET 
hydrophobic 
residues 
7.0 6.8 5.4 
Kidney, lung Lung, Heart, Brain 
Small intestine Pancreas, Placenta Uterus 
Striatum Endothelial cells, Testis 
Lymph nodes Brain 
3.5 nM 3.5 µM 4 nM 
Thiorphan 5 nM 200 µM > 200 pM 
sensitivity 
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Studies by Xu et al. (1994) did show PR inhibitable conversion of exogenous big ET-1 
by ECE-1 transfected COS cells though this conversion was found to be relatively 
inefficient with only 5-10 % of big ET-I being converted. The I5o for PR inhibition of 
endogenous big ET-1 hydrolysis was found to be only 100 µM which is consistent with entry of 
1% of PR into cells, compared with 1 pM for exogenous conversion. Since PR is a 
phosphorylated sugar derivative it would not be expected to enter the cells at any 
appreciable rate and would therefore have limited access to the intracellular 
compartment consistent with these data. Double transfection studies in conjunction 
with inhibitor profiles indicated that some of the expressed ECE-1 protein is located as 
an ectoenzyme on the plasma membrane of the cell whilst the majority of ECE activity 
was located intracellularly in a membrane bound compartment, possibly within the 
Golgi apparatus. This hypothesis has been found to be consistent with 
immunohistochemical studies which have shown mature ET-1 in the cytoplasm of 
endothelial cells and the reported ability of a low density intracellular fraction to 
convert big ET-1 to the mature ET-1 peptide (Gui et al., 1993; Harrison et al., 1993). 
More recent evidence for an intracellularly localised ECE-1 is the accumulation of 
ECE-1 when cells are grown in the presence of PR concentrations suggesting this 
increase is mediated by inhibition of intracellular as opposed to cell-surface ECE 
(Schmidt et al., 1994). Whilst it is possible that ECE-1 mediates both cell-surface and 
some intracellular processing it is likely that ECE-2, with an acidic pH optimum of 5.5, 
is responsible exclusively for intravesicular conversion of big ET-1 (Emoto & 
Yanagisawa, 1995). Current opinion is that the intracellular location of ECE-1 is in 
the Golgi (Xu et al., 1994), though this has not yet been confirmed. 
1.8 The existence of a metalloprotease sub-family 
Characterisation of the genes encoding E-24.11 (D'Adamio et al., 1989) and ECE-1 
Valdenaire et al. (1995), allowed comparison of these genes encoding with those 
encoding other zinc metalloproteases. Analysis of gene structure, organisation, 
phylogenetic studies and comparisons of biochemical characteristics revealed the 
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existence of a sub-family of proteins which is now thought to include ECE-1 ((x and ß 
isoforms), ECE-2, and lactococcal endopeptidase. Two other mammalian gene 
products have been shown to exhibit strong homology with E-24.11: the Kell blood 
group antigen of erythrocytes and the putative product of the PEX gene. 
Molecular cloning of the Kell cDNA predicted a protein of 732 amino acids which 
showed both structural and sequence homology with E-24.11 (Lee et al., 1991; 1995). 
In common with E-24.11, the Kell protein was found to have a short N-terminal 
cytoplasmic sequence, a single hydrophobic transmembrane-spanning sequence, a 
cluster of cysteine residues on the extracellular side immediately following the 
transmembrane sequence and a HExxH zinc-binding motif. In addition there is 
conservation of two residues (Glu646 and Hiis711) which are critical for catalytic activity 
in E-24.11 though in common with ECE, Kell lacks a residue equivalent to Arg102 of 
E-24.11 essential for dipeptidylcarboxypeptidase activity suggesting these enzymes act 
predominantly as endopeptidases. To date the physiological substrate of Kell remains 
unidentified. 
The PEX gene product has been implicated in patients suffering from X-linked 
hypophosphataemic rickets (The HYP consortium, 1995). It was found that the PEX 
amino acid sequence shared a high degree of homology to the corresponding 
sequences of E-24.1 1, ECE-1 and Kell suggesting PEX to be a membrane bound zinc 
metallopeptidase and a member of this important sub-family of proteins. 
1.9 Aims of the project 
At the time of the start of this work, there was limited knowledge regarding the 
biochemistry of ECE. Research had shown phosphoramidon inhibitable ECE activity 
distinct from E-24.11 though the 2 activities were thought to be related. In view of 
this one of the initial aims of the project was to establish a sensitive radio-immunoassay 
procedure for detection of ECE activity in a human endothelial cell line which was 
known to express both ECE and E-24.11. Once these activities had been distinguished 
using the assay, a variety of methods were used to establish ECE as a type II integral 
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membrane protein. This was later confirmed to be the case when ECE-1 amino acid 
sequence was determined from the cloning of ECE cDNA. Following the cloning of 
the ECE-1 a and ß isoforms by Schmidt et al. (1994) and Shimada et al. (1995), it 
became possible to raise antibodies specific for each isoform due to N-terminal 
differences in the signal sequence. The procedure of antibody production is outlined in 
chapter 6. The reported expression of ECE-1 a mRNA in TRLEC-03 cells has led 
some researchers to believe that this is the predominant form. 
A further aim of the project was to study possible regulatory mechanisms of ECE 
production. In the course of this work two key compounds were examined to study 
regulatory effects in a variety of cell lines. Phosphoramidon was thought to possibly 
have an up-regulatory effect on ECE production either by increasing the rate of 
biosynthesis or inhibiting a protein responsible for its breakdown (Schmidt et al., 
1994). Cytokine action on endothelial cells had been implicated in the regulation of 
ET-1 expression (Kurihara et al., 1989; Yoshizumi et al., 1990; Shimizu, 1994), and 
this was investigated further using the phosphotyrosine phosphatase inhibitor vanadate. 
The differing actions of each of these treatments aimed to show ECE up-regulation in 
neural and endothelial cell lines. Additional aims of this work were to show that the 
up-regulatory effects were specific for ECE and did not extend to other membrane 
peptidases including the related E-24.11 activity. By examining the effects on ECE 
expression of these compounds, which exert their effects in very different ways, it was 
hoped to gain an insight into the complex mechanisms by which the cell is able to 
regulate ECE activity. 
1.9.1 The use of cell culture as a basis for the investigation of ECE 
Cell culture has become a convenient and powerful research tool for the study of a 
wide and diverse range of proteins. Whilst the technique offers many advantages, it is 
not without some problems. To establish the most effective research system it is 
necessary to consider these and how effective cell culture will address the aims of the 
project. A major advantage of using cell culture is that the general state of the cells 
can be monitored throughout the experiment. It is important that healthy, viable cells 
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are used throughout the experiment, to create a standard population of cells. This is 
particularly important when cells are treated with specific reagents (in the case of this 
work phosphoramidon, thiorphan and sodium orthovanadate) which are cytotoxic at 
higher concentrations. The administration of such compounds to cells and also the 
environment in which they are cultured (media composition, pH, temperature and 02 / 
CO2 levels) can be controlled very precisely. Much less of the compound is required 
and there is no problem with the compound being metabolised by the liver, stored in 
muscles or excreted by the kidney as there would be if animals were used. Cells grown 
in culture remain viable for a much longer period of time, whilst organ cultures or 
primary cell cultures are only viable for hours or days and this allowed sufficient cells 
to be grown to perform all necessary assays. A typical membrane preparation was 
found to yield approximately 5 mg protein and this, coupled with the use of the 
radioimmunoassay procedure sensitive to picomolar levels, provided sufficient cellular 
material, with all the advantages of cell culture outlined above. 
1.9.2 The use of EA. hy926 as a model system for the study of ECE 
The EA. hy926 cell line is a permanent human endothelial cell line resulting from the 
fusion of human umbilical vein cells with the human lung cell carcinoma cell line A549. 
Previous work with this cell line has shown EA. hy926 cells to sustain expression of 
many differentiated functions associated with the vascular endothelium, (Edgell et al., 
1983). Prior to this work, the cell line had previously been shown to express ET-1 
mRNA and to secrete big ET-1 and ET-1 into the culture media, (Saijonmaa et al., 
1991). This evidence suggested that the cell line expressed a specific big ET-1 
processing enzyme and this was a possible candidate for the putative physiological 
endothelin converting enzyme. For this reason the EA. hy926 cell line was used in the 
initial part of this study as a model for the study of ECE biochemistry and regulation of 
expression. Whilst in many ways this cell line is a convenient model for the study of 
ECE (relatively high ratio of ECE activity : E-24.11 activity), any work using cell lines 
is not without problems. Cells which undergo repeat passaging are prone to genetic 
shifts, often changing the phenotype of the cell line. The original work by Edgell et al., 
(1983) tested these cells for the expression of one highly specific function of the 
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vascular endothelium; the expression of factor VIII-related antigen (VIIIRAg). This 
protein is an endothelial cell product (Jaffe et al., 1973) maintained in normal human 
plasma at approximately 10 pg/ml. This protein is also known as Von Willebrand 
factor as decreased levels are found in patients suffering from Von Willebrands disease. 
The expression of VIIIRAg by EA. hy926 cells was found to be consistent through 50 
passages and 3 cloning steps (Edgell et al., 1983 ), indicating EA. hy926 to be a 
permanent cell line. Whilst during the course of this work expression of VIIIR: Ag was 
not monitored there are several indicators that the genotype of the cell line was 
maintained. Repeat passaging of the cells did not result in any morphological change 
in the cells or affect growth characteristics and media requirements. In addition the 
specific activities of several proteases were assayed during the course of this work and 
were found to be consistent throughout, indicating no significant changes to the cell 
line characteristics had occurred. Whilst the EA. hy926 cell line has been used as a 
model system for the study of the physiologically relevant ECE, it cannot be said that 
this truly reflects the conditions of cells in vivo. The transformation of any cell line is 
likely to alter the genotype and therefore enzyme expression by the cell and in addition 
the lack of organised tissue structure in a cultured environment may also contribute to 
promoting changes to the expression of enzymes by the cell. Examples of this include 
E-24.11 expression in vivo on neuronal cells (Barnes et al., 1988) an activity which is 
not expressed on some neuroblastoma cell lines (Medeiros et al., 1991). Such 
differences in peptidase expression were also found in the EA. hy926 cell line which 
was found not to express ACE or DPP-IV activity (chapter 3) although these 
activities have previously been considered to be markers for endothelial cells (Caldwell 
et al., 1976; Walsh et al., 1993). ACE activity has also been found in human umbilical 
vein endothelial cells (HUVEC) (Watanabe et al., 1991 and 1993). Since EA. hy926 
cells did not express these marker activities this cell line cannot be said to reflect the 
true physiological situation of endothelial cells, however since they do show limited 
expression of other membrane peptidases including ECE, they have been used here and 
elsewhere as a model for the study of ECE biochemistry. 
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1.9.3 The selection and use of other cell lines 
Whilst the EA. hy926 cell line was to prove an invaluable and convenient source of 
ECE, the expression of ECE in brain remained a controversial issue (section 1.6.4). In 
order to further understand tissue specific expression of ECE within the brain, several 
brain cell types were examined for the possible expression of ECE and other membrane 
peptidases. The cell lines were selected primarily on the basis of their origin, with the 
intention of attempting to define ECE expression in certain tissues. The cell lines 
selected included glial lines, an astrocytoma clone, a neuroblastoma line and a 
pheochromocytoma with characteristics of cells of the adrenal medulla. 
Through the course of this work, a range of cell types have been investigated for ECE 
expression and possible induction of expression by various agents. Further explanation 
regarding their use is given where they are mentioned. Culture details are given in 
section 2.4. 
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CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Peptidase inhibitors 
Amastatin, Di-isopropylfluorophosphate (Dip-F), 3,4 Di-isochlorocoumarin (DCI), 
ethylenediaminetetra-acetic acid (EDTA), trans-epoxysuccinyl-leucylamido-(4- 
guanido) butane (E-64), enalaprilat and thiorphan ([DL-3-mercapto-2- 
benzylpropanoyl]-glycine) were purchased from the Sigma Chemical Co. (Poole, 
Dorset, U. K. ). Phosphoramidon (N-(a-rhamnopyranosyloxyhydroxyphosphinyl)-Leu- 
Trp) was obtained from Peninsula Laboratories Europe Ltd. (St. Helens, Merseyside, 
U. K. ). Pepstatin A was purchased from the Peptide Institute, (Osaka, Japan). 
2.1.2 Peptides 
Porcine big ET-1 (1-39) and human ET-1 (1-21) were purchased from the Peptide 
Institute, (Osaka, Japan). Succinyl-Ala-Ala-Leu-nitroanilide and Streptomyces griseus 
aminopeptidase (SGAP) were kind gifts from Dr. S. Blumberg (University of Tel Aviv, 
Tel Aviv, Israel). 
BzGly-His-Leu (Hip-His-Leu), L-ala p-nitroanilide and Gly-Prop-nitroanilide were 
obtained from the Sigma Chemical Co. (Poole, Dorset, U. K. ). [D-Ala2, Leu5] 
enkephalin was obtained from Cambridge Research Biochemicals Ltd. (Cambridge, 
U. K. ). Radioiodinated endothelin (I125-ET-1) used for RIA determination of ET-1 was 
purchased from Amersham International Ple. (Amersham, Bucks, U. K. ). 
Synthetic peptides (>80 % purity) used for the production of antibodies to ECE-1 a 
and ß isoforms, (NH3+CTYKRATLDEED-NH2 and NH3+CQRNPFLQGKRG-NH2) 
respectively, were purchased from Zinsser Analytic (U. K. ) Ltd. (Maidenhead, 
Berkshire, U. K. ). Mass spectrometry of these peptides (performed by Dr. J. Keen, 
University of Leeds, Leeds, U. K. ) confirmed both peptides to be > 85 % pure. 
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2.1.3 Antibodies 
The polyclonal antibody RP 161 was generated in rabbits immunised with porcine 
kidney E-24.11 and affinity purified as described in Barnes et al., (1991). Monoclonal 
antibodies, GK4A9 and 3C7 were raised to porcine E-24.11 as described in (Gee et 
al., 1983). The polyclonal antibody (E5) recognising the C-terminal ET-1 (16-21) 
sequence was a gift from Dr. R. Corder (The William Harvey Research Institute, 
London, U. K. ). 
Sheep anti-(rabbit IgG Fc) and normal rabbit serum were obtained from ImmunoGen 
International Ltd. (Gateshead, Tyne and Wear, U. K. ). The monoclonal antibody, AEC 
32-236, raised to rat ECE-1 was a gift from Dr. Tanzawa (Sankyo Co. Ltd., Tokyo, 
Japan). Peroxidase-conjugated rabbit anti-mouse IgG and goat anti-rabbit IgG used as 
second antibodies for protein detection were from Amersham International Plc. 
(Amersham, Bucks., U. K. ). 
2.1.4 Enzymes 
Phospholipase C (PLC) from B. cereus was from Fluka Chemicals (Gillingham, 
Dorset, U. K. ). This commercial preparation of PLC is known to contain 
phosphatidylinositol-specific PLC activity (Ikezawa & Taguchi, 1981; Ferguson et al., 
1985). Endopeptidase E-24.11 was immunoaffinity purified from porcine kidney 
cortex (Gee et al., 1983) by using the monoclonal antibody GK4A9 immobilised to 
Sepharose 4B. Purification of the enzyme to homogeneity was confirmed by SDS- 
PAGE. 
2.1.5 Antibody Production 
All reagents were from the Sigma Chemical Co. (Poole, Dorset, U. K. ), except the 
sulpholink affinity gel which was purchased from the Pierce Chemical Co. (Chester, 
Cheshire, U. K. ). 
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2.1.6 Electrophoresis and western blotting 
Acrylamide/ bis acrylamide stock solution (30% w/v acrylamide- 0.8% w/v bis 
acrylamide was from Severn Biotech Ltd. (Kidderminster, Worcs., U. K. ). Sodium 
dodecyl sulphate, 2-mercaptoethanol, Coomassie blue R250 and bromophenol blue 
were from BDH Chemicals, (Poole, Dorset, U. K. ). Ammonium persulphate, CAPS 
(3- [cyclohexylamino]-1-propanesulfonic acid), TEMED (N, N, N'N- 
tetramethylethylene diamine) and high molecular weight markers were from the Sigma 
Chemical Co. (Poole, Dorset, U. K. ). Immobilon-P PVDF transfer membranes were 
from the Millipore Corporation, (Bedford, MA, U. S. A. ). Enhanced 
chemiluminescence (ECL) Western blotting detection reagents were from Amersham 
International Plc. (Amersham, Bucks., U. K. ). Additional chemicals were of analytical 
grade and supplied by BDH Chemicals Ltd. (Poole, Dorset, U. K. ). 
2.1.7 Cell culture 
Cell culture reagents and flasks were supplied by Gibco BRL, Life Technologies Ltd. 
(Paisley, Scotland, U. K. ). Additional reagents used for studies in membrane peptidase 
expression (sodium orthovanadate, thiorphan, tunicamycin and phenylarsine oxide) 
were obtained from the Sigma Chemical Co. (Poole, Dorset, U. K. ). Phosphoramidon 
was purchased from the Peptide Institute (Osaka, Japan). 
2.1.8 Detergents 
Octyl glucopyranoside and t-octylphenoxypolyethoxyethanol (Triton X-100) were 
obtained from ICN Biochemicals Ltd. (Thame, Oxfordshire, U. K. ) and BDH 
Chemicals (Poole, Dorset, U. K. ) respectively. Triton X-1 14, polyoxyethylene-sorbitan 
monolaurate (Tween 20) and Nonidet P-40 were from the Sigma Chemical Co. (Poole, 
Dorset, U. K. ). 
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2.2 Protein assays 
2.2.1 BCA protein assay 
Protein concentrations were determined by the BCA protein assay (Smith et al., 1985). 
The working reagent was prepared by addition of 4% w/v copper sulphate solution to 
the BCA solution at a ratio of 1: 50. A standard curve using bovine serum albumin 
(BSA) was set using dilutions ranging from 2 Vg to 10 Vg in 10 p1 total volume. 
Unknown samples (10 pl) and standards were mixed with 200 p1 of BCA working 
reagent. The plate was briefly shaken and incubated at 37°C for 30 min. The 
absorbance was then read at 570 nm using an Anthos plate reader, model 2001 
(Anthos Labtech Instruments, Salzburg, Austria), and sample protein concentrations 
were calculated by comparison of absorbance readings with those recorded for a 
standard curve, linear up to 10 Vg of protein. 
2.3 Enzyme assays 
2.3.1 Endopeptidase-24.11 (EC 3.4.24.11) 
Endopeptidase-24.11 (EC 3.4.24.11; neprilysin) was assayed using [D-Ala2, Leus] 
enkephalin (0.5 mM) as substrate and the specificity of breakdown was checked with 
phosphoramidon (10 µM). The Tyr-D-Ala-Gly product was resolved by reverse phase 
HPLC and quantified by measuring absorbance at 214 nm (Turner et al., 1989). 
Endopeptidase-24.11 was also assayed using the colorimetric method described by 
Indig et al., (1989) using Succinyl-Ala-Ala-Leu-nitroanilide (0.4 mM) as substrate, and 
adapted for use on a microtitre plate. Specificity was checked with phosphoramidon 
(10 µM). Endopeptidase-24.11 activity was determined using the rapid colorimetric 
assay unless otherwise stated. 
41 
2.3.2 Dipeptidyl peptidase IV (EC 3.4.15.5) and Aminopeptidase-N (EC 
3.4.11.2) 
Dipeptidyl peptidase-IV (DPP-IV) and aminopeptidase-N (AP-N) assays were 
performed on microtitre plates with Gly-Pro p-nitroanilide (1 mM) and L-Alap- 
nitroanilide (1 mM) as substrates respectively. Thep-nitroanilide product was 
determined spectrophotometrically at 405 nm. Specificity of substrate breakdown was 
checked using Dip-F (1 mM) and amastatin (100 µM) respectively. 
2.3.3 Angiotensin converting enzyme (EC 3.4.15.1) 
Angiotensin converting enzyme (ACE) was assayed using Hip-His-Leu (5 mm) as 
substrate and specificity was checked with enalaprilat (10 µM). The Hip product was 
resolved by reverse phase HPLC and quantified by absorbance at 214 nm (Turner et 
al., 1989). 
2.3.4 Alkaline phosphatase (EC 3.1.3.1) 
Alkaline phosphatase was assayed on microtitre plates using p-nitrophenyl phosphate 
as substrate at pH 10.5. Thep-nitrophenol product was quantified by absorbance at 
405 nm (Bessey et al., 1946). 
2.3.5 Lactate dehydrogenase (EC1.1.1.27) and 5'-nucleotidase 
Lactate dehydrogenase (LDH) was assayed on microtitre plates and determined 
spectrophotometrically according to the method of Schwartz & Bodansky (1966). 
The activity of 5'-nucleotidase was determined by the measuring the release of 
inorganic phosphate from 5'-Adenosine monophosphate (Aronson & Touster, 1974). 
The reaction was carried out in a microtitre plate in a volume of 50 µl and terminated 
by the addition of 50 µl of 12 % SDS. Phosphate was then estimated colorimetrically 
(Ames, 1966). 
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2.3.6 Endothelin converting enzyme 
Endothelin converting enzyme (ECE) was assayed in 50mM Tris/HCl (pH 7.0) 
containing 0.1% w/v BSA and 0.1% w/v Triton X-100 in the presence and absence of 
100 pM phosphoramidon. Membranes (10-20 gg of protein) were incubated with 
inhibitors (pepstatin A, 10 µM; amastatin, 10 µM; E-64,10 µM; 3,4-DCI, 100 µM; 
Dip-F, 1 mM; thiorphan, 10 µM) and incubated at 37°C for 1 h. Reactions were 
started by the addition of big ET-1 to a final concentration of 1 µM (in a total volume 
of 100 µl) and incubated at 37°C for 90 min unless stated otherwise. All reactions 
were stopped by heating at 100°C for 4 min followed by centrifugation (12,000 g, 10 
min) at 4°C. The endothelin produced was then quantified by RIA (2.3.7.1), 
2.3.7 Radioimmunoassay for ET-1 
Endothelin-1 was quantified using a RIA specific for the C-terminal ET-1 (16-2 1) 
sequence. The E5 antibody used in this method was a kind gift from Dr. R. Corder 
(William Harvey Research Institute, St Bartholomew's Hospital, London, U. K. ). This 
antibody had previously been shown to have < 0.015 % cross reactivity with big ET-1 
(Corder et al., 1993) and was raised by injecting rabbits with His-Leu-Asp-Ile-Ile-Trp 
conjugated to bovine thyroglobulin with glutaraldehyde. The antibody as supplied was 
used at a final concentration of 1: 2000. Radioiodinated ET-1 was used as a tracer 
and serial dilutions (7.8 fmol to 4000 fmol) of human ET-1 were used as standards. 
The standard curve is shown in Fig. 2.1. 
2.3.7.1 Radioimmunoassay procedure 
Standards or unknowns (200 µl) were diluted in an appropriate volume of RIA buffer 
(50 mM sodium phosphate containing 0.15 % w/v BSA, 0.005 % v/v Triton X-100 
and 0.01 % w/v sodium azide) and were incubated for 16 h at 4°C with 50 Al antibody 
and 50 µl tracer (8000 c. p. m. ). Sheep anti-(rabbit IgG Fc region) serum (diluted 1: 10 
in RIA buffer, 100 µl) and 100 µl of normal rabbit serum (diluted 1: 70 in RIA buffer), 
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were added to each tube, mixed briefly then incubated for 3h at 4°C. Following 
incubation, 4% w/v polyethylene glycol (500 µl) was added to each tube and bound 
ligand separated from free by centrifugation at 3000 g for 30 min. Scintillation 
counting of the bound ligand complex was used to calculate the relative amounts of 
ET-1 present in the samples. For this a Wallac 1261 Multigamma counter was used 
with RIAcalc software. 
2.3.8 Reverse phase HPLC protocols 
Reverse-phase HPLC was used to monitor angiotensin converting enzyme and 
endopeptidase-24.11 activity. In both cases assay products were separated with a 
µBondapak CIS column (3.9 mm x 300 mm) (Millipore Corporation, Milford, MA, 
U. S. A. ) using a Waters HPLC system. Samples were injected on to the column via a 
Waters 712 WISP and elution was at a flow rate of 1.5 ml/min with a gradient of 4.5 
%-30 % v/v acetonitrile in 0.08 % H3P04 at pH 2.5 followed by 5 minutes elution at 
the final conditions. The column effluent was monitored at 214 nm using a Waters 
tunable absorbance detector. 
2.4 Cell culture 
2.4.1 EA. hy 926 cell culture 
EA. hy926 cells were obtained from Dr. C. -J. S. Edgell (North Carolina, U. S. A. ). The 
EA. hy926 cell line was routinely grown in Dulbecco's modified eagle medium 
supplemented with HAT (100 pM hypoxanthine, 0.4 pM aminopterin, 16 [LM 
thymidine), 40 mM glutamine, 10 % foetal calf serum, 100 IU/ml penicillin and 100 
pg/ml streptomycin at 37°C in 5% CO2 in air. Confluent monolayers were passaged 
using trypsin-EDTA (0.05 %: 0.02 % w/v) and seeded at a density of 0.75 x 106 cells 
per 75 cm2 flask. 
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Fig. 2.1 Radioimmunoassay standard curve for ET-1 
The curve was prepared using increasing concentrations of ET-1 in RIA buffer (7.8 - 
4000 fmoUml). Standards (200 µl of each) were assayed in duplicate as described in 
section 2.3.7.1. Standard curve data were fitted by a four parameter logistic equation 
using the RiaCalc programme (LKB) on line to a multi-head gamma counter (Wallac 
1261 Multigamma). Samples for analysis were diluted appropriately in RIA buffer to 
yield a response (B/Bo) in the range of 0.25 - 0.8. 
o -; - 1 10 100 
(ET-1] (fiwUml) 
1000 10000 
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2.4.2 Culture of other cell lines 
Cells were cultured in either plastic flasks or in 24 well plates. All cell lines, unless 
otherwise stated were cultured in media supplemented with 10 % foetal calf serum and 
maintained at 37°C in 5% CO2 in air. EA. hy926 cells were cultured as described in 
section 2.4.1 . 
C6 (Amberger et al., 1994) and Bu17 (Kametani et al., 1990) cells 
were grown in supplemented Dulbecco's modified Eagle's medium. D384 (Balmforth 
et al., 1986) were maintained in a culture medium (1 : 1) of Ham's F10 and 
Dulbecco's modified Eagle's medium. The neuroblastoma cell line SH-SY5Y (Ross et 
al., 1985) was cultured in a1: 1 mix of Ham's F12 and minimal essential medium 
supplemented with non-essential amino acids ( Murphy et al., 1991). Rat 
pheochromocytoma PC12 cells (Greene & Tischler, 1976) were cultured in RPMI 
1640 supplemented with 5% foetal calf serum and 10 % horse serum. In all cases 
culture media was supplemented with penicillin/streptomycin (100 IU/ml : 10 µg/ml) 
and glutamate (40 mM). Correct media pH was maintained by the addition of NaHCO3 
and NaOH. 
2.4.3 Preparation of EA. hy 926 membranes 
EA. hy 926 cells (cultured as described in 2.4.1) were seeded at a density of 1.5 x 106 
in 150 cm2 flasks. Confluent monolayers were rinsed with PBS, then scraped into 50 
mM Tris-HCI (pH 7.4), containing 100 mM NaCl, 18 mM CaC12, and homogenised by 
N2 cavitation (800 psi at 0°C for 10 min) in a PARR cell disruption bomb. 
Homogenates were centrifuged at 1000 g for 10 min to remove nuclei and cell debris 
and the supernatants centrifuged again (100,000 g, 90 min) to yield a membrane pellet 
which was resuspended in 50 mM Tris-HCI (pH 7.4) containing 100 mM NaCl. 
Resuspended membranes were either assayed immediately or stored at -70°C. 
2.4.4 Porcine lung membrane preparation 
All operations were performed at 4°C. Fresh porcine lung (<2 h old) was washed in 
10 mM Tris-HCI (pH 7.4 ) to remove excess blood and then cut into small pieces. 
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The washed porcine lung tissue (300 g) was homogenised in 3 vol. 10 mM Tris-HC1 
pH 7.4 ) and centrifuged at 1000 g for 15 min. The supernatant was removed and 
filtered through a1 mm pore nylon mesh and the filtrate retained as the post nuclear 
fraction. This fraction was then centrifuged at 150,000 g for 40 min to obtain the 
membrane fraction (pellet) and cytosolic fraction (supernatant). The membrane pellet 
was resuspended in 10 mM Tris-HC1(pH 7.4) to give a membrane preparation with a 
final concentration of approx. 10 mg/ml. 
2.4.5 Preparation of kidney brush border membranes 
Kidney brush border membranes were prepared according to the method of Booth & 
Kenny (1974), with the exception that all 12,000 g centrifugation steps were increased 
to 15,000 g. 
2.4.6 Preparation of reagents used for regulation studies 
Thiorphan, phosphoramidon and tunicamycin were dissolved in Millipore grade water 
to a final concentration of 10 mM, sterilised by passing through a 0.2 µm filter and 
aliquots stored frozen at -20°C. For treatment of cell cultures, aliquots were thawed 
and further diluted in the appropriate amount of cell culture media. Sodium 
orthovanadate was activated prior to use according to the method of Mahadevan & 
Bell, (1989). Briefly, a 10 mM solution of Na3VO4 was adjusted to pH 10.0 using 
either NaOH or HCI. The solution was boiled then cooled to room temperature and 
the pH re-adjusted to 10.0. This procedure was repeated until the solution remained 
colourless at room temperature. Aliquots were stored frozen at -20°C. Phenylarsine 
oxide was dissolved in acidified DMSO and added to cell culture media immediately. 
2.4.6.1 Application of reagents used for expression regulation studies 
Frozen aliquots of thiorphan, phosphoramidon, tunicamycin or sodium orthovanadate 
were thawed and passed througha 0.2 µm filter then diluted with cell culture media to 
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give a final concentration of 1 mM. Appropriate volumes of this solution were added 
to cultured flasks or plates of cells to give the desired final concentration. 
2.5 Solubilisation of cell membranes 
2.5.1 Detergent solubilisation 
Triton X-100 detergent solubilisation of EA. hy926 membranes was performed in 
detergent solubilisation experiments and in preparation for immunoadsorption 
experiments using the GK4A9 immunoaffinity column. All operations were performed 
at 4°C. Triton X-100 in 10 mM Tris-HCI (pH 7.4) was added to EA. hy926 
membranes to give a final protein concentration of 1 mg/ml of protein and a final Triton 
X-100 concentration of 7 mg/ml (i. e. a ratio of 7: 1, detergent : protein). The 
detergent/membrane suspension was gently agitated for 1 h, then centrifuged at 
100,000 g for 90 min to obtain the detergent-solubilised membrane preparation. 
2.5.2 Precondensation of Triton X-114 
Triton X-1 14 used for temperature induced phase separation was precondensed before 
use by the method of Bordier, (1981). Butylated hydroxytoluene (16 mg) was 
dissolved in 20 g of Triton X-1 14. This solution was added to 980 ml of 10 mM Tris- 
HCI, 150 mM NaCl, pH 7.4 and incubated at 0°C for 4 h. After incubation the 
solution was transferred to a 30°C water bath and incubated overnight to allow 
condensation of the detergent. Following this the large aqueous phase was removed 
from above the smaller detergent enriched phase and replaced with an equal volume of 
10 mM Tris-HCI, 150 mM NaCl, pH 7.4. The solution was mixed and the 
condensation repeated a further two times. Following the third condensation the upper 
aqueous phase was removed and discarded. The concentration of detergent in the final 
lower phase was determined by comparing the absorption at 280 nm before and after 
condensation. The precondensed Triton X-114 was then stored at room temperature. 
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2.5.3 Temperature-induced phase separation of proteins 
Temperature-induced phase separation was carried out according to the method of 
Bordier (1981). EA. hy926 membranes were prepared as described in section 2.4.3. 
Cell membranes (50 µl, 0.5 mg/ml) were diluted to a total volume of 250 µl in 10 mM 
Tris-HCI, 0.15 M NaCl, 1% v/v Triton X-114, pH 7.4. Temperature-induced phase 
separation was performed by incubating on ice for 5 min and layering the solution on 
to a sucrose cushion (300 µl of 6% w/v sucrose, 10 mM Tris-HCI, 0.15 M NaCl, 
0.06 % v/v Triton X-114, pH 7.4). This was then incubated at 30°C for 3 min then 
centrifuged at 3000 g for 3 min using an MH2 Desaspeed centrifuge (Sarstedt, 
Leicester, U. K. ). The upper aqueous phase was removed and fresh Triton X-114 was 
added to a final concentration of 0.5 % v/v. This sample was phase separated as 
described above and the aqueous phase removed. Triton X-114 was then added to a 
final concentration of 2% (v/v) then again phase separated. The resultant supernatant 
(0.15 ml) was removed, this representing the aqueous phase and the remainder, 
representing the detergent-rich phase was made up to a total volume of 0.15 ml with 
10 mM Tris-HC1 , 
0.15 M NaCl, pH 7.4. The aqueous and detergent-rich phases were 
then assayed for several membrane peptidase activities and protein concentration. 
2.5.4 Detergent solubilisation profiling 
EA. hy926 cell membranes (1 mg/ml), prepared as described in 2.4.3, were incubated 
with rotation at 4°C in 10 mM HEPES (pH 7.4). Enzyme activities were determined 
in the total incubation mixture and in the supernatant following centrifugation at 
31,000 g for 90 min. Detergent solubilised activity was expressed as a percentage of 
the total activity in the original incubation sample. The detergents used with CMC 
data and the actual concentration used were octyl glucopyranoside (CMC 25 mM ; 
concentration used, 60 mM ): Nonidet P-40 (0.29 mM; 6.1 mM) and Triton X-100 
(0.24 mM; 5.9 mM). 
2.5.5 Solubilisation of membrane proteins with phospholipase C 
EA. hy926 cell membranes (1 mg/ml) prepared as described in 2.4.3 were incubated 
with rotation for 2h at 37°C in 10 mM Tris-HCI (pH 7.4) with up to 2 units of B. 
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Cereus PLC in a total volume of 1 ml. Following incubation membranes were 
centrifuged (31,000 g, 90 min) and assayed for membrane peptidase activity. (1 unit 
corresponds to the amount of PLC needed to hydrolyse 1 µmol of L-(x- 
phosphatidylcholine per min at pH 7.5 and 37°C). 
2.6 Separation and detection of proteins by PAGE 
2.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to the method of Laemmli (1970) on 10 % w/v polyacrylamide 
mini-slab gels, or 5%-20% w/v polyacrylamide gradient gels. Non-reducing SDS- 
PAGE samples were prepared by dilution with SDS dissociation buffer to give a final 
concentration of 62.5 mM Tris-HCI, pH 6.8 containing 3% w/v SDS, 10% v/v glycerol 
and 0.001% bromophenol blue. Samples for reducing SDS-PAGE were prepared with 
2-mercaptoethanol to a final concentration of 5% v/v. In all cases samples, including 
molecular weight markers were heated to 100°C for 4 min then centrifuged at 10,000 g 
for 5 min prior to loading. All gels were run at constant voltage (80 V) for up to 2 h. 
High molecular weight standard markers were from Sigma and consisted of: myosin 
(Mr 205,000), ß- galactoside (Mr 116,000), phosphorylase b (Mr 97,400), ovalbumin 
(Mr 45,000) and carbonic anhydrase (Mr 29,000). Medium weight molecular weight 
markers used to monitor antibody purification were from BDH Chemicals Ltd and 
consisted of ovotransferrin (Mr 76-78,000), albumin (Mr 66,250), ovalbumin (Mr 
42,500), carbonic anhydrase (Mr 29,000), myoglobin (Mr 17,200) and cytochrome c 
(Mr 12,300). 
2.6.2 Staining of acrylamide gels 
Acrylamide gels were stained using Coomassie blue (30 min), except in the monitoring 
of antibody purification for which the more sensitive technique of staining using silver 
nitrate was used (Oakley et al., 1980). 
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2.6.3 Immunoelectrophoretic (Western) blotting. 
Proteins separated by electrophoresis were electophoretically transferred (30 mA 
constant current for 80 min) in CAPS-NaOH (pH 11.0) containing 10% methanol to 
an Immobilon-P PVDF membrane (Millipore). The transferred marker lane was cut 
from the membrane and stained with a solution of 25% isopropanol, 10% acetic acid 
and 0.1% Coomassie blue R250 followed by destaining using a solution of 5% v/v 
isopropanol and 10% v/v acetic acid. The remainder of the membrane was washed in 
TBST (10 mM Tris-HCI, pH 7.4, containing 150 mM NaCl and 0.1% Tween 20) and 
incubated at room temperature in: blocking buffer (5% w/v low fat milk powder in 
TBST) for 1 h; ECE antibody (AEC32-236, raised to rat ECE) at a concentration of 
20 µg /ml in TBS containing 0.02% sodium azide for 1h and peroxidase-conjugated 
rabbit anti mouse IgG or goat anti rabbit IgG (Amersham), diluted 5000 fold in TBST 
for 1 h. Between each incubation, the membrane was washed liberally with TBST for 
40 min. Protein bands were visualised using the ECL detection system (Amersham) 
according to the manufacturer's instructions. 
2.7 Production of anti-peptide antibodies 
2.7.1 Coupling of peptides to keyhole limpet haemocyanin (KLH) 
Peptides 1 and 2, NH3+CTYKRATLDEED-NH2 and NH3+CQRNPFLQGKRG-NH2, 
respectively, were coupled to KLH through the cysteine residue of the peptide as 
described by Stephenson & Duggan (1991). KLH (20 mg/ml) was dissolved in 10 mM 
potassium phosphate (pH 7.2), dialysed overnight at 4°C against 10 mM potassium 
phosphate (pH 7.2) and then the concentration was adjusted to 16 mg/ml. This 
preparation (250 µl) was mixed with MBS (m-maleimidobenzoyl-N- 
hydroxysuccinimide ester (3 mg/ml in dimethyl formamide) for 30 min at room 
temperature. Unbound MBS was removed by gel filtration through a column of 
Sephadex G-25 equilibrated with 50 mM potassium phosphate (pH 6.0). Fractions of 
0.5 ml were collected and elution of the KLH-MBS complex was followed by 
measuring absorbance at 280 nm. KLH-MBS (3 ml) was mixed with iml of peptide 
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solution (5 mg/ml in 10 mM potassium phosphate, pH 7.2), the pH adjusted to 7.4 and 
the solution mixed by gentle rotation for 3h at room temperature. Solid NaCl was 
added to a final concentration of 0.09% (w/v). Aliquots of the peptide conjugate were 
stored at -20°C until required for injection. Efficiency of peptide coupling was 
monitored using the Ellman reaction (Ellman, 1959). 5,5'-Dithio-bis(2-nitrobenzoic 
acid) (DTNB) (4 mg/ml) was freshly prepared in 0.1 M sodium phosphate buffer (pH 
8.0) and 20 pl of this solution was mixed with 20 pl of samples taken before and after 
peptide coupling. Absorbance at 405 nm was measured to determine the relative 
concentration of free sulphydryl groups remaining and uses a molar extinction 
coefficient for the thionitrobenzoate anion of s= 14,100 M'1 cm 1. 
2.7.2 Antiserum production 
Two male New Zealand White rabbits were injected per peptide. Rabbits were 
immunised by a series of sub-cutaneous injections of KLH-conjugated peptide (each 
containing 0.25 - 0.5 mg of peptide) at 3 week intervals (Widdows et al., 1987). The 
first sample was mixed with an equal volume of Freund's complete adjuvant whilst 
subsequent booster injections were performed using samples mixed with an equal 
volume of Freund's incomplete adjuvant. Maintenance of the rabbits and all 
immunisation procedures were carried out by the staff of the University of Leeds 
animal house. 
2.7.3 Coupling of peptide to resin 
Synthetic peptide (3 mg) was dissolved in 50 mM Tris-HCI, 5 mM EDTA, pH 8.5. 
DTT 0.5 M, (50µl) was added and the solution incubated under nitrogen for 1h at 
room temperature. The reduced peptide was then separated from excess DTT on a 
Sephadex G-10 column equilibrated in 50 mM Tris-HCI, 5 mM, pH 8.5. Fractions of 
1 ml were collected and monitored for absorbance at 280 nm. The peak void volume 
fractions were pooled and the second, larger peak containing only DTT was 
discarded. Sulpholink coupling gel (3 ml) was washed at 25°C in a sintered glass 
funnel with 50 mM Tris-HCI, 5 mM EDTA, pH 8.5 (20 ml). The gel was then 
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centrifuged (400g, 2 min) and the supernatant removed. The peptide solution eluted 
from the G-10 column was incubated with the sulpholink gel for Ih in the dark with 
gentle rotation, then centrifuged (400 g, 2 min) and the supernatant removed. 
Efficiency of peptide coupling was then assessed using the Ellman reaction (Ellman 
1959) to compare the sulphydryl content of duplicate samples (100 RI) of the final 
supernatant with that of the peak fractions from the G-10 eluate. Excess peptide was 
removed by washing the gel with 50 mM Tris-HCI, 5 mM EDTA, pH 8.5. This was 
repeated a further 4 times. The gel was then incubated for 1h at 25°C with 50 mM 
cysteine in 50 mM Tris-HCI, 5 mM EDTA, pH 8.5. Following transfer to a sintered 
filter funnel the gel was washed repeatedly with 1M NaCl. The gel was equilibrated in 
PBS containing 0.02 % w/v sodium azide and stored at 4°C. 
2.7.4 Affinity purification of antisera 
The peptide-sulpholink affinity gel, synthesised as described in section 2.7.3 was 
washed with 250 ml of PBS. Antisera (5 ml) were passed through an 80 µm filter and 
incubated with the gel overnight at 4°C with gentle agitation. The gel was transferred 
to a column and washed at 10 ml/h with 10 mM sodium phosphate buffer containing 
800 mM NaCI (pH 7.2). Eluted fractions of 1 ml were collected and the absorbance 
at 280 nm monitored. When the absorbance of the eluted fractions had decreased to 
<0.05, the antibody bound to the column was eluted by washing the column with 0.2M 
glycine-HCI, pH 2.4 and by collecting 1 ml fractions into tubes containing 1M Tris- 
HCI buffer (pH 8.0). Absorbance at 280 nm was again monitored and peak fractions 
with an absorbance of >0.05 were combined and dialysed against 1L PBS for 24 h at 
4°C. Antibodies were concentrated by PEG dialysis followed by dialysis against 1L 
PBS for 24 h at 4°C. Antibodies were then dialysed against PBS containing 0.02 % 
w/v sodium azide and stored at 4°C. Following elution, the peptide-sulpholink affinity 
gel was equilibrated with PBS until the pH returned to 7.5. The column was then 
stored in PBS containing 0.02 % sodium azide. 
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2.7.5 E. L. I. S. A. (Enzyme-linked immunosorbent assay) 
Immunoreactivity of test bleeds taken from immunised rabbits was monitored by using 
an adaptation of the methods of Stephenson & Duggan (1991) and Howell et al., 
(1991). Pro-bind 96-well plates were coated with 80 Al peptide per well (0.25 gg/ml 
in 50 mM NaHCO3,10 mM NaOH, pH 9.6) overnight at room temperature. The 
plates were then washed five times with phosphate buffered saline (PBS), 0.05 % v/v 
Tween-20 and each well then incubated with 200 Al of PBS containing 5% (w/v) low- 
fat milk powder for 2 hours at 37°C. Washing was repeated and antisera added in 
serial dilutions in antibody buffer (PBS containing 1% low-fat milk powder) and 
incubated overnight at 37°C. The plates were again washed and then incubated with 
100 Al horseradish peroxidase linked IgG (goat anti-(rabbit IgG) IgG) diluted 1: 
1000 in antibody buffer, for I hat 37°C. The washing was repeated and 100 Al of 
substrate solution added to each well, (0.55 mg/mi 2,2'-Azino-bis(3- 
ethylbenzthiazoline-6-sulphonic acid) (ABTS) with 0.01 % v/v H202 in citrate buffer 
(2.85 ml of 0.1 M citric acid and 21.5 ml of 0.2 M sodium phosphate made up to a 
total volume of 50 nil with millipore grade H2O). The plate was then incubated at 
room temperature in the dark for 30 min. After 30 min the reaction was terminated by 
the addition of 100 Al of 0.1 M citric acid to the wells and absorbance measured at 405 
nm using an Anthos 2001 plate reader. Each sample was tested in quadruplicate using 
the complementary peptide as a control to detect non-specific antigen recognition. 
2.7.6 Western blotting of transfected cell lines 
The specific recognition of the ECE-1 a isoform by purified antibodies was monitored 
using western blotting of membranes prepared from transfected and non-transfected 
COS and chinese hamster ovary cells (CHO). These membranes were provided by M. 
V. Hoang and C. D. Brown (University of Leeds, Leeds, U. K. ). Briefly, the 
expression vectors pcDL-SRa296/rECE-la and pcDL-SRa296/rECE-lß were used 
to transfect COS and CHO cells. The cells were transfected at 50 - 80 % confluence in 
175 m12 flasks. Plasmid DNA (88 µg) was added to 4.4 ml of OptiMem and 200 µl of 
Lipofectamine reagent was added. This mixture was incubated at room temp. (20 min) 
54 
then added to the cells which were first washed with OptiMem. The cells were 
incubated with the DNA complexes for 3h at 37°C, 5% CO2. An equal volume of 
growth medium was added without removing the transfection mixture. All media were 
replaced after 24 h. Cells were collected and membrane fractions prepared 48 h after 
transfection. 
2.8 Immunoadsorption of peptidase activities 
2.8.1 Coupling of antibody to cyanogen-bromide activated Sepharose 4B 
Affinity purified GK4A9 antibody (5 mg/ml, 1m1), previously dialysed against 0.25 M 
NaHCO3/ NaOH, 0.5 M NaCl, pH 8.7 (coupling buffer) was coupled to cyanogen 
bromide-activated Sepharose 4B beads (1 ml swollen beads) according to the 
manufacturer's instructions. The coupling procedure was performed at room 
temperature for 2h after which the remaining active groups on the gel matrix were 
blocked by transferring the gel and resuspending in 0.2 M glycine, pH 8.0 for 2h at 
room temperature. Excess glycine was removed by alternate washing with 1M 
sodium acetate buffer (pH 4.0) and coupling buffer (pH 8.7). The gel matrix with 
coupled antibody was transferred to PBS containing 0.02 % w/v sodium azide and 
stored at 4°C. 
2.8.2 Immunoadsorption of membrane peptidase activities 
GK4A9, a monoclonal antibody was immobilised to Sepharose 4B beads as described 
in section 2.8.1. The immunoaffinity beads were stored in a1: 1 suspension of beads 
: buffer. Immunoaffinity column volumes were determined by measuring a known 
volume of this suspension and sedimenting beads by centrifugation at 10,000 g for 2 
min. The supernatant was removed and discarded, the beads resuspended and 
incubated at 4°C with rotation in an equal volume of 0.1 M Tris-HC1 (pH 7.5), 
containing 1M NaCl and 3.5 % w/v Triton X-100. Beads were again sedimented 
(10,000 g, 2 min. ) and the supernatant removed. The precipitated beads were then 
incubated with rotation with a standard volume (500 µl ) of detergent solubilised 
55 
membrane sample (w/w ratio of 7: 1, detergent : protein) for 16 hat 4°C. Samples 
were centrifuged (400 g, 2 min), supernatants collected and assayed for E-24.11, AP- 
N, ECE and protein, comparing activities found in the immunoadsorbed samples with 
those found in the original detergent solubilised sample. Beads were washed with 0.2 
M glycine, then equilibrated in PBS (pH 7.4) containing 0.02 % w/v sodium azide. 
The beads were then stored at 4°C. 
56 
CHAPTER THREE 
THE BIOCHEMISTRY OF ECE 
3.1 AIMS 
To characterise the human endothelial cell line, EA. hy926 with regard to 
peptidase content and to assess its suitability for the study of ECE. 
To determine the type of membrane anchorage by which ECE associates with 
the membrane. 
To screen mono and polyclonal antibodies against E-24.11 for cross reactivity 
with ECE. 
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3.2 Introduction 
In the initial stages of this work there was limited knowledge regarding ECE activity 
and the biochemical nature and characteristics of this protein. The human endothelial 
cell line, EA. hy926, had previously been found to show sustained expression of many 
functions associated with the vascular endothelium (Edgell et al., 1983) and had also 
been found to express big ET-1 mRNA and to secrete ET-1 into the culture medium 
(Saijonmaa et al., 1991), suggesting this cell line did express ECE activity. For this 
reason, EA. hy926 was used as a model system for the study of ECE. The potential 
benefits and problems associated with tissue culture compared with the use of primary 
tissue types are discussed further in section 1.9.1. 
The early work of this project involved the optimization of conditions for the 
preparation of cell membranes from these cells and the assay of enzyme activities in the 
membrane fraction. A number of membrane peptidases were assayed to produce a 
profile of peptidase expression in this cell line which was used later in comparison with 
other cell lines and to determine the effects on expression of peptidases in response to 
peptidase and tyrosine phosphatase inhibitors. 
Having established EA. hy926 as a cell line suitable for the study of the physiological 
ECE protein, the work focused on the identification of the anchorage mechanism by 
which the ECE protein associates with cellular membranes. This work relied on 
detergent solubilisation techniques and involved comparisons with E-24.11 which was 
known to be a type 11 integral membrane protein. 
At the time of this part of the work, no antibodies to ECE were available. As a 
method of overcoming this problem existing polyclonal and monoclonal antibodies 
raised to E-24.11 were examined for possible co-recognition of ECE. The primary 
objective of this part of the study was to investigate the possibility of a rapid 
purification of ECE from cell membrane preparations. 
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3.3 Membrane peptidase expression in EA. hy926 cells 
3.3.1 Expression of E-24.11 by EA. hy926 cells 
In order to characterize the levels of expression of E-24.11 by EA. hy926 cells and also 
to determine the suitability of the RP 161 polyclonal antibody to E-24.11 for use in 
western blotting, EA. hy926 membrane preparations were prepared as described in 
section 2.4.1 and subjected to SDS-PAGE and western blotting (Fig. 3.1). Kidney 
brush border membranes, known to be a rich source of E-24.11 were examined in 
parallel with various amounts of EA. hy926 membrane preparation. 
As expected, E-24.11 was strongly detected in the kidney brush border membrane 
preparation (Mr 90 kDa) and the specificity of the antibody was supported by the fact 
that no other protein bands were detected. The expression of E-24.11 by EA. hy926 
cells was also confirmed by immunoblotting (Fig. 3.1) and enzyme assay which showed 
E-24.11 levels to be <1 % of those found in kidney brush border membrane 
preparations. 
Significantly, the RP 161 polyclonal antibody did not reveal immunorecognition of any 
protein of molecular weight >90 kDa indicating this antibody had no immunoreactivity 
towards ECE. 
3.3.2 Profile of membrane peptidase activities 
Initial studies using the EA. hy926 cell line involved assaying membrane preparations 
for a range of peptidase activities. Six different membrane preparations were assayed 
for each activity. All assays were conducted in parallel with kidney brush border 
membranes except for ECE which, due to the high levels of E-24.11, precluded an 
accurate determination of ECE in these membranes. 
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Fig. 3.1 Detection of the E-24.11 protein expressed by EA. hy926 cells by western 
blotting of membrane preparations using the polyclonal antibody RP161 
90kDa 
1 2 
Flask cultured EA. hy926 cells were grown until confluent and then harvested and 
membranes prepared as described in section 2.4.1. Cell membranes prepared from 
EA. hy926 cells were loaded on lane 1 (15 µg protein) and membranes prepared from 
fresh pig kidney (5 µg) were loaded into lane 2. Proteins were separated by gel 
electrophoresis using a 10 % SDS-polyacrylamide gel followed by immunoblotting 
with the polyclonal E-24.11 antibody, RP 161. 
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Enzyme assay of membranes prepared from EA. hy926 cells failed to detect ACE and 
DPP-IV activities, often considered to be markers of the endothelial cell phenotype. 
This finding may have been due to the limits of sensitivity of the assay but was 
supported by attempted immunostaining for both activities which showed neither to be 
present in this cell line (Dr. K. Barnes, unpublished data). 
Other activities assayed included AP-N, E-24.11 and ECE which were all found to be 
expressed by this cell line, indicating EA. hy926 cells to be a suitable endothelial model 
system. The specific activity of E-24.11 activity relative to ECE showed this cell line 
could be used for the study of ECE since virtually all the E-24.11 big ET-1 degrading 
activity could be selectively inhibited by thiorphan. The reproducibility of these values 
over six different membrane preparations showed expression levels to be essentially 
constant at the time at which cells were harvested. Table 3.1. 
3.4 Identification of the ECE membrane anchor 
3.4.1 Temperature-induced phase separation of membrane proteins 
Integral membrane proteins are characterised by the presence of a hydrophobic domain 
which interacts directly with the hydrophobic core of the lipid bilayer (Tanford & 
Reynolds, 1976). Triton X-114 is effective at solubilising membrane proteins at low 
temperatures forming mixed detergent-protein micelles (Egan et al., 1976). Phase 
separation of Triton X-114 (Bordier, 1981) occurs at 30° C and results in the 
formation of two separate phases. The mixed micelles of amphiphilic proteins and 
detergent were found to aggregate with the remaining detergent while hydrophilic 
proteins, which have lost their hydrophobic membrane anchoring domain were found 
to remain in the aqueous phase. This allows the effective separation of membrane- 
bound from cytosolic and peripheral membrane proteins. Temperature-induced phase 
separation of proteins expressed by EA. hy926 cells was performed according to the 
method described in section 2.5.3. The partitioning of E-24.11, ECE and LDH was 
compared by determination of the percentage of the total activity found localised in the 
detergent-rich phase (Table 3.2). 
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Table 3.1 Profile of specific activities of membrane peptidases expressed in 
EA. hy926 endothelial cells 
Membrane Peptidase EA. hy926 Kidney Brush Border 
E-24.11 4.9 t 0.2 576.8 ± 30.1 
AP-N 23.3 ± 4.8 232.2 f 9.8 
DPP-IV N. D 284.1 ± 14.7 
ACE N. D 296.6 ± 15.6 
ECE 1.5 ±O. 1 N. A 
Specific activities are given in nmol/min/mg except the value for ECE which is given as 
pmol/min/mg. 
N. D Activity not detected 
N. A Activity not available. The high expression levels of E-24.11 found in kidney 
brush border membranes, coupled with the relatively low levels of ECE in this tissue 
type precluded determination of ECE activity. 
Specific activities of a range of membrane peptidases were determined in membrane 
preparations from EA. hy926 cells and compared with the activities found in 
membranes prepared from kidney brush borders. E-24.11 and ACE were assayed 
using the HPLC methods described in section 2.3.1 and 2.3.3. DPP-IV and AP-N 
were assayed using the spectrophotometric methods described in sections 2.3.2. ECE 
was assayed using the radioimmunoassay protocol described in section 2.3.6 and 2.3.7. 
Results are the mean of 6 experiments ± S. E. M. 
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Table 3.2 Temperature-induced phase separation of E-24.11, ECE and lactate 
dehydrogenase (LDH) 
Total Activity Recovered in the 
Activity Detergent-Rich Phase (%) 
E-24.11 
ECE 
LDH 
87.3 ± 6.7 
78.2 ± 7.2 
12.4 ± 7.8 
Membranes prepared from EA. hy926 cells were subjected to temperature-induced 
phase separation using Triton X-114 as described in section 2.5.3. Following the 
recovery of the detergent-rich phase, enzyme assays were performed and the activities 
of E-24.1 1, ECE and LDH determined in this phase and compared to the total activity 
in untreated membrane preparations. Results are given as the mean ± S. D. for 6 
separate experiments. 
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LDH a known cytosolic protein was found to partition predominantly in the detergent- 
depleted phase. In contrast, the majority of both ECE and E-24.11 activity was found 
to be located in the detergent-rich phase. These data suggested that ECE, like E-24.11 
was an integral membrane protein. 
3.4.2 Detergent solubilisation profiles of membrane peptidases in EA. hy926 Cells 
Detergent solubilisation profiling is a useful technique used for distinguishing between 
G-PI (glycosyl-phosphatidylinositol) anchored and transmembrane proteins (Hooper & 
Turner, 1988 a, b; Hooper, 1992). Differentiation of G-PI and non G-PI anchored 
proteins is accomplished on the basis of the ability of detergents of varying critical 
micellar concentrations (CMC) to solubilise proteins to differing extents. In this study 
the solubilisation profile of E-24.11 and ECE was compared with that of an established 
G-PI anchored protein, 5'-nucleotidase (Fig. 3.2). 5'-nucleotidase was assayed in 
preference to alkaline phosphatase (EC 3.1.3.1) (section 2.3.4) since the assay was less 
susceptible to interference due to the detergent content of the samples. 
Three detergents of varying CMC were used to solubilise each activity. Whilst 
detergents of relatively high CMC, including octyl glucoside and Nonidet P-40, were 
adept at solubilising all three activities it can be seen that a detergent with a low CMC 
such as Triton X-100 is unable to solubilise the G-PI anchored protein. This pattern of 
solubilisation suggested neither ECE nor E-24.11 was G-PI anchored and the similar 
solubilisation profile of E-24.11 and ECE further suggested close topological 
similarities between the two peptidases. 
3.4.3 Bacterial phospholipase C solubilisation of EA. hy926 membrane proteins 
A property of G-PI anchored proteins is the ability of most of these to be released from 
cell membranes by the degradation of the G-PI moiety by bacterial phosphatidylinositol 
specific phospholipase C (PLC). It was the discovery of this property which gave the 
first indications of the existence of G-PI anchored proteins (Low, 1989,1990). 
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Fig. 3.2 Detergent solubilisation profile of E-24.1 1, ECE and 5'-nucleotidase 
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Cell membranes prepared from EA. hy926 cells (1 mg/ml) were solubilised with 
detergents of various critical micellar concentrations (section 2.5.4). Assays were 
carried out to determine the extent to which each detergent was able to solubilise E- 
24.1 1 and ECE. The HPLC protocol (section 2.3.1) was used to assay E-24.11 
activity since this method was found to be less susceptible to interference by 
detergents. These data were compared with the solubilisation of a known G-PI 
anchored protein, 5'-nucleotidase assayed as described in section 2.3.5. 
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Table 3.3 Solubilisation of membrane proteins using bacterial 
phosphatidylinositol-specific phospholipase C 
Activity Total activity solubilised (%) 
E-24.11 22.1 ± 9.1 
ECE 13.7 ± 5.2 
5'-nucleotidase 74.9 ± 7.6 
Cell membranes prepared from EA. hy926 cells were incubated with bacterial 
phosphatidylinositol specific phospholipase C and the solubilised fractions retrieved 
(section 2.5.5). The results are the means ± S. D. for four separate experiments. 
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EA. hy926 membranes (lmg/ml) were incubated with a commercial preparation of PLC 
from B. Cereus for 2h at 37°C and peptidase activities assayed in the supernatant to 
determine the extent of solubilisation. The results are shown in Table 3.3. 
The percentage of ECE and E-24.11 activity solubilised by PLC was relatively low and 
probably due to contamination of the PLC preparation with protease activity. The 
inability of PLC to solubilise either activity to a major extent supported the evidence 
that neither ECE nor E-24.11 was anchored by a G-PI moiety and these two proteins 
shared the same membrane anchorage. This was ultimately confirmed when ECE was 
finally purified, cloned and sequenced (Xu et al., 1994; Shimada et al., 1994; Schmidt 
et al., 1994; Ikura et al., 1994; Yorimitsu et al., 1995). 
3.5 Recognition of ECE by antibodies raised to E-24.11 
Prior to the purification, cloning and sequencing of ECE, no antibodies were yet 
available to the protein. Evidence was mounting that both E-24.11 and ECE shared 
many common biochemical characteristics and it was therefore considered likely that 
these proteins originated from the same peptidase family, suggesting the possibility of a 
degree of sequence homology between the two. The purpose of this work was to 
investigate whether monoclonal antibodies to E-24.11 might share a common epitope 
with ECE. Further studies investigated whether this approach might prove useful for 
rapid purification of ECE. 
3.5.1 Immunoprecipitation of ECE and E-24.11 by GK4A9 
A monoclonal antibody raised to E-24.11, GK4A9 (Gee & Kenny, 1985) was 
immobilised on Sepharose as described in section 2.8.1. Volumes of GK4A9 coated 
Sepharose beads (Oµ1 to 300µl) were incubated with Triton X-100 solubilised 
EA. hy926 cell membranes (0.5 mg protein) and the beads precipitated by 
centrifugation. The specific activities of E-24.11, ECE and AP-N and protein content 
were determined in the immunodepleted supernatants and given as a percentage of 
total activity in untreated membranes (Fig. 3.3). 
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These data showed ECE and E-24.11 to co-precipitate when incubated with GK4A9 
coated Sepharose beads. The control incubation of CNBr activated Sepharose beads 
with no GK4A9 attached did not show any reduction in either of these activities 
suggesting specific immunorecognition by GK4A9 of both ECE and E-24.1 1. The 
specificity of this binding was further supported by the finding that there was no 
significant reduction in protein nor AP-N activity. The effectiveness of the 
immunodepletion of E-24.11 activity from EA. hy926 cells using this antibody is 
demonstrated by immunoblotting with the RP161 polyclonal antibody to E-24.11 (Fig. 
3.4). This shows a significant reduction in levels of E-24.11 protein following 
immunodepletion. 
3.5.2 Immunodepletion of ECE from transfected CHO cells using GK4A9 
To examine whether GK4A9 immunoprecipitated ECE activity, volumes of GK4A9 
labelled Sepharose beads (300 µl) were incubated with Triton X-100 solubilised 
membranes prepared from ECE transfected CHO cells which did not express E-24.11. 
Beads were precipitated and, 
_ 
the immunoreactivity of the membrane preparations following 
immunoadsorption determined (Fig. 3.5). Bound proteins were eluted into the same 
volume using glycine (pH 2.3) and samples examined for ECE content by 
immunoblotting with the monoclonal antibody to ECE, AEC32-236. 
Since this cell line did not express E-24.11 activity, any substrate breakdown could be 
attributed to ECE activity. Volumes applied to the column, the immunodepleted 
fraction and the eluted fractions were consistent in volume (100 µl). The total activity 
in the immunodepleted fraction was found to be approximately 10 % of the activity 
present in the same sample prior to incubation with the GK4A9 antibody. This is 
consistent with immunoblotting (Fig. 3.5) which showed a significant reduction in 
levels of ECE protein in the sample following immunodepletion. Following removal of 
bound protein from the column, there is evidence that ECE is detectable in the eluted 
fractions. 
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3.5.3 Assessment of the effectiveness of thiorphan and PR inhibition 
of E-24.11 activity 
The assay of immunodepleted fractions and the apparent recognition of ECE was 
dependent on the distinction between ECE and E-24.11 activity. The compound 
thiorphan was routinely used to inhibit E-24.11 activity selectively ensuring all big ET- 
1 degrading activity was solely due to breakdown by ECE. Oxidation of the 
sulphydryl groups of thiorphan has been shown to reduce its potency which would 
allow cleavage of big ET-1 by E-24.11. In order to ensure this was not the case and 
that all big ET-1 breakdown was due exclusively to ECE activity, the inhibition of E- 
24.11 by both phosphoramidon and thiorphan was determined. These data 
demonstrated both thiorphan and phosphoramidon inhibited >90 % of total E-24.11 
activity in membranes prepared from both EAhy926 cells and pig lung. 
3.5.4 Immunoprecipitation of peptidase activities by 3C7 monoclonal antibody 
to E-24.11 
The apparent recognition of ECE by GK4A9 supported the hypothesis that ECE and 
E-24.11 may originate from the same protein family and therefore likely to share 
significant sequence homology. With this in mind, a second monoclonal antibody to E- 
24.11,3C7 (Gee & Kenny, 1985), was tested for potential co-immunorecognition of 
ECE and E-24.11 using the same protocols used for GK4A9. Immunoadsorbed 
samples were assayed for E-24.11, ECE, AP-N and protein (Fig. 3.6). 
These data showed 3C7 to be considerably less effective at precipitating E-24.11 
protein from membrane preparations compared with the GK4A9 antibody. In addition, 
this antibody showed no specificity toward ECE since levels of immunoprecipitation of 
this protein mirrored that of protein binding in general and also the precipitation of AP- 
N. No further studies were carried out involving this antibody. 
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Fig. 3.3 Immunodepletion of EA. hy926 cell membranes using GK4A9 labelled 
Sepharose beads 
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EA hy926 cell membranes (I mg/ml) were solubilised with Triton X-100 and incubated 
with 0 to 300 pl of GK4A9 labelled Sepharose beads for 24 h at 4°C. Beads were 
removed by centrifugation and the remaining immunodepleted fraction was assayed for 
E-24. II (using the spectrophotometric protocol described in section 2.3.1), ECE, AP- 
N and protein. These data were compared with values for untreated membranes 
(shown here as 0 pl beads). Levels of enzyme activity in the immunodepleted fractions 
were then calculated as a percentage of the total in untreated membranes. 
The results are shown as the mean ± S. D. for four experiments. 
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Fig. 3.4 Immunoprecipitation of E-24.11 from EA. hy926 cells detected by the 
polyclonal antibody to E-24.11, RP161 
kDa 
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EA. hy926 cell membranes (1 mg/ml) were solubilised with Triton X- 100 and incubated 
with GK4A9 labelled Sepharose beads (300 µl) for 24 h at 4°C. Beads were removed 
by centrifugation (10,000g, 2 min. ) and bound proteins eluted from the beads. 
Samples (10 µg of protein) of EA. hy926 membranes prior to immunodepletion (lane 
1), following immunodepletion (lane 2) and proteins precipitated by GK4A9 (lane 3) 
were separated on 10 % SDS-polyacrylamide gels under reducing conditions and 
immunoblotted, using the polyclonal antibody to E-24.11, RP 161. 
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Fig. 3.5 Immunoprecipitation of ECE activity from CHO cells transfected with 
ECE detected by the monoclonal antibody AEC32-236 
lill kl); 
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Triton X- 100 solubilised membranes (1.4 mg/ml protein) were prepared from CHO 
cells transfected with ECE cDNA and incubated with GK4A9 labelled Sepharose 
beads (300 µl) for 24 h at 4 °C. Beads were recovered by centrifugation (10,000 g, 10 
min) and the supernatant retained as the immunodepleted fraction. Bound proteins 
were eluted using glycine (pH 2.3). Volumes applied to the column (lane 1), the 
immunodepleted fraction (lane 2) and the eluted fractions (lanes 3 and 4) were 
consistent in volume (100 µl). 
Samples (12 µd / well) were examined for ECE protein content by separating proteins 
on a 10 % SDS-polyacrylamide gel. ECE was detected using the monoclonal antibody 
to ECE, AEC32-236. 
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Fig. 3.6 Immunoadsorption of solubilised EA. hy926 cell membranes using 3C7 
labelled and unlabelled Sepharose beads 
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EA. hy926 cell membranes (1 mg/ml) were solubilised using Triton X-100 and 
incubated with various volumes of unlabelled and 3C7 labelled Sepharose beads for 24 
h at 4°C. Beads were removed by centrifugation (10,000 g, 10 min) and the 
supernatants assayed for E-24.11 (using the spectrophotometric protocol), ECE, AP-N 
and protein. Results are shown as the mean ± S. D. for 4 experiments. 
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3.5.5 Immunoprecipitation of peptidase activities by GK4A9 from pig lung 
membranes 
To confirm the immunoprecipitation of ECE and E-24.11 activity with GK4A9 
antibody, pig lung membranes were used in a similar protocol to that used with 
EA. hy926 cells. Following immunoprecipitation with GK4A9 labelled Sepharose 
beads, supernatants were assayed for protein, AP-N, DPP-IV, ECE and E-24.11 (Fig. 
3.7). Whilst AP-N, DPP-IV and protein levels showed no significant reduction 
following incubation with the GK4A9 labelled beads, the levels of ECE were found to 
decrease by approximately 55 %. This showed significant immunorecognition by 
GK4A9 of ECE from this tissue source though this figure was much lower than that 
reported for EA. hy926 cells (Fig. 3.3). In contrast the degree of immunodepletion of 
E-24.11 showed approximately 90 % of the total activity was precipitated by GK4A9, 
consistent with the degree of immunodepletion of this activity from EA. hy926 cells. 
3.6 Immunodetection of ECE-1 using the monoclonal AEC32-236 antibody 
A monoclonal antibody against ECE raised to the C-terminal domain of ECE-1 was 
kindly donated by Dr. K. Tanzawa (Sankyo Co. Ltd., Tokyo, Japan). Confirmation 
that this antibody was specific for ECE is shown in Fig. 3.8. This immunoblot shows 
ECE to be expressed as a 240 kDa dimeric protein under non-reducing conditions with 
a monomeric weight of 120 kDa as shown by incubation with ß-mercaptoethanol. 
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Fig. 3.7 Immunodepletion of solubilised pig lung membranes by GK4A9 
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Membranes prepared from pig lung membranes (5 mg/ml) were incubated with GK4A9 
labelled Sepharose beads (300 µl) at 4°C for 24 h. Beads were recovered by 
centrifugation (10,000 g, 10 min) and the supernatant retained as the immunodepleted 
fraction. Membrane peptidase activities were assayed before and after incubation with 
the beads and activities in the immunodepleted fraction calculated as a percentage of 
the total activity prior to incubation with the beads. 
E-24.11 was assayed using the spectrophotometric protocol described in section 2.3.1. 
ACE and DPP-IV were assayed by the protocol described in section 2.3.2. Protein 
was assayed by the BCA method (section 2.2.1) and ECE assayed using the RIA 
protocol described in sections 2.3.6 and 2.3.7. 
Results are mean ± S. D. for 4 separate experiments 
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Fig. 3.8 Western blot of EA. hy926 cell membrane preparations under reducing 
and non-reducing conditions using the monoclonal antibody AEC32-236 
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EA. hy926 cell membrane proteins (12 µg protein) were separated on a 10 % SDS- 
polyacrylamide gel under reducing (lane 1) and non-reducing (lane 2) conditions and 
then immunoblotted using the monoclonal antibody AEC32-236. 
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3.7 Effect of tunicamycin on ECE expression 
Tunicamycin is an antibiotic which inhibits lipid carrier-dependent protein glycosylation 
(Duksin & Mahoney et al., 1982). The inhibitory properties of this molecule are 
thought to be due to either its activity as a multi-analogue, competitive inhibitor 
(Keller et al., 1979) or a non-competitive inhibitor of the UDP-G1cNAc: dolichyl 
phosphate-G1cNAc-1-phosphatetransferase activity which catalyses the first step in 
lipid carrier-dependent protein glycosylation (Heifetz et al., 1979). The interference of 
glycoprotein synthesis by tunicamycin was first demonstrated in mammalian (Takatsuki 
& Tamura, 1971 a) and microbial (Takatsuki & Tamura, 1971 b; Kuo & Lampen, 
1974) cells. 
In order to investigate the potential effects of tunicamycin on ECE synthesis and 
activity EA. hy926 cells were grown until confluent, the culture medium was removed 
and tunicamycin supplemented culture medium added. Membranes were prepared 48 h 
following the application of tunicamycin and levels of ECE expression compared in 
treated and untreated cells by enzyme assay and immunoblotting (Fig. 3.9). 
The effect of glycosylation on ECE synthesis and activity can be seen from these data. 
Comparison of the specific activities of tunicamycin treated and untreated membranes 
showed levels of ECE to diminish by approximately three-fold following treatment of 
cells with tunicamycin. These data were consistent with the levels of ECE detected by 
immunoblotting which showed tunicamycin treated cells to express much lower levels 
of the immunoreactive protein. 
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Fig. 3.9 Investigation of the effect of glycosylation on ECE expression and 
activity 
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Flask cultured EA. hy926 cells were grown until confluent before the culture media was 
removed and replaced with tunicamycin supplemented media (final concentration 10 
µM). Membrane samples were either assayed for ECE activity or membrane proteins 
(12 µg / lane) were separated on a 10 % SDS-polyacrylamide gel and then 
immunoblotted with the monoclonal ECE antibody AEC32-236. 
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3.8 Discussion 
3.8.1 The biochemical characteristics of the ECE protein 
In the absence of cloning and structural information regarding ECE at the start of this 
thesis, it was decided to characterise the protein in terms of its biochemical properties. 
At the time ECE had yet to be cloned or sequenced, E-24.11 was regarded as a 
possible, though unlikely candidate for the physiological ECE and there was no 
sensitive, reproducible assay for ECE activity. The initial work therefore was intended 
to characterize the EA. hy926 cell line and determine the suitability of this cell line for 
use as a model system for the study of ECE. The profile of membrane peptidases 
expressed by this cell line did show some unexpected results. The enzyme activities, 
ACE and DPP-IV, considered to be markers of the endothelial cell phenotype were 
found not to be expressed in assays of crude membrane preparations, a result 
confirmed by subsequent immunostaining of this cell line. Whilst this indicated that 
these cultured cells did not reflect the true physiological state of the vascular 
endothelium, the development of the radioimmunoassay protocol to detect ECE 
activity in these cells showed expression levels suitable for study of this protein. An 
additional consideration given the apparent ability of E-24.11 to hydrolyse big ET-1 
was the relatively low levels of E-24.11 activity expressed by this cell line. In this case, 
the assayed levels of both enzymes allowed the accurate and specific determination of 
ECE activity in membranes prepared from these cells. 
An important aspect of the biochemistry of membrane peptidases is the mechanism by 
which they are anchored to the cell membrane. Identification of this was accomplished 
using several solubilisation techniques and comparing these data with those obtained 
for E-24.11, a known type II integral membrane protein. The relative resistance of 
ECE to solubilisation by bacterial phosphatidylinositol-specific PLC gave an initial 
indication that the protein was not anchored by a G-PI moiety. Detergent 
solubilisation profiling supported this evidence since both ECE and E-24.11 were 
effectively solubilised by Triton X-100, a non-ionic detergent of relatively low CMC 
which was unable to solubilise a known G-PI anchored protein. The similarity of the 
79 
solubilisation profiles for ECE and E-24.11 suggested, but did not prove, that these 
proteins also shared a common anchoring mechanism. The data from temperature- 
induced phase separation studies, designed to identify amphipathic proteins were 
consistent with this theory. Both ECE and E-24.11 were found to localize in the 
detergent-rich phase while the hydrophilic protein, LDH, which was included as a 
positive control was localized in the detergent-depleted phase. All of these studies 
suggested ECE to be, like E-24.1 1, an integral transmembrane protein. This was 
confirmed when ECE was subsequently cloned and sequenced (Xu et al., 1994; 
Shimada et al., 1994; Schmidt et al., 1994; Ikura et al., 1994; Yorimitsu et al., 1995). 
3.8.2 Glycosylation of ECE protein 
The importance of glycosylation on ECE synthesis and activity was investigated using 
the antibiotic tunicamycin. Membranes of eukaryotic cells are usually between 2% 
and 10 % carbohydrate, a significant proportion of which is in the form of 
glycoprotein. Glycosylation of proteins is thought to play a role in both intercellular 
recognition and protein orientation within the membrane. Tunicamycin is a useful 
inhibitor of protein glycosylation and its effect on the synthesis and activity of ECE, a 
known glycoprotein with 10 N-linked glycosylation sites was demonstrated by both 
assay and immunoblotting. Determination of the specific ECE activity in treated and 
untreated membranes showed treatment of EA. hy926 cells with 10 µM tunicamycin 
diminished ECE activity by approximately 3-fold. 
Immunoblotting of membranes with the monoclonal ECE antibody AEC32-236 was 
carried out to determine whether this was due to decreased synthesis of ECE or if 
tunicamycin was inhibiting ECE breakdown of big ET-1. The decrease in the size of 
the immunoreactive band in treated cell membranes was consistent with decreased 
synthesis of the mature ECE-1 protein rather than the inhibition of ECE activity and 
suggested glycosylation to be an important step in the correct synthesis of the mature 
active protein. 
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3.8.3 Co-precipitation of E-24.11 &. ECE using monoclonal antibodies 
There was mounting evidence to suggest there were many common biochemical 
characteristics between ECE and E-24.11. Both proteins were now thought to be 
integral membrane metalloproteases with a pH optimum of around neutral sharing 
some inhibition similarities. Further characterisation of ECE revealed the possibility 
that these proteins might have originated from the same protein family and therefore 
might share a significant degree of sequence and structural homology. Since 
antibodies recognise epitopes of proteins consisting usually of 6-10 amino acids it was 
thought that an antibody raised to one of the proteins may also recognise the 
corresponding sequence if this was conserved between the two. 
Three antibodies to E-24.11 were available; a polyclonal antibody RP 161 and two 
monoclonal antibodies GK4A9 and 3C7. Initial work involving the characterisation of 
E-24.11 levels expressed by the EA. hy926 cell line involved immunoblotting for which 
RP 161 was used (Fig. 3.1). This antibody provided evidence for expression of E- 
24.11 by this cell line revealing a protein band at 90 kDa. However, no bands of 
molecular weight greater than this were revealed indicating this antibody did not cross- 
react with ECE (120 kDa). Further immunoblots of crude EA. hy926 membrane 
preparations using both of the monoclonal antibodies to E-24.11 showed these were 
not suitable for use in western blotting since neither detected E-24.11 at 90 kDa. 
In order to determine if GK4A9 or 3C7 showed any immunoreactivity toward ECE a 
different approach of immunoprecipitation of the activities from solubilised membrane 
preparations was used. Both antibodies were immobilised on Sepharose and 
incubated with Triton X-100 solubilised membrane preparations from EA. hy926 cells. 
The 3C7 antibody was found to be poor at removing E-24.11 from membrane 
preparations and showed no indication of specific immunorecognition of ECE 
whatsoever. CNBr activated Sepharose lacking any bound antibody ligand showed 
only limited, non-specific binding of all proteins assayed and total protein content. In 
contrast to each of these, Sepharose labelled with the GK4A9 ligand appeared to show 
strong recognition of both E-24.11 and ECE whilst control assays of total protein and 
81 
AP-N confirmed this recognition to be specific. This work proved to be reproducible 
and the inhibitory potency of thiorphan and phosphoramidon (approximately 90 %) 
was confirmed since any loss of inhibition by these would have suggested big ET-1 
breakdown by E-24.11 rather than ECE. The immunodepletion of membrane 
preparations was compared between pig lung membrane and EA. hy926 cells. A 
greater proportion of total ECE activity was removed from EA. hy926 membranes, 
suggesting the GK4A9 antibody to have a greater affinity for ECE expressed by this 
cell line compared with the form found in pig lung. 
From these data, the possibility arose that activity being attributed to ECE was due, in 
some part to E-24.11 activity. In order to demonstrate this was not the case, CHO 
cells which had been transfected with ECE cDNA and found to express high levels of 
ECE but did not express E-24.11 were used in immunoprecipitation studies with 
GK4A9. Detergent solubilised membranes prepared from these cells were found to 
have almost (90 %) less ECE activity following incubation with the GK4A9 antibody. 
These data were supported by the observation that levels of ECE protein in the 
samples, detected by immunoblotting with AEC32-236, were significantly reduced 
following immunoprecipitation. In addition, fractions eluted from the GK4A9 column 
showed detectable levels of ECE protein confirming this antibody to 
immunoprecipitate ECE activity. 
The co-precipitation of E-24.11 and ECE by an antibody raised to E-24.11 suggested 
the existence of a common epitope between the two proteins and was consistent with 
the hypothesis that both ECE and E-24.11 originated from the same protein family. 
This has also been confirmed by genetic analysis (Valdenaire et al., 1995). 
The immunoprecipitation of E-24.11 and ECE from membrane samples may also 
provide a rapid and convenient method of purification. CHO cells transfected with 
ECE cDNA had been found to have a specific activity for ECE of approximately 1000- 
fold greater than the levels found in EA. hy926 cells and immunoprecipitation of ECE 
from these cells was confirmed by the detection of ECE protein in the eluted fractions. 
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Since CHO cells do not express E-24.11 activity, problems of contamination with this 
related protein are precluded allowing rapid purification of ECE by this method. 
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CHAPTER FOUR 
TIIE IDENTIFICATION OF ECE IN NEURONAL AND GLIAL CELL LINES 
4.1 AIMS 
To quantify levels of ECE expression in neuronal and glial cell types using 
radioimmunoassay and immunoblotting protocols and to compare levels of E- 
24.11. 
To examine the effect of metalloprotease inhibitors on ECE levels. 
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4.2 Introduction 
4.2.1 Tissue specific expression of ECE 
The endothelin (ET) peptide family was originally identified in porcine endothelial cells 
(Yanagisawa et al., 1988) where the peptides were predicted to be synthesised from 
larger, inactive precursors, the preproendothelins. The three ET isoforms were found 
to be expressed in non-vascular tissues (Inoue et a1., 1989), suggesting ET and its 
production was not confined to vascular cells. Since then much research has focused 
on identification of sites of ET production since ET appears to be involved in many 
disease models afflicting a variety of tissues. It has been proposed that ET production 
in the central nervous system (CNS) plays a major role in the pathophysiology of 
stroke, neuronal damage and may act as a signalling neuropeptide involved in the 
regulation of cerebral blood flow and astrocytic function (Barone et al., 1995). In 
addition, ETs are known to act as powerful morphogens regulating tissues derived 
from the neural crest (Baynash et al., 1994; Kurihara et al., 1994; Puffenberger et al., 
1994). Whilst the identification of the ET-1 and ET-3 peptides in glial and neuronal 
cells has long been established (MacCumber et al., 1990; Ehrenreich et al., 1991; Fuxe 
et al., 1991; Giaid et al., 1991), the expression of ECE by these cell types has 
remained controversial. Most previous studies have focused on the nature and 
localisation of endothelial ECE although enzyme assays have detected ET production 
from big ET by brain homogenates (Warner et al., 1992 a, b) and cultured astrocytes 
(Deschepper et al, 1995). 
Since there was still controversy over the nature of the ECE activity in brain, the aim 
of this part of the work was to determine the levels of ECE-like activity in a variety of 
brain cell types and its possible identity with ECE-1. 
4.2.2 Regulation of ECE by control of protein degradation 
The mechanisms through which the levels of ECE protein expressed by the cell are 
controlled are not yet fully understood and modulating these may prove to be an 
effective method of regulating ET production to control disease. One level at which 
protein levels can be controlled is the rate of protein turnover. In order to identify 
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possible regulatory proteases responsible for the breakdown of ECE, the inhibitors PR 
and thiorphan, were studied for their effects on membrane peptidase expression in a 
number of cell lines. 
4.2.2.1 Regulation of ECE in response to phosphoramidon (PR) 
Previous reports have shown PR to exert a number of effects on the synthesis of ET. 
Early reports suggested exogenously applied PR was able to suppress the secretion of 
ET-1 and the generation of ET-1 from exogenously applied big ET-1 (Ikegawa et al., 
1990 a) in cultured endothelial cells. In addition, Sawamura et al., (1991) 
demonstrated PR inhibited the intracellular conversion of big ET-1 to ET-1 in 
endothelial cells whilst McMahon et al., (1991) reported PR inhibition of big ET-1 in 
vitro. The inhibition of the conversion of exogenously big ET-1 by PR has now been 
reported in bovine endothelial cells (Takada et al., 1991) and rat lung (Takaoka et al., 
1991) in a manner consistent with the inhibition of big ET-1 hydrolysis by ECE. More 
recently, Corder & Vane (1995) reported that the pressor effect of big ET-1 was due 
to local conversion to ET-1 and found PR reduced the pressor response to big ET-1 by 
93 % whilst not altering its rate of clearance from circulation. 
Studies in vivo have also demonstrated that administration of PR inhibits both the 
conversion of big ET-1 and the big ET-1 pressor response, though not the pressor 
response obtained with ET-1 (Matsumura et al., 1990 c; Shinyama et al., 1991; 
McMahon et al., 1991; Bird et al., 1992). More recent reports have suggested PR 
treatment of cultured endothelial cells may have direct effects on the levels of ECE 
expressed by the cells. Schmidt et al., (1994) reported the up-regulation of PR- 
sensitive big ET-1 converting activity of up to 10-fold in foetal bovine heart 
endothelial cells and a 3-5- fold increase in other cell lines (unpublished data). This 
"up-regulation' of ECE in response to µM concentrations of PR was used to aid the 
purification of ECE by this group though the mechanism through which expression of 
ECE was enhanced was not addressed. As part of this work, the effect of PR 
treatment was studied in several cell lines to determine whether the effect was specific 
to endothelial cells and if ECE was up-regulated in response to PR treatment of cells. 
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4.2.2.2 Regulation of ECE in response to thiorphan 
Since PR is an inhibitor of certain metalloproteases and appeared to show up- 
regulation or accumulation of ECE in certain cell types (Schmidt et al., 1994) it was 
considered possible that the mechanism through which PR caused this was by 
inhibiting an enzyme usually involved in the degradation of the ECE protein. To 
further investigate this hypothesis, the effect of a second inhibitor of E-24.11, 
thiorphan, was examined to determine whether administration of this compound 
resulted in a comparable accumulation of ECE and therefore provide further evidence 
for metalloprotease involvement in the physiological regulation of ECE. 
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4.3 Results 
4.3.1 Expression of ECE and E-24.11 in endothelial, glial, neuroblastoma cells 
and in a pheochromocytoma cell line 
To compare the activities of ECE and E-24.11 in membrane preparations of the 
endothelial cell line, EA. hy926, the human neuroblastoma cell line SH-SY5Y, the 
human glial cell line Bu 17, the rat glial cell line C6 and the cloned human astrocyte line 
D384 were assayed for ECE by radioimmunoassay and E-24.11 by HPLC These data 
are shown in Table 4.1. 
Phosphoramidon-sensitive ECE activity was found to be highest in the EA. hy926 cells, 
similar to that found in Bu17 cells and threefold greater than that found in SH-SY5Y 
cells. Low levels of ECE activity were found in the astrocytoma clone D384 and the 
rat pheochromocytoma PC12 cells. ECE was not detected in the rat glial cells, C6 
(Table 4.1). 
In contrast, activity levels ofE-24.11 were 4.5 fold higher in the Bu17 than the 
EA. hy926 cells which showed similar levels of expression to D384 and PC12 cells 
whilst this peptidase was not detected in C6 or SH-SY5Y cells (Table 4.1). 
4.3.2 Immunoblotting of selected cell types to confirm ECE expression 
Immunoblotting for ECE confirmed that the protein was expressed most abundantly in 
the EA. hy926, Bu17 and D384 cell lines compared with the SH-SY5Y line. Limited 
ECE protein was detected in the PC12 cell line but no protein was detected in the C6 
rat glial cells (Fig. 4.1). 
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Table 4.1 Summary of ECE and E-24.11 specific activities in a variety of cell 
types 
Cell Line Cell Type 
EA. hy926 Human Endothelial 
Bu 17 Human Glioma 
C6 Rat Glioma 
SH-SY5Y Human Neuroblastoma 
PC 12 Rat Pheochromocytoma 
D384 Astrocytoma Clone 
PR-Sensitive ECE E-24.11 
(pmol/min/mg) 
1.5 ±0.1 
1.3 ±0.1 
<0.1 
0.6±0.1 
N. D. 
0.2 ± 0.1 
(nmol/min/mg) 
4.9 t 0.2 
23.3 f 0.9 
N. D. 
N. D. 
4.2 ± 0.7 
5.6 ± 1.1 
N. D. Not detectable 
Membrane preparations of each cell line were prepared and assayed for E-24.11 and 
ECE activity. Assays for E-24.11 were performed using the HPLC protocol described 
in section 2.3.1. ECE activity was assayed as described in sections 2.3.6 and 2.3.7. 
All specific activities are the results of the mean ± S. E. M. for 5 separate experiments. 
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Fig. 4.1 Immunoblot analysis of ECE expression in selected cell types using the 
monoclonal antibody AEC32-236 
abc 
120 kDx .. rt .". 
12345 
Membrane preparations of cultured endothelial (a), neuroblastoma (b) and glioma (c) 
lines. Membrane proteins (16 µg/ lane) from EA. hy926 (lane 1), SH-SY5Y (lane 2), 
C6 cells (lane 3), Bu 17 cells (lane 4), D384 cells (lane 5) were separated on a 7.5 % 
SDS-polyacrylamide gel under reducing conditions and immunoblotted using the 
monoclonal antibody AEC32-236 to ECE. 
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4.4 The effects of PR on membrane peptidase expression 
4.4.1 The effects of PR on levels of membrane peptidase expression in EA. hy926 
cells. 
In order to investigate possible regulatory mechanisms involved in the control of ECE 
expression, cells were grown in the presence of PR for periods up to 48 h prior to cell 
harvest. Cell membranes were prepared from treated cells and levels of activity 
compared with those found in untreated cells by enzyme assay. (Table 4.2). 
Treatment with PR was well tolerated in EA. hy926 cells though concentrations of 
>150 pM caused cell death in a concentration-dependent manner. The comparison of 
specific activities shown in Table 4.2 shows that neither E-24.11 nor AP-N were found 
to increase in response to PR treatment. However, in contrast, ECE was found to 
increase in response to all concentrations of PR examined with a maximal increase of 
2.3-fold relative to the untreated cells following treatment with 30 pM PR. 
4.4.2 Immunoblotting of membranes prepared from PR treated SH-SY5Y and 
Bu17 cells 
In order to determine whether the accumulation of ECE in response to PR was specific 
for endothelial cells or if this was a mechanism present in other cells, two cell lines 
expressing different levels of both E-24.11 and ECE were examined for their response 
yýr to PR treatment. SH-SY5Y had previously been shown to express low levels of ECE 
activity whilst Bu17 cells expressed levels of ECE comparable to EA. hy926 cells 
(Table 4.1). Cells were- cultured in 24-well plates and treated with PR concentrations 
up to 100 [M Cells were then solubilised with SDS sample buffer prior to separation 
by SDS-PAGE. Immunoblotting with the AEC32-236 monoclonal antibody to ECE 
revealed changes in the levels of ECE protein expressed by the cell (Fig. 4.2). 
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Table 4.2 Dose-response of membrane peptidase expression in EA. hy926 cells 
following PR treatment 
PR Concentration (pM) 
0 10 30 50 100 
AP-N 
nmoVmin/mg 19.6 ± 1.2 21.7 ± 1.0 16.6 ±2.4 19.3 ±3.4 18.3 ±2.0 
E-24.11 
nmoUmin/mg 5.8 ±0.9 5.5 ±1.2 6.1±1.4 5.5 ±1.6 5.8 ±1.2 
ECE 
pmoVmin/mg 1.4±0.3 1.5±0.2 3.1±0.3 2.3 ± 0.2 1.9±0.3 
Flask cultured EA. hy926 cells were treated with PR supplemented media (0 - 100 }iM 
final concentration) and cell membranes prepared 48h following media application. 
Cell membranes were assayed for AP-N, E-24.11 (spectrophotometric protocol) and 
ECE. The results are the mean ± S. E. M. for 4 experiments. 
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Fig. 4.2 Dose-response of ECE expression in SH-SY5Y and Bu17 cells following 
PR treatment 
Immunoblotting of SH-SY5Y cells 
0 10 30 50 100 150 PR Concentration 
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Immunoblotting of Bu17 cells 
(µM) 
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SH-SY5Y and Bull cells were cultured in 24-well plates and treated with PR- 
supplemented media. Cells were harvested by solubilisation with SDS-sample buffer 
and proteins separated under reducing conditions on a 10 % SDS-polyacrylamide gel 
and immunoblotted, using the monoclonal antibody AEC32-236 to ECE. 
93 
The band intensities seen following immunoblotting with the AEC32-236 antibody 
show a marked increase in the levels of ECE protein following treatment of cells with 
PR. Administration of 10 pM PR was sufficient to induce accumulation of ECE 
protein in both cell lines. The maximal increase in ECE protein in SH-SY5Y cells was 
in response to 10 pM PR though the effect was reduced at concentrations of >50 gM 
PR. At these higher concentrations it would appear that PR is toxic to this cell line 
since cells detached from the culture flask surface. 
In Bu17 cells, the greatest increase in ECE protein was seen in response to 20 µM PR 
treatment. The up-regulation of ECE in this cell line was maintained even at the 
highest concentration of PR tested (150 µM) suggesting this cell line is more resistant 
to the toxic effects of PR 
4.5 The effects of thiorphan on membrane peptidase expression in EA. hy926 
cells 
Pre-treatment of EA. hy926 cells with thiorphan up to 50 µM concentration appeared 
to have no effect on the ability of cells to grow and replicate and resulted in no visible 
morphological change. The compound was well tolerated at the highest of 
concentrations used although higher concentrations proved to be toxic to the cells. 
Assay data of treated cell membranes is shown in Table 4.3. 
These data showed treatment of cells with thiorphan did not cause any significant 
change in AP-N and E-24.11 since levels of these activities remained constant across 
the concentration range used. This was in contrast to the results obtained for ECE 
which showed an increase in specific activity in response to all concentrations of 
thiorphan used with a maximal increase in response to treatment with 50 µM 
thiorphan. 
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Table 4.3 Assays of thiorphan treated EA. hy926 cells 
Activity Final Concentration of Thiorphan (µM) 
0 10 30 50 
AP-N 24.1 ± 4.1 28.4 ±4.7 26.5 ± 5.3 32.4 ± 3.8 
(mnol/min/mg)' 
E-24.11 2.6 ± 0.6 2.8 ± 0.2 2.4 ± 0.4 2.4 ± 0.7 
(nmol/min/mg) 
ECE 1.3 ± 0.2 3.0 ± 0.4 2.7 ± 0.3 3.6 ± 0.3 
(pmollmin/mg) 
E-24.11 activity was determined using the spectrophotometric protocol. 
Specific activities for each activity were determined as the mean ± S. E. M. for 4 
separate experiments. 
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4.6 Discussion 
4.6.1 The identification of ECE in brain cell types 
ECE expression in brain was found to be both cell and species specific. Human glial 
cells, Bu 17 were found to express levels of ECE comparable with those found in the 
human endothelial EA. hy926 cell line and approximately 5-fold more E-24.11 activity 
compared with EA. hy926. In comparison, the rat glioma cell line C6 was found to 
express neither of these activities. Cultured brain astrocytes D384 were found to 
express relatively low levels of ECE activity, consistent with the findings of 
Deschepper et al., (1995). Virtually no ECE activity was detectable in the human 
neuroblastoma SH-SY5Y or the rat pheochromocytoma PC 12 (with characteristics of 
the adrenal medulla) cell lines. This finding was to prove useful in the studies of ECE 
regulation since accumulation of ECE could be more readily quantified against a low 
background level of the enzyme. 
These findings have some implications for the pharmacological prevention of ischaemic 
neuronal damage. Recent research in this field has concerned ET production and the 
role of ECE with the aim of identifying specific and potent inhibitors of ECE to lower 
ET synthesis following ischaemia. Aside from problems such as permeating the blood- 
brain barrier and administration of such inhibitors to their target site additional 
problems may arise by the tissue and cell variations in ECE expression. In addition, 
inhibitors used in this way should ideally be highly specific for ECE since E-24.11 
activity, thought to play a crucial role in terminating synaptic signalling (Turner et al., 
1985), is also expressed by several brain cell types. Inhibition of E-24.11 by inhibitors 
designed for ECE may have some side-effects. 
4.6.2 The regulation of ECE expression 
The apparent involvement of ET in so many disease models has promoted intense 
research activity into its production and much of this research has focused on the 
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control of ET effects by modulating ET activity through inhibitors of ECE and 
antagonists of ET receptors. In comparison, relatively little is known regarding the 
pathways by which ECE production is controlled at a cellular level. Whilst EA. hy926 
was used initially as a model system, the effect of these peptidase inhibitors on other 
brain cell lines was investigated. 
4.6.2.1 The effect of PR and thiorphan on ECE expression 
In this investigation the levels of ECE found in EA. hy926 were found to increase 
specifically in response to both PR and thiorphan. Following administration of each of 
these compounds the levels of both E-24.11 and AP-N remained constant, suggestive 
of a distinct processing pathway involved in ECE turnover. These data suggest a 
number of possible mechanisms by which levels of ECE may be regulated. Inhibition 
of ECE activity by PR would lead to an intracellular accumulation of the ET precursor, 
big ET which in turn could act via a feedback mechanism to increase rates of 
transcription and translation of ECE. Subsequent work by Barnes et al., (1996) 
revealed treatment of TRLEC-03 cells did not lead to an increase in ECE-1 a mRNA 
(the ECE isoform exclusively expressed by TRLEC-03 cells; Shimada el al., 1995) and 
would therefore suggest the most likely mechanism involves the inhibition of an 
activity normally involved in the specific degradation of ECE by the cell. Other 
possible explanations appear unlikely. The up-regulatory effect seen in the case of 
thiorphan would rule out an autocatalytic effect since ECE is considered to be 
insensitive to thiorphan (for review see Turner & Murphy, 1996). The possibility that 
PR treatment alters the post-translational modification of the protein is precluded since 
this would change the Mr of the protein. Changes in the Mr of the immunoreactive 
band detected by AEC32-236 does not occur indicating PR does not alter ECE 
expression in this manner. If the effect were at the level of intracellular transport, PR 
would be expected to alter the expression of AP-N which undergoes the same 
transport pathway. 
The results presented here are indicative of a novel metalloprotease activity involved in 
the normal degradative processing of ECE which would appear to be different from E- 
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24.11. The possibility that E-24.11 might be involved in degradation of ECE appears 
to have been refuted by Barnes et al., (1996) who demonstrated that E-24.11 was 
unable to cleave ECE and is consistent with the previous finding that E-24.11 has strict 
specificity for oligopeptides (Kenny et al., 1987). 
Recent research has focused on the design of specific inhibitors for ECE in order to 
regulate the effects of ET-1 at the level of big ET-1 hydrolysis. These data have 
considerable implications for such research. The use of inhibitors as therapeutic agents 
would seem to present problems since these may have systemic effects possibly causing 
an accumulation of ECE when the therapeutic aim is to reduce levels of ECE. 
Whether this accumulated ECE is functionally active in the cell in ET-1 production 
remains to be established. 
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CHAPTER FIVE 
INVESTIGATION OF THE POSSIBLE ROLE OF TYROSINE 
PHOSPHORYLATION IN THE REGULATION OF ECE 
5.1 AIMS 
To examine whether tyrosine phosphorylation may play a role in the regulation 
of ECE expression. 
To establish dose and time responses to vanadate, an inhibitor of protein 
tyrosine phosphatases, in cell culture systems. 
To use immunoblotting and enzyme assay to quantify changes in membrane 
peptidase expression in several cell types. 
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5.2 Introduction 
5.2.1 Cellular effects of protein tyrosine phosphorylation 
The expression and activity of membrane peptidases is the result of the relative rates of 
breakdown and synthesis of the protein. The signal transduction pathways which 
control protein expression are complex and a number of pathways may influence 
expression levels of any given protein. Many of the cellular responses induced by 
hormones, growth factors and cytokines are mediated by the action of intracellular 
kinases, some of which act by phosphorylating specific proteins on tyrosine residues. 
The ability of the cell to control phosphorylation levels is crucial to the regulation of 
the action of certain proteins and breakdown in cellular control of phosphorylation can 
have damaging physiological consequences on the cell. The phosphorylation state of 
cellular proteins can indirectly influence the rate of synthesis of a protein or may be 
crucial to the activity of the protein itself. 
The promotion of phosphorylation of intracellular proteins by vanadate treatment has 
been shown to result in dramatic physiological changes such as effects on the 
differentiation of a variety of cell types (Gordon, 1991). In addition, cultured cell lines 
including rat pheochromocytoma PC 12 cells have been stimulated to express neurites 
considered to be a marker for the neuronal phenotype whilst human neuroblastoma 
SH-SY5Y cells have extended neurites following culture with vanadate supplemented 
medium (Rogers et al., 1994). 
Previous work has demonstrated that cultured endothelial cells (HUVEC) have been 
shown to suppress ET-1 release following treatment with µM concentrations of 
vanadate (Shimizu et al., 1994), though the effects on ECE were not reported. In 
order to determine whether phosphorylation is indeed a key event in the regulation of 
ECE expression, studies were carried out using the protein tyrosine phosphatase 
inhibitor vanadate to study the effects on expression levels in membrane preparations 
prepared from a number of cell lines. 
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5.2.2 Effects of vanadate on tyrosine phosphorylation 
Sodium orthovanadate (Na3VO4) has been used in this study as a tool for the study of 
the role of protein tyrosine phosphorylation in the regulation of ECE. Vanadate acts 
by mimicking the transition state of phosphate (Gordon, 1991) and is a well established 
inhibitor of protein tyrosine phosphatases and has been used in this context (Simons 
1979; Nechay et al., 1986; Gordon, 1991). However, the cellular effects exhibited by 
vanadate could be related to its ability to alter the activity of certain other enzymes 
including ion channel ATPase (Cantley et al., 1977) and protein kinases (Brown & 
Gordon, 1984) including the insulin receptor kinase (Tamura et al., 1984). 
5.2.3 The investigation of tyrosine phosphorylation effects in ECE regulation 
In order to investigate the possible role of tyrosine phosphatase inhibition on the levels 
of ECE expression, the EA. hy926 cell line was examined for changes in membrane 
peptidase expression following treatment with vanadate. This study was widened to 
determine whether any effects were specific for endothelial cells or whether a common 
regulatory mechanism operated in other cell types. In addition, the rat 
pheochromocytoma PC 12 cell line, which had previously been shown not to express 
ECE (Table 3.1) but had been shown to undergo morphological changes and 
differentiation in response to vanadate treatment, was examined to determine if 
differentiation to the neuronal phenotype resulted in induction of ECE expression. 
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5.3 Results 
5.3.1 The response of EA. hy926 cells to vanadate treatment 
5.3.1.1 The time-dependent response of EA. hy926 cells to vanadate 
Prior to this work, the effects of vanadate on EA. hy926 cells had not been 
documented and in the absence of any known morphological marker the initial work 
involved the use of vanadate concentrations in the µM region which were sufficient to 
induce the cellular changes reported by Rogers et al. (1994). 
EA. hy926 cells were cultured until confluent and the culture medium replaced by 
vanadate supplemented medium (40 pM final concentration) or untreated culture 
medium. Cells were allowed to grow until harvested at intervals up to 48 h and 
membranes prepared immediately. Membranes were assayed for ECE, AP-N and E- 
24.11 activity (Table 5.1). 
The specific activities of ECE in membranes prepared from cells treated with vanadate 
showed a marked increase at all time points up to 48 h with a maximal increase of 
almost 3-fold at 24 h relative to untreated cells at the same time point. Whilst it 
appeared that treatment of cells with vanadate caused a time-dependent increase in 
ECE activity, activity over the same period in untreated cells remained essentially 
constant. (Fig. 5.1). 
Immunoblotting of vanadate treated cell membranes showed an increase in levels of 
ECE protein over the time course period, consistent with the increase in ECE specific 
activity seen in the same membranes. There was no significant increase in levels of 
ECE protein over the time course in untreated cells. 
5.3.1.2 Dose-response of membrane peptidase expression in EA. hy926 cells to 
vanadate treatment 
Having determined the time period following vanadate application at which up- 
regulation of ECE was maximal, the most potent concentration of the compound was 
determined. By using a fixed period of 24 h between application of vanadate- 
supplemented medium and cell harvest, cells were treated with a range of vanadate 
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Table 5.1 Time-related effect of vanadate on peptidase expression in EA. hy926 
cells 
Specific activities of membrane peptidases (untreated EA. hy926 cells) 
Oh 2h 8h 24h 48h 
AP-N 18.8± 3.6 13.9±4.0 18.4±4.9 22.4±5.8 21.1 ±3.8 
E-24.11 4.7 ± 0.9 4.3 ± 0.9 4.0 ± 0.9 4.6 ± 1.3 5.1 ± 1.1 
ECE 1.3 t 0.3 1.3 ± 0.1 1.2 ± 0.2 1.2 ± 0.4 1.1 f 0.2 
Specific activities of membrane peptidases in EA. hy926 cells treated with 40 pM 
vanadate 
Oh 2h 8h 24h 48h 
AP-N 18.8±3.6 16.0±3.2 15.9±4.1 22.7±6.2 18.9±2.1 
E-24.11 4.7 ± 1.3 3.6 ± 1.2 3.8 ± 1.5 4.2 ± 1.0 4.5 ± 0.8 
ECE 1.3±0.3 1.5±0.2 2.4±0.3 3.5±0.4 3.1±0.3 
All activities measured in nmol/min/mg except ECE which is measured in pmol/min/mg 
Flask cultured EA. hy926 cells were grown until confluent and the medium replaced 
with either fresh medium (untreated EA. hy926) or culture medium supplemented with 
40 gM vanadate (final concentration). Cell were harvested at a range of times 
following application and membranes prepared immediately. Specific activities were 
determined for ECE by radioimmunoassay, E-24.11 (spectrophotometric assay) and 
AP-N. 
Results are given as the mean ± S. E. M. for 4 experiments. 
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Fig. 5.1 Time-related effect of vanadate on ECE expression in EA. hy926 cells 
revealed by immunoblotting 
Immunoblotting of vanadate treated EA. hy926 cells 
120 kDa 
0248 24 48 Time (h) Following 
Application of 40 µM 
Vanadate 
.., * 
4"m 
4 
Immunoblotting of untreated EA. hy926 cells 
120kDa 
0248 24 48 Time (h) Following 
Application of Fresh 
Culture Medium 
EA. hy926 cells, cultured in 24-well plates were treated with vanadate-supplemented 
culture medium (final concentration 40 µM) and membranes prepared at different time 
intervals following application of the treated medium by solubilisation with SDS- 
sample buffer. ß-mercaptoethanol (10 % final concentration) was added and proteins 
separated on a 10 % SDS-polyacrylamide gel and immunoblotted with the ECE 
monoclonal antibody AEC32-236. 
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concentrations and membranes were assayed for peptidase activities (Table 5.2 and 
Fig. 5.2). 
Since the samples used in this particular investigation were the same for both enzymic 
assays and immunoblotting, and immunorecognition was quantified by 
phosphorimaging, direct comparisons between the two analytical methods was 
possible. Immunoblotting for ECE (Fig. 5.2) showed the maximal increase in ECE 
expression was in response to treatment with 30 µM vanadate and this was confirmed 
by phosphorimaging which suggested this increase to be of the order of 2.7-fold 
relative to untreated cells. 
Determination of ECE activity by radioimmunoassay (Table 5.2) showed a maximal 
increase of 2.3-fold compared with untreated EA. hy926 cells in response to a 
concentration of 30 pM vanadate, consistent with phosphorimaging data. 
Increase in ECE expression was seen across the concentration range used and 
treatment with vanadate up to 50 µM did not appear to cause any significant change in 
the growth abilities of the cell and did not cause any visible morphological change 
when examined under the microscope. At concentrations above this, significant cell 
death resulted as seen by the stripping of cells from the culture vessel surface over 
large surface areas, though no morphological change resulted in this cell line at lower 
concentrations. 
5.3.2 Dose-response of membrane peptidase expression in Bu17 cells to vanadate 
treatment 
Having established and quantified the degree to which ECE expression is increased in 
EA. hy926 cells in response to vanadate treatment, the human glial cell line, Bu17, 
which had previously been shown to express levels of ECE activity comparable to 
those found in EA. hy926 (Table 4.1) was examined by assay and immunoblotting to 
determine if this cell line showed a similar response to vanadate. 
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Table 5.2 Dose-response of membrane peptidase expression in EA. hy926 cells to 
vanadate treatment 
Vanadate (µM) 
0 10 30 50 
AP-N 23.6 ± 3.4 23.8 ± 2.9 24.1 ± 2.8 27.3 ±2.1 
E-24.11 5.5 ± 1.1 6.3 ± 1.0 6.4±0.5 6.7±0.8 
ECE 1.4 ±0.2 2.1 ± 0.1 3.2 ± 0.2 2.9 ± 0.2 
All activities measured in nmol/min/mg except ECE which is measured in pmol/min/mg 
Using the same samples, assays for each untreated and vanadate treated sample were 
performed to determine the specific activities of ECE, E-24.11 (spectrophotometric 
protocol) and AP-N. 
Assay results are given as the mean ± S. E. M. for 4 separate experiments. 
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Fig. 5.2 Dose-response of ECE expression in EA. hy926 cells to vanadate 
treatment revealed by immunoblotting 
0 10 30 50 Vanadate Concentration 
(µM) 
120 kDa 
Band Intensity 1 1.8 2.7 2.4 
Flask cultured EA. hy926 cells were grown until confluent then treated with medium 
supplemented with vanadate (0 - 100 . iM fmal concentration). Cells were cultured for 
a further 24 h, harvested and membranes prepared from these. Membrane proteins 
were separated on a 10 % SDS-polyacrylamide gel and immunoblotted with the ECE 
monoclonal antibody AEC32-236. The western blot was further analysed by 
comparing band areas by phosphorimaging. The areas given for each band were 
determined as a ratio relative to the band obtained for the immunoblotting of untreated 
membranes. 
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The effect of vanadate treatment on Bu 17 cells was consistent with that observed for 
EA. hy926 cells. Radioimmunoassay data showed the specific activity of ECE to be 
2.2-fold higher in cells treated with 30 gM vanadate compared with untreated cells. (Table 5.3). 
The immunoblot in Fig. 5.3 shows an increase in ECE expression in response to all 
concentrations used though the maximal effect was seen with cells treated with 10 µM 
vanadate. 
In common with EA. hy926 cells, no morphological changes were detected in cells 
cultured with vanadate supplemented medium though concentrations of >50 µM 
vanadate again caused significant cell loss. 
5.3.3 Dose-response of membrane peptidase expression in PC12 cells to vanadate 
treatment 
Previous studies on this cell line (Rogers et al., 1994) had demonstrated vanadate to 
induce the expression of neuntes, a prominent morphological marker of the neuronal 
phenotype. In this study, neunte extension was seen when cells were treated with 
vanadate concentrations of>10 µM. Concentrations of vanadate above 75 µM were 
found to be toxic to this cell line. 
Vanadate treated PC 12 cells were examined to determine the effect of vanadate on 
ECE expression in this cell line. Previous assays had demonstrated that ECE could not 
be detected in this cell line (Table 4.1). Assays of membranes from untreated and 
vanadate treated cells were assayed for ECE activity (Table 5.4). 
Assays of vanadate treated cells demonstrated an apparent increase in ECE activity 
compared with untreated cells. Untreated cells were found to have negligible ECE 
activity whilst cells grown in the presence of vanadate showed significant levels of 
activity. The maximal effect was seen in response to treatment with 30 µM vanadate. 
Immunoblot analysis of membrane preparations from vanadate treated and untreated 
cells showed a similar response in terms of the effect on ECE protein levels (Fig. 5.4). 
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Table 5.3 Dose-response of E-24.11 and ECE activity in Bu17 cells following 
vanadate treatment 
Vanadate (µM) 
0 10 30 50 
E-24.11 15.4 ± 2.7 13.7 ± 2.0 '13.7 ± 3.4 18.1 ± 3.0 
(nmol/min/mg) 
ECE 1.3 ±0.1 2.0 ± 0.3 2.8 ± 0.3 1.9 ± 0.3 
(pmol/min/mg) 
Flask cultures of Bu 17 cells were allowed to grow until confluent and the culture 
medium then replaced with vanadate supplemented medium (10 - 50 PM). Cells were 
cultured for a further 24 h before membranes were prepared from these. E-24.11 
(HPLC protocol), and ECE activities were determined for each sample. 
Results are given as mean ± S. E. M. for 4 experiments. 
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Fig. 5.3 Dose-response of ECE expression in Bu17 cells following treatment with 
vanadate detected by immunoblotting 
Vanadate (uM) 
0 10 30 50 
120 kDa ýA m4 -1 
ý=ý ý": ýýý .w 
Bu 17 cells were cultured in 24-well plates and treated with varying concentrations of 
vanadate. After 24 h cells were solubilised with SDS-sample buffer and ß- 
mercaptoethanol added to a final concentration of 10 %. Proteins were then separated 
on a 10 % SDS-polyacrylamide gel and immunoblotted with the monoclonal antibody 
AEC32-236. 
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Table 5.4 Dose-response of E-24.11 and ECE in PC12 cells following vanadate 
treatment 
Vanadate (µM) 
0 10 30 50 
E-24.11 4.2 ±0.9 3.6 ± 0.4 3.9 ± 0.4 4.1 ± 0.9 
(nmolmin/mg) 
ECE N. D. 1.0±0.2 2.8±0.2 1.9±0.3 
(pmoVmin/mg) 
N. D. Not detectable 
Suspension cultures of PC 12 cells were grown and cell numbers adjusted to 106 cells 
per flask. The existing cell culture medium was then replaced with vanadate 
supplemented medium and cells allowed to grow for a further 48 h. The cells were 
then sedimented by centrifugation and membranes prepared from each flask. 
All membrane preparations were assayed for E-24.11 (HPLC method) and ECE 
activity. Results are the mean ± S. D. for 4 different membrane preparations. 
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Fig. 5.4 Dose-response of ECE expression in PC12 cells to vanadate treatment 
detected by immunoblotting 
0 10 30 50 Vanadate Concentration 
(µM) 
120 kU; i 
9 
&,, Am $"w , 
Flask cultured PC 12 cells were treated with media supplemented with a range of 
vanadate concentrations (0-50 µM). Following treatment with supplemented media 
(24 h) cells were harvested by centrifugation (1000 g, 10 min) and membranes 
prepared. Membrane proteins (14 [tg protein/lane) were separated on a 10 % SDS- 
polyacrylamide gel under reducing conditions then immunoblotted using the ECE 
monoclonal antibody AEC32-236. 
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The immunoblot of PC 12 cells in Fig. 5.4 appears to show a dramatic increase in 
levels of ECE protein expressed by this cell line in response to all concentrations of 
vanadate used. This effect was seen to be maximal in response to 30 PM, consistent 
with the assays of specific activities. 
5.3.4 Protein tyrosine phosphatase inhibition using phenylarsine oxide 
Phenylarsine oxide has been described as a potent inhibitor of protein tyrosine 
phosphatases (Carey et al., 1995). It has been used in previous studies to maintain the 
phosphorylated state of proteins on tyrosine residues (Garcia-Morales et al., 1990; 
Bernier et al., 1987; Santini and Beaven, 1993) and in common with vanadate, 
treatment of cells with phenylarsine oxide induces several additional intracellular 
effects in addition to tyrosine phosphatase inhibition. 
Studies using a number of cell lines, including EA. hy926, Bu17 and SH-SY5Y cells, 
carried out in conjunction with the study of the effects of vanadate on ECE expression 
showed that phenylarsine oxide prepared as described in section 2.4.6 was apparently 
toxic at levels of>30 µM, whilst at lower concentrations the potential up-regulatory 
effects on ECE were not potentiated by phenylarsine oxide. Whilst it would appear 
likely that the toxic effect on the cells was due primarily to the phenylarsine oxide 
content of the media supplement, control cultures of cells supplemented with the 
solvent used to solubilise phenylarsine oxide (HCl acidified DMSO) showed significant 
toxicity to the cells (approximately 50% cell death). This method was recommended 
by the manufacturer and other methods proved ineffective at solubilising phenylarsine 
oxide at the concentrations needed to induce phosphotyrosine phosphatase inhibition. 
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5.4 Discussion 
In this study, the effects of protein tyrosine phosphatase activity on the levels of 
membrane peptidases expressed by a number of cell lines has been determined. 
Previous studies had shown tM concentrations of vanadate were sufficient to induce 
differentiation in SH-SY5Y cells and cause PC 12 cells to exhibit a neuronal phenotype. 
In addition, vanadate had previously been shown to suppress ET-1 release from 
HUVEC cells (Shimizu et at, 1994). The effects of vanadate on levels and activity of 
ECE protein expressed by the human endothelial cell line, EA. hy926, PC12 cells and 
the human glioma cell line were studied by immunoblot analysis and enzyme assay. 
Many of these studies had demonstrated that cells were responsive to treatment with 
gM concentrations of vanadate and on this evidence initial experiments were used to 
determine the optimum vanadate concentrations to influence ECE expression. 
Vanadate effects were studied in EA. hy926 cells to determine whether application of 
this compound had any detectable effects on levels of ECE expressed by this cell line. 
Time-course studies of treated and untreated cells revealed EA. hy926 cells treated 
with 40 gM vanadate prior to cell harvest had levels of ECE specific activity 
approximately 3-fold higher after 24 h compared with untreated cells allowed to grow 
for a similar time period (Table 5.1). This apparent vanadate induced up-regulation of 
ECE activity was consistent with an increase in levels of ECE protein expressed by this 
cell line as demonstrated by immunoblotting (Fig. 5.1). 
Having established 24 h as the optimal period between vanadate administration and cell 
harvest, this period was used in all subsequent experiments. The dose-response of 
membrane peptidase expression in EA. hy926 cells demonstrated a maximal increase 
following treatment with 30 µM vanadate, demonstrating an approximate 2.3 fold 
increase in levels of ECE activity relative to untreated cells (Table 5.2). This effect 
was confirmed by immunoblotting and phosphorimaging analysis (Fig. 5.2) which 
quantified the band intensity of the immunoblot. Using this method band intensity was 
demonstrated to be 2.7 fold higher in cells treated with 30 p. M vanadate compared 
with untreated cells. 
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The effects of vanadate were further studied on other cell lines to determine if the up- 
regulation of ECE in response to vanadate treatment was specific to EA. hy926 cells or 
whether the effect was common to other cell lines. A human glioma cell line, Bu17, 
which had previously been shown to express levels of ECE activity comparable with 
those found in EA. hy926 cells was studied to determine whether ECE was up- 
regulated to a similar extent. Treatment of this cell line with 30 µM vanadate resulted 
in a similar degree of ECE up-regulation (2.2-fold) as determined by enzyme assay 
(Table 5.3). 
A third cell line, the rat pheochromocytoma PC12 line which exhibited a chromaffin 
cell phenotype and had previously been demonstrated to express negligible levels of 
ECE activity (Table 4.1) was investigated to determine if vanadate could "switch on" 
ECE expression in this cell line. Following treatment of PC12 cells with vanadate, this 
cell line was found to express significant levels of ECE activity, demonstrated by 
enzyme assay (Table 5.4) and immunoblotting (Fig. 5.4). ECE activity and levels of 
protein were seen in response to 10 gM up to 50 pM vanadate. Neurite extension was 
seen in this cell line at concentrations of >10 pM vanadate and concentrations in 
excess of 75 µM vanadate were found to be toxic to this cell line. 
These data appear to show inhibition of tyrosine phosphatase to be a crucial event in 
the control of ECE levels in cells though the mechanism through which this occurs is 
not common to the related membrane peptidase, E-24.11 since this activity showed no 
comparable increase following vanadate treatment of EA. hy926 cells (Table 5.2). 
Whilst the response to vanadate treatment suggests phosphorylation of cellular 
proteins to be a key event in the regulation of ECE protein expression, the site at 
which the up-regulatory effect is caused cannot be concluded from these data. 
Vanadate has been shown to stimulate protein tyrosine phosphorylation by inhibiting 
protein tyrosine phosphatases or by activating certain protein tyrosine kinases. 
Previous work by Shimizu et al., (1994) demonstrated that treatment of HUVEC cells 
with pM concentrations of vanadate resulted in a suppression of ET-1 release from this 
cell line. This effect was reproducible on further exposure of the cells to vanadate 
suggesting these effects could be attributable neither to cell growth, nor to cell damage 
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but was due to the influence of vanadate on a specific biochemical pathway through 
the phosphorylation of intermediates. 
The effects on ECE activity following vanadate treatment of the cell lines studied in 
this work would appear to demonstrate there is a specific up-regulation of ECE 
expression as demonstrated by immunoblotting resulting in higher specific activities in 
treated cells. This represents higher activity due to the level of ECE protein produced 
by the cell being increased relative to total cellular protein. These data in parallel with 
the findings of Shimizu et al., (1994) suggest that the response of the cell to 
suppression of ET-1 release is to stimulate greater production of ECE. The hypothesis 
of a direct feedback mechanism in response to suppression of ET-1 release is 
supported by the fact that similar concentrations of vanadate were needed to suppress 
ET-1 release from HUVEC and to up-regulate levels of ECE in EA. hy926 cells. 
Whilst this mechanism may operate through protein tyrosine phosphorylation, other 
cellular effects known to be induced by vanadate cannot be discounted. Previous work 
has demonstrated IL-1, IL-2 and insulin to be implicated in the regulation of ET-1 
production in endothelial cells whilst IL-2 and insulin have both been shown to operate 
through tyrosine kinase activity ( Saltzman et al., 1988; Merida & Gaulton, 1990; 
Petruzzelli, 1984). Insulin has been shown to increase ET-1 production (Hu et al., 
1993) whilst Taniguchi et al., (1992) demonstrated suppression of ET-1 release in 
response to IL-2 in cultured endothelial cells. 
The data presented in this work therefore suggest that protein tyrosine phosphorylation 
may be a key event in a direct feedback mechanism between ECE and ET-1 levels 
produced by the cell. This regulation may be mediated by cytokines acting on 
endothelial cells. 
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CHAPTER SIX 
THE IDENTIFICATION OF ECE-1 ISOFORMS USING ANTI-PEPTIDE 
ANTIBODIES 
6.1 AIMS 
To design immunogenic peptide sequences corresponding to each of the 
reported ECE-1 isoforms. 
To invoke an immune response to these peptides in rabbits and purify specific 
antibodies from the antisera. 
To screen cell lines and tissues for the expression of each isoform using 
western blotting. 
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6.2 Introduction 
The alternative to raising antibodies to a whole protein is to synthesise short peptide 
sequences corresponding to unique regions of the protein sequence. Previous use of 
this strategy has been used for the biochemical and structural characterisation of many 
other proteins (e. g. Kirkness and Turner, 1988; Stephenson and Duggan, 1991; Molnar 
et al., 1993). 
Following the molecular cloning of ECE by several groups in 1993 the generation of 
antibodies to ECE by using the purified protein could now be by-passed by this more 
convenient strategy, particularly since the purification of ECE was not a trivial task. 
Since the yield of ECE from tissues or cell lines was relatively low and the procedure 
for purification time consuming, the alternative of using short peptide sequences 
deduced from the published cDNA sequence offered several advantages. Following 
the discovery of the existence of 2 ECE-1 isoforms, a and ß (Shimada et al., 1994, 
1995; Schmidt et al., 1994; Xu et al., 1994; Ikura et al., 1994) (Fig. 6.1) (these 
isoforms were termed b and a respectively by Valdenaire et al., 1995), it also became 
possible to raise antibodies to distinguish between the individual isoforms by targeting 
the distinct peptide sequences at the N-termini. 
The anti-peptide antibody strategy is not without some disadvantages. For instance, 
the antibodies raised may not recognise the sequence when it is presented as part of the 
native protein and for this reason anti-peptide antibodies are rarely suited to 
immunoprecipitation and occasionally the peptide itself is not sufficiently immunogenic 
and the specific antibody titre of the serum remains low. The production of antibodies 
in this way was carried out with the intention of studying tissue specific expression of 
the ECE-1 isoforms and relied on the identification of sequences unique to each 
isoform which were also predicted to be immunogenic as defined by several criteria 
outlined in section 6.4. 
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Fig. 6.1 Sequence alignment of ECE-1 a and 0 isoforms (page 119) 
Sequences of the ECE-1 a (Schmidt et al., 1994) and ß (Shimada et al., 1995) 
isoforms were aligned to give the best fit between the two sequences. Amino acids 
were colour coded according to characteristics as follows: 
Red, acidic residues (E, D) 
Blue, basic residues (H, K, R) 
Green, polar residues (N, Q, S, T) 
Grey, non-polar residues (A, I, L, M, V) 
Purple, aromatic residues (F, W, Y) 
Brown, structure-disrupting residues (G, P) 
Yellow, cysteine residues (C) 
HUMECEIA Human ECE-1 a sequence 
HUMECEIB Human ECE-1 0 sequence 
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6.3 Selection of peptides 
6.3.1 Selection of peptides for synthesis 
Certain criteria have been established to identify regions of a protein which would be 
most likely to stimulate antibody production in the host animal (Stephenson and 
Duggan, 1991) and while such identification is no guarantee of immunogenicity, this 
method does maximise the chances of generating a specific immune response against 
the peptide. The peptide should correspond to a region of the protein most likely to be 
exposed in the protein. In addition, highly mobile regions of a protein are likely to be 
recognised by anti-peptide antibodies (Niman et al., 1983) and so the N and C termini, 
which are generally less conformationally constrained than other regions, are likely 
candidates. This has been used in the strategies successfully adopted by Stephenson 
and Duggan (1991) and Wenthold et al., (1992). In the present instance, the a and ß 
isoforms of ECE-1 differ only in terms of their N-terminal sequence and this offered an 
ideal opportunity for the raising of specific antibodies to each isoform by this method. 
The likelihood of a given peptide sequence being exposed in the native protein is linked 
to the degree of hydrophilicity and whether the sequence forms or is part of a 
turn/loop structure. Previous work has shown that the ideal sequence length is at least 
6 residues, up to a maximum of 20. Generally peptides of 12-15 amino acids are used 
for antibody production. Whilst shorter peptides may not be sufficiently immunogenic, 
longer sequences may also have the advantage of being able to mimic the conformation 
of the native protein and may also reduce the chances of antibodies cross-reacting with 
other proteins. In addition another important consideration when selecting peptides 
for use is that regions of sequence which are likely to be glycosylated should be 
avoided to ensure structural consistency between the peptide and native protein. 
Assessment of the antigenicity of amino acid residues has been accomplished by 
analysing the frequency with which they occur in known epitopes of proteins. The 
order established, in decreasing antigenicity is histidine, lysine, alanine, leucine, 
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aspartate and arginine (Scheidtman, 1990). Examining the frequency of these residues 
within the selected peptide can be used to give an indication of the potential 
immunogenicity of the peptide. The immunogenicity is also increased by presentation 
of the peptide to the immune system by coupling the peptide to a carrier protein, in this 
case Keyhole Limpet Haemocyanin (KLH). 
As mentioned above, the termini of proteins are likely to be exposed and are therefore 
targets frequently selected for peptide synthesis. Whilst this increases the likelihood of 
raising an antigenic response it is no guarantee of success and it is still advisable to 
check these regions for hydrophilicity. Potential peptides adhering to the criteria 
described were checked with the OWL database for similarity to other proteins and 
were synthesised with a cysteine at the C-terminus to allow linkage to the carrier 
protein. 
In the case of the N-terminal cytosolic sequences of the isoforms, there was a high 
degree of similarity towards the C-terminus but significant differences were seen in the 
N-terminal regions (Fig. 6.1). In order to raise antibodies to each isoform it was 
necessary to identify likely immunogenic regions which were unique to each isoform. 
The rationale for peptide selection involved analysis of the human ECE 1a and ß 
isoforms sequenced by Shimada et al. (1994) and identification of the sequences most 
likely to prove immunogenic using a number of algorithms described below. 
6.4 Computer analysis of potential peptide sequences 
Computer programs were used to identify sequence differences between the ECE-1 a 
and ß isoforms (Fig. 6.1) and analyse certain biochemical characteristics of these 
regions to determine their suitability for use in the production of antibodies. 
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6.4.1 Prediction of hydrophilicity/hydrophobicity 
A prediction of the hydropathy of the protein sequence was created using a program 
design first used by Kyte & Doolittle (1982). The relative degree of hydrophobicity of 
any amino acid side chain within the peptide sequence is presented as a graph about a 
zero x-axis, with hydrophobic regions shown above the x-axis and hydrophilic regions 
below. The hydrophobic transmembrane sequences can thus be potentially identified 
although these need to be confirmed by additional biochemical criteria. 
6.4.2 Surface probability 
Surface probability is calculated according to the formula of Emini et al., (1985) and 
describes the likelihood of any given residue being exposed at the surface of the 
protein. This algorithm is therefore strongly influenced by the hydrophilic nature of the 
window of amino acids being examined. Regions above the base line are predicted to 
be at the surface. 
6.4.3 Flexibility 
Flexibility is calculated according to the formula of Karplus & Schulz (1985), and is an 
analysis of the structural constraints on any given residue and is therefore allied to the 
probability of any given residue participating in secondary structures. The 
measurement of flexibility is given on a scale of 0.8 to 1.2 where the higher the rating, 
the greater the flexibility of the sequence at that point. 
6.4.4 Prediction of secondary structure 
Prediction of secondary structure of proteins is based on the character of amino acids 
in the polypeptide chain and their interaction with adjacent amino acids. Structural 
analysis of many proteins has identified trends of amino acids occurring in certain 
secondary structures. Examples of this include ß-pleated sheet structures which have a 
high isoleucine content whereas a helices contain more glutamate, alanine and leucine. 
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Two algorithms were used to predict the occurrence of secondary structures; the Chou 
and Fasman method (Chou & Fasman, 1978) and the Robson Gamier method (Gamier 
et al., 1978). 
6.4.4.1 Chou & Fasman method 
This method is used to predict helices, sheets and turns. It resolves overlapping 
regions of alpha helices and beta sheets by using the probability procedure introduced 
by Nishikawa (1983). This same procedure is also able to locate turns which are not in 
conflict with other secondary structures. The original Chou Fasman parameters are 
modified as follows: The conditions that p(bound) be greater than 1.0 and that 
p(alpha) be greater than p(beta) are not used and sheet structures must be of 5 residues 
or more. 
6.4.4.2 Robson Garnier method 
This method predicts secondary structure according to the method described in 
Gamier et al. (1978). The minimum length of an alpha helix is six residues and beta 
sheet is four. Regions where accurate predictions are not possible are assigned the 
conformational state of the next best probability. 
A strong prediction for a secondary structure is represented by a large area above the 
baseline shown at the extreme left of the sequence (Figs. 6.2 and 6.3). The accuracy of 
secondary structure prediction is questionable (Creighton, 1993) therefore a selection 
of peptide sequences should be subjected to other parameters to determine their 
immunogenic potential. 
124 
Fig. 6.2 Analysis of ECE-1 a peptide sequence features 
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Fig. 6.3 Analysis of ECE-I 0 peptide sequence features 
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6.4.5 Glycosylation sites 
N-linked glycosylation sites are specific to the consensus motif Asn-X-Ser/Thr 
(Marshall, 1972) although the occurrence of this tripeptide sequence is not sufficient to 
conclude that an asparagine residue is glycosylated since protein folding plays an 
important role in the regulation of N-glycosylation (Pless & Lennarz, 1977). Where X 
is an Asp, Trp or Pro, the site is considered a weak glycosylation site, otherwise it is a 
strong glycosylation site. Predicted glycosylation sites are represented by narrow 
peaks relative to the base line (Fig 6.2 and 6.3). 
6.4.6 Cross-reactivity of candidate peptides with other proteins 
To ensure antibodies raised to each isoform were specific for the ECE-1 protein, 
candidate peptides were compared with all the other proteins in the OWL database. 
For the two peptides chosen, the sequences were found not to have significant 
homology with any protein that might be expressed in the cell lines and tissues used for 
screening. 
6.4.7 Peptide antigenicity 
The antigenic index is a measure of the probability that a region of the sequence is 
antigenic. It is calculated by summing several weighted measures of secondary 
structure. The method is described by Jameson & Wolf (1988). A positive rating 
indicates the sequence at the given point is antigenic. 
6.5 Peptides selected for synthesis 
The sequences chosen for synthesis are shown in Table 6.1. The peptides were 
synthesised with a cysteine residue at the N-terminus to enable linkage with the carrier 
protein. The C-termini of the peptides were amidated. 
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Table 6.1 Peptides selected for synthesis 
Peptides Selected 
CTYKRATLDEED-NH2 CQRNPFLQGKRG-NH2 
Source protein ECE-1 a ECE-1 3 
Amino Acid Position 3-13 9-19 
Reference Schmidt et al., 1994 Shimada et al., 1995 
Mr of peptide (Da) 1443.6 1403.6 
Purity Determined by 87 90 
Manufacturer (%) 
Both peptides were selected on the basis of several algorithms designed to identify 
antigenic regions of proteins. The peptides selected were also scanned by using the 
OWL database and found to have no significant similarities with other proteins likely 
to be expressed in the target cells and tissues. 
Following receipt, peptides were stored under vacuum until required. Purity was 
checked by the manufacturer by using HPLC and further analysis by mass 
spectroscopy was performed by Dr. J. Keen, University of Leeds. Both peptides were 
found to be sufficiently pure for coupling to the carrier protein. 
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6.5.1 Peptide purity 
Following synthesis of the peptides the purity was checked using mass spectrometry 
performed by Dr. J. Keen, University of Leeds. The degree of purity is shown in Table 
6.1. Both peptides were found to be sufficiently pure to require no further treatment 
prior to coupling to the carrier protein. 
6.5.2 Peptide coupling to the carrier protein 
Peptides are linked to a carrier protein in order to increase their immunogenicity and to 
prevent their rapid degradation in the rabbit. In this study, each peptide was 
synthesised with a cysteine residue at the N-terminus to enable coupling with the 
carrier protein, keyhole limpet haemocyanin (KLH). KLH has been used successfully 
although it does have the disadvantages of precipitating due to its high molecular 
weight and generating a high immune response itself. 
Both peptides were coupled to KLH using a linker molecule, 3-maleimidobenzoic acid 
N-hydroxysuccinimide ester (MBS) which attaches to amino groups on the KLH 
protein while the free maleimide group on the linker reacts with the free thiol of the 
peptide, which is reduced prior to joining of the peptide (Fig. 6.4). 
Peptide coupling is described in section 2.7.3. Binding of the protein to the KLH- 
MBS complex was monitored using Oman's reagent. The peptide-carrier protein 
conjugate was stored in aliquots at -20°C. 
6.5.3 Injection protocol 
Peptide conjugates were injected into New Zealand white rabbits (2 rabbits per 
peptide). Pre-immune serum was collected prior to any injections being given. 
Antisera were collected following each boost injection (every 2-3 weeks) and stored at 
-20°C for long term storage or 4°C for short term storage. Since two rabbits were 
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injected per peptide, there were a total of 4 samples of antisera. The nomenclature 
regarding these is as follows: 
ECE-1 a peptide antisera designated ECE1a 1 and ECE1a 2 
ECE-1 0 peptide antisera designated ECE1b 1 and ECE1b 2 
6.6 Analysis of antisera following final injection 
6.6.1 Assessment of immunoreactivity of antisera 
Inmunoreactivity against the immobilised peptide was tested using an enzyme linked 
immunoassay (E. L. I. S. A. ) as described in section 2.7.5. Serial dilutions of antisera 
were incubated on plastic plates, the wells of which had been coated with each peptide. 
Immunoreactivity was determined by measuring colour development at 405 nm. 
Controls were performed by using pre-immune serum and, in each case, cross- 
reactivity with the other peptide was assessed (Figs. 6.5 & 6.6). The results of the 
E. L. I. S. A showed only antiserum ECE1a 1 was sufficiently immunogenic and specific 
for the peptide against which it was raised. A further booster injection (the fifth in 
total) of each of the rabbits immunised to the ECE-10 peptide failed to stimulate a 
powerful and specific response and the only antiserum to undergo further treatment 
was therefore ECE1a 1. 
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Fig. 6.4 Structure of the peptide conjugate 
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Fig. 6.5 E. L. I. S. A. analysis of immunoreactivity of ECE1a I and ECE1a 2 
antisera 
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Plate wells were coated with 20 ng of peptide 1 and incubated with dilutions of 
antisera ECE 1a1 (i) and ECE 1a2 (ii) and pre-immune serum (PIS). Plate wells 
coated with the peptide corresponding to the ECE-1 a protein (20 ng/well) were 
incubated to check if this cross-reacted with either of the ECE-1 antisera. 
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Fig. 6.6 E. L. I. S. A. analysis of immunoreactivity of ECE1b 1 and ECEIb 2 
antisera 
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Plate wells were coated with 20 ng of peptide I and incubated with dilutions of 
antisera ECE 1bI (i) and ECE 1b2 (ii) and pre-immune serum (PIS). Plate wells 
coated with the peptide corresponding to the ECE-1 ß protein (20 ng/well) were 
included to check if this cross-reacted with either of the ECE-1 antisera. 
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6.6.2 Affinity purification of anti-peptide antibodies 
Previous studies have shown that affinity purification of anti-peptide antibodies is 
beneficial (Stephenson & Duggan, 1991). The antisera with the highest 
immunoreactivity (as determined by E. L. I. S. A. above) were purified by peptide affinity 
chromatography (section 2.7.4). The peptide was immobilised first by reducing the 
free thiol group at the N-terminal and reacting with thiopropyl Sepharose-6B. The 
efficiency of coupling was monitored using Ellman's reagent. The affinity 
chromatography column was then incubated with 5 ml of antisera. After washing, 
bound antibodies were eluted by low pH (50 mM glycine, pH 2.3) and the eluant 
immediatel' neutralised to prevent denaturation of the antibodies. Elution of the 
antibodies was monitored by measuring Also (Fig. 6.7) and the fractions with the 
highest protein content pooled. Antibodies were stored in PBS at -70°C for long term 
storage. Purity was assessed by SDS-PAGE and silver staining (Fig. 6.8). 
6.7 The characterisation and use of anti-peptide antibodies 
The antibody which was successfully raised to ECE-1 a was characterised to 
determine whether this antibody recognised the protein from which the peptide had 
been chosen. In order to characterise the antibody, western blotting of transfected 
cells expressing ECE-1 a was carried out (Fig. 6.9). 
Since western blotting involves the recognition of the denatured protein and the anti- 
peptide antibody was designed to recognise a linear epitope it is probable that the 
antibody will successfully recognise the denatured protein. Samples suspected of 
expressing ECE-1 a were applied to denaturing SDS-PAGE and the separated 
proteins electrophoretically transferred to a PVDF membrane. Binding of antibodies 
to polypeptides was detected using the ECL enhancement system and the relative 
molecular mass (Mr) of the polypeptides recognised was then calculated by 
comparison with molecular weight standards. 
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Fig. 6.7 Elution profile of ECEIa I antibody from ECE-1 a peptide affinity 
column 
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The ECE IaI antiserum was affinity purified using the method described in section 
2.7.4. Once the initial peak in absorbance had decreased to <0.05, representing the 
removal of non-specific proteins bound to the column, antibodies were eluted using 0.2 
M glycine-HCI, pH 2.4 and fractions of I ml were collected and immediately 
neutralised using 1M Tris-HCI buffer (pH 8.0). Absorbance at 280 nm was monitored 
and peak fractions with the greatest absorbance were combined and dialysed against 
PBS. 
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Fig. 6.8 SDS-PAGE of affinity purified ECE1a 1 antibody 
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25 
1 
Affinity purified ECEIa 1 antibody was loaded on a 10 % SDS-polyacrylamide gel 
(lane 1,5 µg) under reducing conditions. Following separation, proteins were 
detected by silver staining and molecular weights calculated by comparison to 
commercially available standards. 
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6.7.1 The specificity of immunorecognition by the ECE1a 1 antibody 
The purity of the antibody was seen by protein separation on a polyacrylamide gel and 
subsequent silver staining (Fig. 6.8). This resolved the heavy and light chains of the 
antibody and demonstrated the affinity purification had been successful. In order to 
determine if the antibody recognised the ECE-1 a protein and was specific in this 
recognition, CHO and COS cells expressing ECE-1 a and COS cells expressing ECE- 
10 were applied to SDS-PAGE and immunoblotted with the ECEIa 1 antibody (Fig. 
6.9'). The western blotting procedure used goat anti-(rabbit IgG) IgG as the second 
antibody. The results show strong immunorecognition of the ECE band at 120 kDa in 
transfected cells expressing ECE-1 a and no band detected in the cells expressing 
ECE-1 0 or in COS and CHO cells which had not been transfected. This indicated the 
antibody was specific for the ECE-1 a isoform. Blotting of the same cells with the 
AEC32-236 antibody showed ECE recognition at 120 kDa in all transfected cell lines 
expressing either of the ECE-1 isoforms. 
6.7.2 Immunoblotting of cultured cells and pig lung membranes using the 
ECEIa 1 antibody 
To further examine expression of the a form of the ECE-1 protein, membranes were 
prepared from a range of cultured cell lines and tissues and immunoblotted with the 
ECE 1a1 antibody (Fig. 6.10). Under reducing conditions, TRLEC-03 cells showed 
immunorecognition at 120 kDa consistent with the findings of Shimada et al., (1995). 
ECE-1 a was also detected in membranes prepared from EA. hy926 cells, smooth 
muscle cells and pig lung membranes though the clarity of recognition was diminished 
by the high degree of non-specific binding. 
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Fig. 6.9 Immunorecognition of ECE-1 a expressed by transfected and non- 
transfected cell lines using ECE1a 1 and AEC32-236 antibodies 
ECE1a 1 AEC32-236 
120 kDa "4ýf lose 
12345671234567 
1 CHO cells transfected with ECE-1 a 
2 CHO cells not transfected 
3 COS cells transfected with ECE-1 a 
4 COS cells transfected with ECE-1 ß 
5 COS cells not transfected 
6 EA. hy926 cell membranes 
7 COS cells transfected with E-24.11 
All lanes except (6) were loaded with 6 µg protein. Lane (6) was loaded with 10 µg of 
protein. Proteins were separated on a 10 % SDS-polyacrylamide gel under reducing 
conditions. Following electrophoretic transfer to PVDF membrane, proteins were 
detected with either the ECE 1a1 or AEC32-236 antibody. Immunorecognition was 
detected using the ECL detection system. 
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6.7.3 Immunoblotting of PR treated EA. hy926 cell membranes using the ECEIa 
1 antibody 
In order to enhance immunorecognition of ECE-1 a in cultured cell lines, EA. hy926 
cells were treated with a range of PR concentrations (0-100 µM) which had previously 
been shown to increase levels of ECE activity and protein. Cells were harvested 24 h 
following administration of PR, membranes prepared and proteins separated by SDS- 
PAGE under reducing conditions. Following electrophoretic transfer to PVDF 
membrane, samples were immunoblotted using the ECEIa 1 antibody to ECE-1 a 
(Fig. 6.11). 
These data revealed an increase in the band intensity at 120 kDa, consistent with 
previous findings (section 4.2) which showed ECE to be up-regulated in this cell line in 
response to PR treatment. In common with this previous work, the effect was 
maximal following treatment with 30 pM PR. 
6.7.4 Immunoblotting of PR treated Bu17 cell membranes using the ECE1a 1 
antibody 
The up-regulatory effect of PR on ECE expression had previously been reproduced in 
Bu 17 cells (section 4.2). In order to determine if this enhanced ECE-1 a protein 
levels, membranes prepared from Bu17 cells treated with 0-100 µM PR, 24 h prior to 
cell harvest, were separated by SDS-PAGE under reducing conditions. Proteins were 
electophoretically transferred to PVDF membrane and ECE-1 a expression detected 
using ECEIa 1 antibody (Fig. 6.12). 
In common with the immunorecognition profile seen in EA. hy926 cells in response to 
PR, Bu17 cells were seen to express detectable levels of ECE-1 a following treatment 
with PR. A PR concentration of 30 µM induced the greatest increase in ECE-1 a. 
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Fig. 6.10 Immunoblotting of membranes prepared from cells and tissues with the 
ECEIa 1 antibody to ECE-1 a 
120 kDa 
1234 
I Pig lung membranes 
2 TRLEC-03 cell membranes 
3 EA. hy926 cell membranes 
4 Porcine smooth muscle cell membranes 
All lanes were loaded with 14 pg of protein. proteins were separated on a 10 % SDS- 
polyacrylamide gel. Following separation, proteins were electrophoretically 
transferred to a PVDF membrane. Samples were immunoblotted using the ECEIa 1 
polyclonal antibody to the ECE-1 a isoform. Immunorecognition was detected using 
the ECL development system. 
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Fig. 6.11 Immunoblotting of PR treated EA. hy926 cell membranes using the 
ECEIa 1 polyclonal antibody to ECE-1 a 
PR (µM) 
0 10 30 50 100 
Flask cultured EA. hy926 cells were treated with 0-100 µM PR 24 h prior to cell 
harvest. Membranes were prepared and proteins separated by SDS-PAGE on a 10 % 
SDS-polyacrylamide gel (10 µg/well). Following transfer to PVDF membrane, 
proteins were detected using the ECE 1a1 polyclonal antibody to ECE-1 a. 
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Fig. 6.12 Immunoblotting of PR treated Bu17 cells using the ECE1a I polyclonal 
antibody to ECE-I a 
PR (µM) 
0 10 30 50 100 
kDa 1? i 
Flask cultured Bu17 cells were treated with 0-100 . iM PR 24 h prior to cell harvest. 
Membranes were prepared and proteins separated by SDS-PAGE on a 10 % 
polyacrylamide gel (10 µg/well). Following transfer to PVDF membrane, proteins 
were detected using the ECEI at polyclonal antibody to ECE-1 a. 
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6.8 Discussion 
The objective of this part of the work was to raise antibodies to each of the ECE-1 
isoforms, a and ß which were cloned and expressed by Schmidt et al, (1994) and 
Shimada et al. (1995). Protein sequences were analysed using several computer based 
algorithms to determine the immunogenicity of peptide sequences within the protein. 
N-terminal sequence differences between the a and ß isoforms allowed immunogenic 
peptides unique to each isoform to be designed. These peptides were synthesised and 
coupled to a carrier protein (KLH) for presentation to the immune system of a rabbit. 
A course of 4 injections of the protein were administered (5 in the case of the ECE-1 ß 
peptide). Test bleeds were taken throughout the injection protocol and analysed by 
E. L. I. S. A. to determine the strength and specificity of the immune recognition. Whilst 
one rabbit elicited a strong immune reaction to the ECE-1 a (designated ECE-1a 1) 
there was no significant immune response by either the second rabbit injected with the 
ECE-1 a peptide or the rabbits immunised with the ECE-10 peptide. 
The antiserum which did show specific immunorecognition of the ECE-1 a peptide 
was affinity purified by immobilising the peptide to an inert resin and bound antibodies 
eluted and neutralised. Antibody samples isolated in this way were examined for purity 
by SDS-PAGE which revealed two bands corresponding to the light and heavy chains 
of the antibody protein which demonstrated the purity of the antibody. 
The purified antibody, which had been raised to a peptide sequence of 11 amino acids 
was analysed to determine if it recognised the entire protein sequence expressed by 
CHO and COS cells transfected with ECE-1 a. These cells, which had been shown to 
express high levels of the ECE-1 a protein, were immunoblotted using the ECE-1a 1 
antibody. Bands were detected at approximately 120 kDa under reducing conditions in 
cells transfected with the ECE-1 a cDNA indicating the antibody did recognise the 
ECE-1 a protein. The specificity of this recognition was further supported by the fact 
that non-transfected cells and cells transfected with ECE-10 did not show any 
immunoreactivity. Whilst this demonstrated that specific antibodies to ECE-1 a had 
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been successfully raised, the recognition of the entire protein had only been 
demonstrated in transfected cell lines known to express high levels of ECE. 
Previous work by Shimada et al., (1995) had demonstrated ECE-1 a mRNA to be 
more abundant in a range of cells and tissues including brain, kidney, heart and lung. 
In addition, ECE-1 a mRNA was found to be exclusively expressed by TRLEC-03 
cells. Western blotting using the ECE1a 1 antibody revealed a polypeptide of 
approximately 120 kDa in this cell line corresponding to ECE1a 1, but the detection 
was weak with a relatively high degree of background staining (Fig. 6.10). Western 
blotting of other cell lines detected some ECE-1 a expression in EA. hy926 cells and in 
pig lung membranes. 
144 
CHAPTER SEVEN 
DISCUSSION 
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At the commencement of the work in this thesis, prior to the molecular cloning of ECE 
by several groups in 1994 little was known concerning the biochemical characteristics 
and topology of the ECE protein. With no antibodies available to the protein, many of 
the cells and tissues which expressed ECE were unidentified. The cloning and 
expression of ECE revolutionised the study of this protein with considerable 
information now accumulated regarding ECE and its role in the production of the 
potent vasoconstrictive peptide, ET and the expression of the two isoforms of ECE-1, 
a and P. 
In order to study ECE activity, a human endothelial cell line, EA. hy926, was used. This was a 
fusion between HUVECs and a continuous human epithelial cell line (A549), originally 
derived from a human lung cell carcinoma (Edgell et al., 1983). EA. hy926 cells had 
been shown to exhibit sustained expression of many differentiated functions of the 
vascular endothelium, though were found not to express ECE or DPP-IV, considered 
to be markers of the endothelial phenotype. The EA. hy926 cell line had been 
demonstrated to express prepro ET-1 mRNA and to secrete both ET-1 and big ET-1 
into the culture medium in a PR-sensitive manner and was considered a good model 
for the system of ET-1 production by the physiologically relevant ECE activity. 
ECE was thought to share several different biochemical characteristics with E-24.11 
including a neutral pH optimum, sensitivity to metal chelators and sensitivity to PR. 
The observation that both ECE and E-24.11 were expressed at detectable levels in 
membranes prepared from EA. hy926 cells facilitated the study of the mechanism by 
which ECE was anchored to the plasma membrane. 
Since E-24.11 was known to be a type II integral membrane protein, characterisation 
of the ECE membrane anchor was attempted by comparing the behaviour of the two 
activities in temperature-induced phase separation studies, detergent solubilisation 
profiling and their ability to resist solubilisation by bacterial PI-PLC. Generally, 
detergents which are anchored by a G-PI moiety are resistant to solubilisation by 
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detergents of relatively low CMC, such as Triton X-100, though these are often 
solubilised by detergents of high CMC such as octyl glucoside. The ability of both 
Triton X-100 and Nonidet P-40 to effectively solubilise both ECE and E-24.11 
suggested neither of these proteins was G-PI anchored. This was later confirmed by 
studies which demonstrated both ECE and E-24.11 to be resistant to bacterial PI-PLC 
solubilisation. These data were compared with the solubilisation of a known G-PI 
anchored protein, 5'-Nucleotidase, which was found to be effectively solubilised by 
this activity. Temperature-induced phase separation using Triton X-114 of EA. hy926 
cell membranes allowed the comparison of E-24.11 and ECE with a known cytosolic 
protein, LDH. Both E-24.11 and ECE were found to localise predominantly in the 
detergent-rich phase whilst the majority of LDH activity was found to localise in the 
detergent-depleted or aqueous phase. This observation suggested both ECE and E- 
24.11 to be integral membrane proteins which, when considered with other data, 
indicated ECE was not G-PI anchored. ECE was later confirmed to be a type II 
integral membrane protein with a large extracellular C-terminal catalytic domain. 
The identification of an ECE activity distinct from E-24.11 was confirmed by the 
selective inhibition of E-24.11 by thiorphan though this did not preclude the possibility 
of these proteins shared significant structural and sequence homology. This hypothesis 
was investigated by the screening of mono and polyclonal antibodies to E-24.11 for 
possible cross-reactivity to the ECE protein. Whilst the polyclonal antibody, RP 161 
and the monoclonal antibody, 3C7 did not show any detectable immunoreactivity to 
the ECE protein, a monoclonal antibody, GK4A9 immobilised to an inert resin was 
found to immunoprecipitate ECE from Triton X-100 solubilised EA. hy926 
membranes. Following immunoprecipitation by GK4A9, both ECE and E-24.11 
activities were reduced by >80 % in the solubilised membrane sample though there was 
no comparable decrease in AP-N or protein content, suggesting this 
immunorecognition to be specific for E-24.11 and ECE. To further examine the 
immunorecognition of ECE by GK4A9, the experiment was repeated using CHO cells 
transfected with ECE. This cell line had been shown to express approximately 500- 
1000-fold more ECE activity per mg of protein compared with EA. hy926 cells and did 
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not express E-24.11 ensuring any activity attributed to ECE was not due to substrate 
hydrolysis by E-24.11. Incubation of GK4A9bound toSepharose with Triton X-100 
solubilised transfected CHO cell membranes resulted in removal of >85 % of the total 
ECE activity. This observation was supported by the results of immunoblotting which 
confirmed removal of the ECE protein from the membrane sample. These data 
supported the hypothesis that this antibody raised to E-24.11 also recognised the ECE 
protein and suggested that ECE and E-24.11 shared a common epitope. This was 
consistent with hypothesis that these proteins originated from the same protein family, 
later confirmed by genetic analysis (Valdenaire et at, 1995). In addition, ECE protein 
was detected by immunoblotting with AEC32-236 in fractions eluted from the GK4A9 
column, suggesting that ECE might be rapidly affinity purified by GK4A9 from cell 
membranes. This process would be greatly aided by the use of transfected cell lines 
overexpressing large amounts of ECE whilst avoiding contamination with E-24.11 by 
using cells which do not express this protein. Using large scale preparations, this 
observation may be used to rapidly purify large quantities of ECE. 
Studies by Schmidt et al., (1994) reported that treatment of FBHE cells with PR 
resulted in an accumulation of ECE, an observation which was exploited to aid 
purification of ECE from this cell line. In this study, the effect was reproduced in an 
endothelial cell line (EA. hy926), a human neuroblastoma (SH-SY5Y) and the human 
glial cell line (Bu 17). Consistent with the findings of Schmidt et al., (1994), the 
increase in ECE protein and activity was found to be in response to treatment of cells 
with PR in the µM range. The increase in ECE in FBHE cells reported by Schmidt et 
al. (1994) was found to be 10-fold though the increase seen in other cell lines was 
found to be between 3 and 5-fold. The increase in ECE in the cell lines used in this 
study was found to be approximately 3-fold following treatment with 30 µM PR as 
estimated by enzymic assay and immunoblotting. 
Further investigation into the regulation of ECE using thiorphan, an inhibitor of E- 
24.11, resulted in an apparent increase in the levels of ECE in response to treatment of 
cells with µM concentrations of thiorphan. The ability of both these peptidase 
inhibitors to increase ECE levels detectable in cell membrane preparations ruled out 
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the possibility of autocatalytic regulation of ECE since ECE is generally considered to 
be insensitive to thiorphan. 
The possibility that inhibition of ECE was resulting in an intracellular accumulation of 
the ET processing intermediate, big ET-1 which in turn regulated ECE transcription or 
translation could be discounted by the observation that the administration of thiorphan 
would not diminish the rate of big ET-1 conversion, and would not be expected to 
increase ECE levels by this mechanism. In addition, TRLEC-03 cells, which were 
found not to express ECE-10 (Shimada et al., 1995) showed there was no increase in 
ECE-1 a mRNA following PR treatment suggesting the mechanism did not involve 
control of ECE-1 transcription. 
The most likely explanation consistent with these data is that treatment of cells with 
either PR or thiorphan inhibits the turnover of ECE resulting in an intracellular increase 
in the levels of this protein. Since E-24.11 is the only known mammalian enzyme 
which has been found to be sensitive to both PR and thiorphan, this was considered a 
candidate activity for ECE degradation. However, Barnes et al., (1996) demonstrated that 
E-24.11, which has been shown to have a strict specificity for oligopeptides (Kenny et 
al., 1987), was unable to degrade ECE protein and these findings, together with the 
data presented in this work suggests the existence of a novel metalloprotease activity, 
sensitive to both PR and thiorphan which is involved in the turnover of ECE and 
possibly other, as yet unidentified proteins. These data suggest this activity may be a 
protein of the E-24.1 1, ECE and Kell family of proteins. 
Further studies concerning the regulation of ECE expression involved the study of the 
role of protein tyrosine phosphorylation using the inhibitor of the protein tyrosine 
phosphatase inhibitor, vanadate. Previous studies had demonstrated that ET-1 release 
from HUVECs was suppressed following treatment of cells with vanadate. In this 
study, the effect of vanadate was studied in several cell lines and found to increase 
levels of ECE using enzymic assay and immunoblotting. The levels of increase were 
found to be approximately 2-3-fold in EA. hy926 and Bull cell lines. Previous work 
by Rogers et al., (1994) had demonstrated that rat pheochromocytoma PC 12 cells 
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responded to differentiation stimuli, including vanadate, by developing a phenotype 
resembling that expressed by neurons involving neunte extension to form a network. 
Using this observation as a morphological marker for this cell line, the effects of 
vanadate on ECE expression were studied. Interestingly, vanadate treatment appeared 
to induce ECE expression which showed negligible levels of ECE activity in untreated 
cells but was found to express significant levels of ECE following treatment of cells 
with vanadate suggesting differentiation to a neuronal phenotype induced ECE 
expression. 
The effect of vanadate on ECE expression observed in these cell lines , 
in parallel with 
the findings of Shimizu et al., (1994) suggest a possible feedback mechanism between 
the release of ET-1 and ECE production. Though the pathway through which this occurs 
cannot be conclusively proved from these data, the increase of ECE in response to 
vanadate treatment would suggest protein tyrosine phosphorylation is likely to be 
involved and this may prove to be a key event in the regulation of ECE expression 
levels by the cell. Cytokine regulation of ET production and ECE expression is a likely 
candidate. 
The publication of ECE-1 cDNA sequence data, and the identification of two distinct 
isoforms of ECE-1, a and ß allowed the generation of specific antibodies to each of 
these. Using a number of computer algorithms, including predictions of secondary 
structure, hydrophilicity and glycosylation sites, immunogenic regions of amino acids 
within the protein sequence were identified. Polyclonal antibodies were raised to these 
sequences and antibodies were affinity purified from antisera. One antibody specific 
for the ECE-1 a protein was successfully purified and was used to identify cells and 
tissues expressing this isoform. However, whilst immunoblotting of transfected CHO 
cells expressing high levels of the ECE-1 a isoform revealed the antibody to be highly 
specific for the a isoform compared with the ß form, the lower levels of ECE 
expressed in cultured cell lines and tissues, coupled with the lack of a positive control 
for the ß form made accurate quantification of ECE-1 a expression levels difficult. 
The identification of ECE-1 a in tissues may be accomplished by adapting the 
ISO 
immunoblotting protocol to reduce background staining, and altering the antibody 
incubation conditions to enhance immunorecognition of the protein. 
The molecular cloning of ECE led to rapid advances in the understanding of ECE and 
its physiological role in the generation of the vasoconstrictive peptide, ET in a variety 
of cells and tissues. There are however a number of questions concerning ECE which 
have remained unanswered. Data presented in this work have some implications 
regarding the treatment of pathophysiological conditions by inhibitors of ECE. The 
co-expression of ECE and E-24.11 in several brain cell types was identified by 
immunoblotting and enzymic assay (chapter 4) and emphasises the need for the design 
of specific inhibitors for both E-24.11 and ECE if these are to prove of therapeutic 
value. The accumulation of ECE in response to treatment of cells with PR or 
thiorphan raises the possibility that inhibitors of ECE, designed with the intention of 
inhibiting ECE to reduce levels of circulating ET may cause an increase in the levels of 
ECE in cells. Candidate inhibitors with the potential for therapeutic value would need 
to be thoroughly characterised in terms of their effect on overall ECE expression. 
The regulatory mechanisms involved in ECE production have not yet been identified 
but may represent novel targets for the pharmacological intervention of ET production 
by ECE. The effects of vanadate suggest protein tyrosine phosphorylation may prove 
to be a key event in the control of ECE expression, though other pathways involving 
kinase activity may be involved. 
The identification of the ECE-1 isoforms is intriguing. No significant difference in 
substrate specificity has been reported though it appears ECE-1 a is the predominant 
form in all cells and tissues examined so far (Shimada et al., 1995). To date, the 
physiological significance of the ECE-1 ß isoform remains unclear, though the 
exclusive expression of the ECE-1 a in transformed cell lines such as TRLEC-03 cells 
supports the possibility that ECE-1 0 may be down-regulated under certain conditions. 
To date, the apparent therapeutic potential of regulating production of ET by ECE has 
not yet been realised. In addition to the disease models in which ET has been 
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implicated (Table 1.1), recent studies indicate ET-1 may play a role in the pathogenesis 
of diseases other than those afflicting the cardiovascular system. Nelson et al., (1995), 
identified ET-1 overproduction in the pathogenesis of prostate cancer, and in cases 
such as this where direct reduction in ET levels is required, the inhibition of ECE-1 
activity may prove to be of therapeutic value. To date, there are no specific inhibitors 
selective for ECE over E-24.11. In addition, ECE has recently been shown to 
hydrolyse bradykinin at the Pro? -Phe8 bond (Hoang & Turner, 1997) suggesting 
further physiological substrates may exist for ECE. This observation may have 
implications concerning the design and therapeutic potential of ECE inhibitors. 
152 
REFERENCES 
Amberger, V. R., Paganetti, PA, Seulberger, H., Eldering, J. A. & Schwab, M. E. 
(1994) Cancer Res. 54,4017-4025. 
Ames, B. (1966) Methods Enn-jmol. 8,115-118. 
Arai, H., Hori, S., Aramori, I., Ohkubo, H. & Nakanishi, S. (1990) Nature 348,730- 
732. 
Aronson, N. N. & Touster, O. (1974) Methods Enzymol. 31,90-102. 
Auguet, M., Delaflotte, S., Chabrier, P. E. & Braquet, P. (1992) Eur. J. Pharmacol. 
224,101-102. 
Bacon, C. R, Carey, N. R. & Davenport, A. P. (1996) Circulation Res. 79,794-80 1. 
Balmforth, A. J., Ball, S. G., Freshney, R. I., Graham, D. I., McNamee, H. B. & Vaughan, 
P. F. T. (1986) J. Neurochem. 47,715-719. 
Barnes, K., Matsas, R, Hooper, N. M., Turner, A. J. & Kenny, A. J. (1988) 
Neuroscience 27,799-817. 
Barnes, K., Bourne, A., Cook, P. A., Turner, A. J. & Kenny, A. J. (1991) Neuroscience 
44,245-261. 
Barnes, K., Shimada, K., Takahashi, M., Tanzawa, K. & Turner, A. J. (1996) J. Cell. 
Sci. 109,919-928. 
Barone, F. C., Willette, RN., Yue, T. L. & Feuerstein, G. (1995) Neurol. Res. 4,259- 
264. 
Baynash, A. G., Hosoda, K., Giaid, A., Richardson, J. A., Emoto, N., Hammer, R. E. & 
Yanagisawa, M. (1994) Cell 79,1277-1285. 
Bdolah, A., Wollberg, Z., Fleminger, G. & Kochva, E. (1989) FEBS Left. 256,1-3. 
Benigni, A., Zoja, C., Coma, D., Orisio, S., Langaretti, L., Bertani, T. & Remuzzi, G. 
(1993) Kidney Int. 44,440-444. 
Bernier, M., Laird, D. M. & Lane, M. D. (1987) Proc. Natl. Acad. Sci. USA 84,1844- 
1848 
Bessey, O. A., Lowry, O. H. & Brock, M. J. (1946) J. Biol. Chem. 184,321-329. 
Bird, J. E., Waldron, T. E., Little, D. K., Asaad, M. M., Dorso, C. R, DiDonato, G. & 
Norman, J. A. (1992) Biochem. Biophys. Res. Commun. 182,224-23 1. 
Booth, A. G. & Kenny, A. J. (1974) Biochem. J. 142,575-581. 
Bordier, C. (1981)J. Biol. Chem. 256,1604-1607. 
Brown, D. J. & Gordon, J. A. (1984) J. Biol. Chem. 259,9580-9586. 
Budzik, G. P., Dillon, T. P., Devine, E. M., Marselle, C. A., Wu-Wong, J. R, & 
Opgenorth, T. J. (1991) FASEB J. 5, A1017. 
Bums, J. F. (1995) J. Clin. Pharmacol. 35,337-342. 
Caldwell, P. R. B., Seegal, B. C. & Hsu, K. C. (1976) Science 191,1050-1051. 
153 
Cantley, R. C., Josephson, L., Warner, it, Yanagisawa, M., Lechene, C. & Guidotti, 
G. (1977) J. Biol. Chem. 252,7421-7423. 
Cardell, L. O., Uddman, R. & Edvinsson, L. (1992) Br. J. Pharmacol. 105,376-380. 
Carey, J. O., Azevedo, J. L., Morris, P. G., Pories, W. J. & Dohm, G. L. (1995) Diabetes 
44,682-688. 
Chou, P. Y. & Fasman, G. D. (1978) Adv. Enzymnol. 47,45-158. 
Clozel, M., Gray, G. A., Breu, W., Loffler, B. M. & Osterwalder, R. (1992) Biochem. 
Biophys. Res. Commun. 186,867-873. 
Clozel, M., Breu, V., Burn, K., Cassal, J., Fischli, W., Gray, G. A., Hirth, G., Loffler, 
B. M., Muller, M., Neidhart, W. & Ramuz, H. (1993) Nature 365,759-761. 
Connelly, J. C., Skidgel, R. A., Schulz, W. W., Johnson, A. R. & Erdos, E. G. (1985) 
Proc. Natl. Acad. Sci. USA 82,8737-8741. 
Corder, R., Harrison, V. J., Khan, N., Anggard, E. E. & Vane, J. R. (1993) J. 
Cardiovasc. Pharmacol. 22, S73-S78. 
Corder, R., Khan, N. & Harrison, V. J. (1995) Biochem. Biophys. Res. Commun. 207, 
355-362. 
Corder, R. & Vane, J. R. (1995) Biochem. Pharmacol. 49,375-380. 
Creighton, T. E. (1993) In: Proteins, structures and molecular properties pp. 255- 
257, W. H. Freeman & Co. 
D'Adamio, L., Shipp, M. A., Masteller, E. L. & Reinherz, E. L. (1989) Proc. Natl. 
Acad. Sci. USA 86,7103-7107. 
Danthuluri, N. R. & Brock, T. A. (1990) J. Pharmacol & Exp. Ther. 254,393- 99. 
Davitz, M. A., Hereld, D., Shak, S., Krakow, J., Englund, P. T. & Nussenzweig, V. 
(1987) Science 238,81-84. 
Davitz, M. A., Hom, J. & Schenkman, S. (1989) J. Biol. Chem. 264,13760-13764. 
DeClerck, Y. A. & Imren, S. (1994) Eur. J. Cancer 30A, 2170-2180. 
De Mey, J. G. & Vanhoutte, P. M. (1983) J. Physiol. (Loud. ) 335,65-74. 
Denault, J. B., Claing, A., D'Orleans-Juste, P., Sawamura, T., Kido, T., Masaki, T. & 
Leduc, R. (1995) FEBS Lett. 362,276-280. 
Deng, Y., Savage, P., Shetty, S. S., Martin, L. L. & Jeng, A. Y. (1992) J. Biochem. 
(Tokyo) 111,346-351. 
Deschepper, C. F., Houweling, A. D. & Picard, S. (1995) Eur. J. Pharmacol. 275,61- 
66. 
Devault, A., Lazure, C., Nault, C., LeMoual, H., Seidah, N. G., Chretien, M., Kahn, P., 
Powell, J., Mallet, J., Beaumont, A., Roques, B. P., Crine, P. & Boileau, G. 
(1987) EMBOJ. 6,1317-1322. 
Devine, E. M., Marselle, C. A., Pederson, T. M., Wu-Wong, J. R. Budzik, G. P., Dillon, 
T. P. & Opgenorth, T. J. (1991)FASEBJ. 5, A1417 
154 
Duksin, D. & Mahoney, W. C. (1982) J. Biol. Chem. 257,3105-3109. 
Edgell, C. -J. S., McDonald, C. C. & Graham, J. B. (1983) Proc. Natl. Acad. Sci. USA 
80,3734-3737. 
Egan, R. W., Jones, M. A. & Lehninger, A. L. (1976) J. Biol. Chem. 251,4442-4447. 
Ehrenreich, H., Kehrl, J. H., Anderson, R. W., Rieckmann, P., Vitkovic, L., Coligan, 
J. E. & Fauci, A. S. (1991) Brain Res. 538,54-58. 
Ellman, G. L. (1959) Arch. Biochem. Biophys. 82,70-74. 
Elshourbagy, N. A., Adamou, J. E. Gagnon, A. W., Wu, H. -L., Pullen, M. & Nambi, P. 
(1996) J. Biol. Chem. 271,25300-25307. 
Emini, E. A., Hughes, J. V., Perlow, D. S & Boger, J. (1985) J. Virol. 55,836-839. 
Emori, T., Hirata, Y., Ohta, K., Shichiri, M., Shimokado, K. & Marumo, F. (1989) 
Biochem. Biophys. Res. Common. 162,217-223. 
Emoto, N& Yanagisawa, M. (1995) J. Biol. Chem. 270,15262-15268. 
Ferguson, M. A. J., Low, M. G. & Cross, G. A. M. (1985) J. Biol. Chem. 260,14547- 
14555 
Fox, J. A., Soliz, N. M. & Saltiel, AR- (1987) Proc. Natl. Acad. Sci. USA 84,2663- 
2667. 
Fulcher, I. S. & Kenny, A. J. (1983) Biochem. J. 211,743-753. 
Furchgott, R. F. & Zawadzki, J. V. (1980) Nature 288,373-376. 
Fuxe, K., Tinner, B., Staines, W., Hemsen, A., Hersh, L. & Lundberg, J. M. (1991) 
Neurosci. Lett. 123,107-111. 
Garcia-Morales, P., Minami, Y., Luong, E., Klausner, RD. & Samelson, L. E. (1990) 
Proc. Natl. Acad. Sci. USA 87,9255-9259. 
Gardner, J. P., Tokudome, G., Tomonari, H., Maher, E., Hollander, D. & Aviv, A. 
(1992) Am. J. Physiol. 262, C148-C155. 
Garner, J., Osguthorpe, D. J. & Robson, B. (1978) J. Mol. Biol. 120,97-120. 
Gee, N. S., Matsas, R. & Kenny, A. J. (1983) Biochem. J. 214,377-386. 
Gee, N. S. & Kenny, A. J. (1985) Biochem. Soc. Trans 13,101-102. 
Gee, N. S., Bowes, M. A., Buck, P. & Kenny, A. J. (1985) Biochem. J. 228,119-126. 
Giaid, A., Gibson, S. J., Herrero, M. T., Gentleman, S., Legon, S., Yanagisawa, M., 
Masaki, T., Ibrahim, N. B. N., Roberts, G. W., Rossi, M. L. & Polak, J. M. (1991) 
Histochemistry 95,303-314. 
Gillespie, M., Owasoyo, J., McMurty, I. & O'Brien, R. (1986) Fxp. Ther. 236,339- 
343. 
Gordon, J. A. (1991)Meth. Enymol. 201,477-482. 
Goto, K., Kasuya, Y., Matsuki, N., Takuwa, Y., Kurihara, H., Ishikawa, T., Kimura, 
S., Yanagisawa, M. & Masaki, T. (1989) Proc. Natl. Acad. Sci. USA 86,3915- 
3918. 
155 
Gray, G. A. & Clozel, M. (1994) Br. J. Pharmacol. 112, U62. 
Gray, G. A., & Webb, D. J. (1996) Pharmacol. Ther. 72,109-148. 
Greene, L. A. & Tischler, A (1976) Proc. Natl. Acad. Sci. 73,2424-2428. 
Grover, G. J., Dzwonczyk, S. & Parham, C. S. (1993) Cardiovasc. Res. 27,1613-1618. 
Gui, G., Xu, D., Emoto, N. & Yanagisawa, M. (1993) J. Cardiovasc. Pharmacol. 22, 
S53-S56. 
Harrison, V. J., Corder, R, Anggard, E. E. & Vane, J. R. (1993) J. Cardiovasc. 
Pharmacol. 22, S57-S60. 
Hartley, B. S. (1960) Annzi. Rev. Biochem. 29,45-72. 
Heifetz, A., Keenan, R. W. & Elbein, A. D. (1979) Biochemistry 18,2186-2192. 
Hickey, K. A., Rubanyi, G., Paul, R. I. & Highsmith, R. F. (1985) Am. J. Physiol. 248, 
C550-C556. 
Hioki, Y., Okada, K., Ito, H., Matsuyama, K. & Yano, M. (1991) Biochem. Biophys. 
Res. Common. 174,446-451. 
Hoang, M. V. & Turner, A. J. (1997) Biochem. J. 327,23-26. 
Hooper, N. M., Low, M. G. & Turner, A. J. (1987) Biochem. J. 244,465-469. 
Hooper, N. M. & Turner, A. J. (1988 a) FEBSLett. 229,340-344. 
Hooper, N. M. & Turner, A. J. (1988 b) Biochem. J. 250,865-869. 
Hooper, N. M. (1992) Identification of a glycosyl-phosphatidylinositol anchor on 
membrane proteins. In: Lipid modification of proteins, a practical approach 
(Eds. Hooper, N. M. & Turner, A. J. ), pp. 89-115, Oxford University Press, 
Oxford, U. K. 
Hosoda, K., Hammer, RE., Richardson, J. A., Baynash, A. G., Cheung, J. C., Giaid, A. 
& Yanagisawa, M. (1994) Cell 79,1267-1276. 
Howell, S., Murray, H., Turner, A. J. & Kenny, A. J. (1991) Biochem. J. 278,417-421. 
Hu, R-M., Levin, E. R, Pedram, A. & Frank, H. J. L. (1993) Diabetes 42,351-358. 
Hunziker, W., Spiess, M., Semenza, G. & Lodish, H. F. (1986) Cell 46,227-234. 
Ichai, C., Chevallier, N., Delaere, P., Dournaud, P., Epelbaum, J., Hauw, J. J., Vincent, 
J. P. & Checler, F. (1994) J. Neurochem. 62,645-655. 
Ignarro, L., Buga, G., Wood, K., Byms, R. & Chaudhuri, G. (1987) Proc. Natl. Acad. 
Sci. USA 84,9265-9269. 
Ikegawa, R, Matsumura, Y., Tsukahara, Y., Takaoka, M. & Morimoto, S. (1990 a) 
Biochem. Biophys. Res. Commun. 171,669-675. 
Ikegawa, R, Matsumura, Y., Takaoka, M. & Morimoto, S. (1990 b) Biochem. 
Biophys Res. Common. 167,860-866. 
Ikezawa, H. & Taguchi, R. (1981) Methods Enzymol. 71,731-741. 
156 
Ikura, T., Sawamura, T., Shiraki, T., Hosokawa, H., Kido, T., Hoshikawa, H., 
Shimada, K., Tanzawa, K., Kobayashi, S., Miwa, S. & Masaki, T. (1994) 
Biochem. Biophys. Res. Commun. 203,1417-1422. 
Indig, F. E., Ben-Meir, D., Spungin, A. & Blumberg, S. (1989) FEBSLett. 255,237- 
240. 
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K. & Masaki, 
T. (1989) Proc. Natl. Acacl Sci. USA 86,2863-2867. 
Itoh, S., Sasaki, T., Ide, K., Ishikawa, K., Nishikibe, M. & Yano, M. (1993) Biochem. 
Biophys. Res. Commun. 195,969-975. 
Jaffe, E. A., Nachman, R. L. & Becker, C. G. (1973) J. Clin. Invest. 52,2745-2758. 
Jaffe, E. A. (1987) Human Path. 18,234-239. 
Jameson, B. A. & Wolf, H. (1988) Computer Applications in the Biosciences 4,181- 
186. 
Jochum, M., Machleidt, W. & Fritz, H. (1993) Agents Actions Suppl. 42,51-69. 
Jones, C. R., Hiley, C. R., Pelton, J. J. & Mohr, M. (1989) Neurosci. Lett. 97,276-279. 
Kai, H., Kanaide, H. & Nakamura, M. (1989) Biochem. Biophys. Res. Commun. 158, 
235-243 
Kametani, F., Haga, S., Tanaka, K. & Ishii, T. (1990) J. Neurol. Sci. 97,43-52. 
Karplus, P. A. & Schulz, G. E. (1985) Naturwissenschaften 72,212-213. 
Kashiwabara, T., Inagaki, Y., Ohta, H., Iwamatsu, A., Nomizu, M., Morita, A. & 
Nishikori, K. (1989) FEBSLett. 247,73-76. 
Kasuya, Y., Takuwa, Y., Yanagisawa, M., Kimura, S., Goto, K. & Masaki, T. (1989) 
Biochem. Biophys Res. Commun. 161,1049-1055. 
Keller, R. K., Boon, D. Y. & Crum, F. C. (1979) Biochemistry 18,3946-3952. 
Kennedy, R. L., Haynes, W. G. & Webb, D. J. (1993) Clin. Endocrinol. (Oxf. ) 39,259- 
265. 
Kenny, A. J. (1977) Proteinases associated with cell membranes. In : Proteinases in 
mammalian cells and tissues (Ed. Barrett, A. J. ), pp 393-444, Elsevier/North 
Holland Biochemical Press, Amsterdam. 
Kenny, A. J., Stephenson, S. L. & Turner, A. J. (1987) Cell Surface Peptidases. In : 
Mammalian ectoenzymes (Eds. Kenny, A. J. & Turner, A. J. ), pp. 169-210, 
Elsevier, Amsterdam. 
Kenny, A. J. & Hooper, N. M. (1991) Peptidases involved in the metabolism of 
bioactive peptides. In: Degradation of bioactive substances: physiology and 
pathophysiology (Ed. Henriksen, J. H. ), pp. 47-79, CRC Press, Florida. 
Kerr, M. A. & Kenny, A. J. (1974 a) Biochem. J. 137,489-495. 
Kerr, M. A. & Kenny, A. J. (1974 b) Biochem. J. 137,477-488. 
157 
Kido, T., Sawamura, T., Hoshikawa, H., D'Orleans-Juste, P., Denault, J. B., Leduc, R., 
Kimura, J. & Masaki, T. (1997) Eur. J. Biochem. 244,520-526. 
Kimura, S., Kaysuya, Y., Sawamura, T., Shinmi, 0., Sugita, Y., Yanagisawa, M., 
Goto, K. & Masaki, T. (1989) J. Cardiovasc. Pharmacol. 13, S5-S7. 
Kirkness, E. F. & Turner, A. J. (1988) Biochem. J. 256,291-294. 
Kloog, Y., Ambar, I., Sokolovsky, M., Kochva, E., Wollberg, Z. & Bdolah, A. (1988) 
Science 242,268-270. 
Kuo, S. -C. & Lampen, J. O. (1974) Biochem. Biophys. Res. Commun. 58,287-295. 
Kurihara, H., Yoshizumi, M., Sugiyama, T., Takaku, F., Yanagisawa, M., Masaki, T., 
Hamaoki, M., Kato, H. & Yazaki, Y. (1989) Biochem. Biophys. Res. Commun. 
159,1435-1440. 
Kurihara, M., Ochi, A., Kawaguchi, T., Niwa, M., Kataoka, Y. & Mori, K. (1990) 
Neurosurgery 27,275-281. 
Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R., Oda, H., 
Kuwaki, T., Cao, W., Kamada, N., Jishage, K., Ouchi, Y., Azuma, S., Toyoda, 
Y., Ishikawa T., Kumada, M. & Yazaki, Y. (1994) Nature 368,703-710. 
Kyte, J. & Doolittle, R. F. (1982) J. Mol. Biol. 157,105-132. 
Laemmli, U. K. (1970) Nature 227,680-685. 
Laperche, Y., Bulle, F., Aissani, T., Chobert, M., Aggerbeck, M., Hanoue, J. & 
Gullaen, G. (1986) Proc. Natl. Acad. Sci. USA 83,937-941. 
Lazarini, F., Strosberg, A. D., Couraud, P. O. & Cazaubon, S. M. (1996) J. Neurochem. 
66,459-465. 
Lee, M. E., de la Monte, S. M., Ng, S. C., Bloch, K. D. & Quertermous, T. (1990) J. 
Clin. Invest. 86,141-147. 
Lee, S., Zambas, E. D., Marsh, W. L. & Redman, C. M. (1991) Proc. Natl. Acad. Sci 
USA 88,6353-6357. 
Lee, S., Zambas, E. D., Green, E. D. & Redman, C. M. (1995) Blood 85,1364-1370. 
Lees, W. A., Kalinka, S., Meech, J., Capper, S. J., Cook, N. D. & Kay, J. (1990) FEBS 
Lett. 273,99-102. 
Letarte, M., Vera, S., Tran, R., Addis, J. B., Onizuka, R. J., Quackenbush, E. J., 
Jongeneel, C. V. & McInnes, R. R. (1988) J. Exp. Med 168,1247-1253. 
Low, M. G. (1989) Biochem. Biophys. Acta 988,427. 
Low, M. G. (1990) Degradation of glycosyl-phosphatidylinositol anchors by specific 
phospholipases. In: Cell and molecular biology of membrane proteins (Ed. 
Turner, A. J. ), pp. 35-63, Ellis Horwood, Chichester. 
Luscher, T. F. (1992) Eur. Heart. J. 13, D50-D55. 
MacCumber, M. W., Ross, C. A. & Snyder, S. H. (1990) Proc. Natl. Acad. Sci. USA 87, 
2359-2363. 
158 
Mahadevan, L. C. & Bell, J. C. (1989) In: Receptors, a practical approach (Ed. Hulme, 
E. ), pp. 181-201, IRL Press, Oxford, U. K. 
Malfroy, B., Schofield, P. R., Kuang, W. -J., Seeburg, P. H., Mason, A. J. & Henzel, 
W. J. (1987) Biochem. Biophys. Res. Commun. 144,59-66. 
Malfroy, B., Kuang, W. -J., Seeburg, P. H., Mason, A. J. & Schofield, P. R. (1988) 
FEBS Lett. 229,206-210. 
Marshall, RD. (1972) Annu. Rev. Biochem. 41,673-702. 
Masaki, T., Kimura, S., Yanagisawa, M. & Goto, K. (1991) Circulation 84,1457- 
1468. 
Masaki, T. & Yanagisawa, M. (1992) Essays Biochem. 27,79-89. 
Masuda, Y., Miyazaki, H., Kondah, M., Watanabe, H., Yanagisawa, M., Masaki, T. & 
Murakami, K. (1989) FEBS Lett. 257,208-210. 
Matsas, R., Fulcher, I. S., Kenny, A. J. & Turner, A. J. (1983) Proc. Natl. Acad. Sci. 
USA 80,3111-3115. 
Matsumura, Y., Ikegawa, R, Takaoka, M. & Morimoto, S. (1990 a) Biochem. 
Biophys. Res. Commun. 167,203-210. 
Matsumura, Y., Ikegawa, R., Tsukahara, Y., Takaoka, M. & Morimoto, S. (1990 b) 
FEBSLett. 272,166-170. 
Matsumura, Y., Hisaki, K., Takaoka, M. & Morimoto, S. (1990 c) Eur. J. Pharmacol. 
185,103-106 
Matsumura, Y., Ikegawa, R, Tsukahara, Y., Takaoka, M. & Morimoto, S. (1991 a) 
Biochem. Biophys. Res. Commun. 178,531-538. 
Matsumura, Y., Ikegawa, R, Tsukahara, Y., Takaoka, M. & Morimoto, S. (1991 b) 
Biochem. Biophys. Res. Commun. 178,899-905. 
McMahon, E. G., Fok, K. F., Moore, W. M., Smith, C. E., Siegel, N. R. & Trapani, A. J. 
(1989) Biochem. Biophys. Res. Commun. 161,406-413. 
McMahon, E. G., Palomo, M. A., Moore, W. M., McDonald, J. F. & Stern, M. K. (1991) 
Proc. Natl. Acad. Sci. USA 88,703-707. 
Medeiros, M. S., Balmforth, A. J., Vaughan, P. F. T. & Turner, A. J. (1991) 
Neuroendocrinology 54,295-302. 
Merida, I. & Gaulton, G. N. (1990) J. Biol. Chem. 265,5690-5694. 
Mikulewicz, W., Berdowska, I., Jarmulowicz, J. & Siewinski, M. (1993) Anti-cancer 
Drugs 4,341-344. 
Molnar, E., Baucle, A., Richmond, S. A., Patel, P. B., Somogyi, P. & Mellhinney, 
R. A. J. (1993) Neuroscience 53,307-326. 
Moncada, S., Gryglewski, R, Bunting, S. & Vane, J. R. (1976) Nature 263,663-665. 
Murphy, L. J., Corder, R., Mallet, A. I. & Turner, A. J. (1994) Br. J. Pharmacol. 113, 
137-142. 
159 
Murphy, N. P., Ball, S. G. & Vaughan, P. F. T. (1991) J. Neurochem. 56,1810-1814. 
Nambi, P., Pullen, M. & Feuerstein, G. (1990) Neuropeptides 16,195-199. 
Nechay, B. R, Nanninga, L. B., Nechay, P. S. E., Post, R. L., Grantham, J. J., Macara, 
I. G., Kubena, L. F., Phillips, T. D. & Nielsen, F. H. (1986) Fedn. Proc. 45,123- 
132. 
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, 
M. A. & Simons, J. W. (1995) Nature Med 1,944-949. 
Niman, H. L., Houghton, R. A., Walker, L. E., Reisfeld, R. A., Wilson, I. A., Hogle, J. M. 
& Lerner, R. A. (1983) Proc. Natl. Acad. Sci. USA 80,4949-4953. 
Nishikawa, K. (1983) Biochim. Biophys. Acta 748,285-299. 
Oakley, B. R., Kirsch, D. R. & Morris, N. R. (1980) Anal. Biochem. 105,361-363. 
O'Brien, R, Robbins, R. J. & McMurty, IF. (1987) J. Cell Physiol. 135,263-270. 
Ohlstein, E. H., Nambi, P., Douglas, S. A., Edwards, R. M., Gellai, M., Lago, A., Leber, 
J. D., Cousins, RD., Gao, A., Frazee, IS., Peishoff, C. E., Bean, J. W., 
Eggleston, D. S., Elshourbagy, N. A., Kumar, C., Lee, J. A., Brooks, D. P., 
Weinstock, J., Feuerstein, G., Poste, G., Ruffolo, RR., Gleason, J. G. & Elliot, 
J. D. (1994) Proc. Natl. Acad. Sci. USA 91,8052-8056. 
Ohnaka, K., Takayanagi, R., Yamauchi, T., Okazaki, H., Ohashi, M., Umeda, F. & 
Nawata, H. (1990) Biochem. Biophys. Res. Commun. 168,1128-1136. 
Ohnaka, K., Takayanagi, R., Nishikawa, M., Haji, M. & Nawata, H. (1993) J. Biol. 
Chem. 268,26759-26766. 
Okada, K., Miyazaki, Y., Takada, J., Matsuyama, K., Yamaki, T. & Yano, M. (1990) 
Biochem. Biophys. Res. Commun. 171,1192-1198. 
Palmer, R, Ferrige, A. & Moncada, S. (1987) Nature 327,524-526. 
Pekonen, F., Nyman, T., Ammala, M. & Rutanen, E. -M. (1995) Br. J. Cancer 71,59- 
63. 
Petruzzelli, L., Herrera, R& Rosen, O. M. (1984) Proc. Natl. Acad. Sci. USA 81, 
3327-3331. 
Pless, D. D. & Lennarz, W. J. (1977) Proc. Natl. Acad. Sci. USA 74,134-138. 
Pollock, D. M. & Opgenorth, T. J. (1991) Am. J. Physiol. 261, R257-R263. 
Puffenberger, E. G., Hosoda, K., Washington, S. S., Nakao, K., deWit, D., Yanagisawa, 
M. & Chakravarti, A. (1994) Cell 79,1257-1266. 
Relton, J. M., Gee, N. S., Matsas, R., Turner, A. J. & Kenny, A. J. (1983) Biochem. J. 
215,519-523. 
Remme, W. J. (1995) Eur. Heart J. 16,73-78. 
Resink, T. J. Scott-Burden, T. & Buhler, F. R. (1988) Biochem. Biophys. Res. 
Commun. 157,1360-1368. 
Robinson, P. S., Lees, W. E., Kay, J. & Cook, N. D. (1992) Biochem. J. 284,407-409. 
160 
Rogers, M. V., Buensuceso, C., Montague, F. & Mahadevan, L. (1994) Neuroscience 
60,479-494. 
Ross, R., Spengler, B. & Biedler, J. (1985) J. Cancer Inst. 71,741-747. 
Saijonmaa, 0., Nyman, T., Hohenthal, U. & Fyhrquist, F. (1991) Biochem. Biophys. 
Res. Commun. 181,529-536. 
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K. & 
Masaki, T. (1990) Nature 348,732-735. 
Sakurai, T., Yanagisawa, M. & Masaki, T. (1992) Trends Pharmacol. Sci. 13,103- 
108. 
Saltzman, E. M., Thom, R. R. & Casnellie, J. E. (1988) J. Biol. Chem. 263,6956-6959. 
Samson, W. K., Skala, D., Alexander, B. D. & Huang, F. L. S. (1990) Biochem. Biophys. 
Res. Commun. 169,737-743. 
Samson, W. K., Skala, K. D., Alexander, B. D. & Huang, F. L. (1991 a) J. Cardiovasc. 
Pharmacol. 17, S346-S349. 
Samson, W. K., Skala, K. D., Huang, F. L., Gluntz, S., Alexander, B. & Gomez- 
Sanchez, C. E. (1991 b) Brain Res. 539,347-351. 
Samson, W. K., Skala, K. D., Alexander, B. D. & Huang, F. L. (1991 c) Endocrinology 
128,1465-1473. 
Santini, F. & Beaven, M. A., (1993) J. Biol. Chem. 268,22716-22722. 
Sawamura, T., Kimura, S., Shinmi, 0., Sugita, Y., Yanagisawa, M., & Masaki, T. 
(1989) Biochem. Biophys. Res. Commun. 162,1287-1294. 
Sawamura, T., Kimura, S., Shinmi, 0., Sugita, Y., Kobayashi, M., Mitsui, Y., 
Yanagisawa, M., Goto, K. & Masaki, T. (1990 a) Biochem. Biophys. Res. 
Commun. 169,1138-1144. 
Sawamura, T., Kimura, S., Shinmi, 0., Sugita, Y., Yanagisawa, M., Goto, K. & 
Masaki, T. (1990 b) Biochem. Biophys. Res. Commun. 168,1230-1236. 
Sawamura, T., Shinmi, 0., Kishi, N., Sugita, Y., Yanagisawa, M., Goto, K., Masaki, 
T. & Kimura, S. (1990 c) 172,883-889. 
Scheidtmann, K. H. (1990) In: Protein Structure, a practical approach (Ed. Creighton, 
T. E. ), IRL Press, Oxford, U. K. 
Schmidt, M., Kroger, B., Jacob, E., Seulberger, H., Subkowski, T., Otter, R., Meyer, 
T., Schmalzing, G. & Hillen, H. (1994) FEBSLett 356,238-243. 
Schwartz, M. K. & Bodansky, O. (1966) Methods Enz mol. 9,294-302. 
Shields, P. P., Gonzales, T. A., Charles, D., Gilligan, J. P. & Stern, W. (1991) Biochem. 
Biophys. Res. Commun. 177,1006-1012. 
Shimada, K., Takahashi, M. & Tanzawa, K. (1994) J. Biol. Chem. 269,18275-18278. 
Shimada, K., Takahashi, M., Ikeda, M. & Tanzawa, K. (1995) FEBSLett. 371,140- 
144. 
161 
Shimizu, H., Takayama, H., Lee, J. -D., Satake, K., Taniguchi, T., Yamamura, H. & 
Nakamura, T. (1994) Thrombosis and Haemostasis 72,973-978. 
Shinyama, H., Uchida, T., Kido, H., Hayashi, K., Watanabe, M., Matsumura, Y., 
Ikegawa, R, Takaoka, M. & Morimoto, S. (1991) Biochem. Biophys. Res. 
Commun. 178,24-30. 
Shipp, M. A., Vijayaraghavan, J., Schmidt, E. V., Masteller, E. L., D'Adamio, L., Hersh, 
L. B. & Reinherz, E. L. (1989) Proc. Natl. Acad. Sci. USA 86,297-301. 
Simons, T. J. B. (1979) Nature 281,337-338. 
Smith, P. K., Krohn, RI., Hermanson, G. T., Mallia, AK., Gartner, F. H., Provenzano, 
M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. & Klenk, D. C. (1985) Anal. 
Biochem. 150,76-85. 
Sokolovsky, M., Galron, R, Kloog, Y., Bdolah, A., Indig, F. E., Blumberg, S. & 
Fleminger, G. (1990) Proc. Natl. Acad. Sci. USA 87,4702-4706. 
Sokolovsky, M., Ambar, I. & Galron, R (1992) J. Biol. Chem. 267,20551-20554. 
Sossin, W. S., Fisher, J. M. & Scheller, RH. (1989) Neuron 2,1407-1417. 
Stein, P. D., Hunt, J. T., Floyd, D. M., Moreland, S., Dickinson, K. E. J., Mitchell, C., 
Liu, E. C. -K., Webb, M. L., Murugesan, N., Dickey, J., McMullen, D., 
Zhang, R., Lee, V. G., Serafino, R., Delaney, C., Schaeffer, T. R & Kozlowski, 
M. (1994) J. Med Chem. 37,329-331. 
Stephenson, F. A. & Duggan, M. J. (1991) Chapter 9 in: Molecular Neurobiology, a 
practical approach (Eds. Chad, J. & Wheal, H. ), pp 183-204, IRL Press, 
Oxford, U. K. 
Suda, H., Aoyagi, T., Takeuchi, T. & Umezawa, H. (1973) J. Antibiot. (Tokyo) 26, 
621-623. 
Sumner, M. J., Cannon, T. R, Mundin, J. W., White, D. G. & Watts, I. S. (1992) Br. J. 
Pharmacol. 107,858-860. 
Takada, J., Okada, K., Ikenaga, T., Matsuyama, K. & Yano, M. (1991) Biochem. 
Biophys. Res. Commun. 176,860-865. 
Takahashi, M., Matsushita, Y., Iijima, Y. & Tanzawa, K. (1993) J. Biol. Chem. 268, 
21394-21398. 
Takahashi, M., Fukuda, K., Shimada, K., Barnes, K., Turner, A. J., Ikeda, M., Koike, 
H., Yamamoto, Y. & Tanzawa, K. (1995) Biochem. J. 311,657-665. 
Takaoka, M., Miyata, Y., Takenobu, Y., Ikegawa, R, Matsumura, Y. & Morimoto, S. 
(1990 a) Biochem. J. 270,541-544. 
Takaoka, M., Takenobu, Y., Miyata, Y., Ikegawa, R., Matsumura, Y. & Morimoto, S. 
(1990 b) Biochem. Biophys. Res. Commun. 166,436-442. 
Takaoka, M., Hukumori, Y., Shiragami, K., Ikegawa, R., Matsumura, Y. & 
Morimoto, S. (1990 c) Biochem. Biophys. Res. Commun. 173,1218-1223. 
162 
Takaoka, M., Shiragami, K., Fujino, K., Miki, K., Miyake, Y., Yasuda, M., Wang, 
G. F., Hisaki, K., Matsumura, Y. & Morimoto, S. (1991) Biochem. 11111.25, 
697-704 
Takatsuki, A. & Tamura, G. (1971 a) J. Antibiot. 24,785-794. 
Takatsuki, A. & Tamura, G. (1971 b) J. Antibiot. 24,224-23 1. 
Takuwa, Y., Kasuya, Y., Takuwa, N., Kudo, M., Yanagisawa, M., Goto, K., Masaki, 
T. & Yamashita, K. (1990) J. Clin. Invest. 85,653-658. 
Takuwa, Y., Masaki, T. & Yamashita, K. (1991) Contributions To Nephrology 90,99- 
104. 
Tamura, S., Brown, T. A., Whipple, J. H., Fujita-Yamaguchi, Y., Dubler, R. E., Cheng, 
K. & Larner, J. (1984) J. Biol. Chem. 259,6650-6658. 
Tanford, C. & Reynolds, J. A. (1976) Biochim. Biophys. Acta 457,113-170. 
Taniguchi, K., Morimoto, S., Fukuo, K., Yanagisawa, M., Masaki, T., Suzuki, N. & 
Ogihara, T. (1992) Hypertens. Res. 15,171-175. 
The HYP Consortium (1995) Nature Genet. 11,130-136. 
Turner, A. J., Matsas, R& Kenny, A. J. (1985) Biochem. Pharmacol. 34,1347-13 56. 
Turner, A. J., Hooper, N. M. & Kenny, A. J. (1989) Neuropeptide-degrading enzymes. 
In: Neuropeptides: a methodology (Eds. Fink, G. & Harmer, A. J. ), pp. 189- 
223, John Wiley & Sons, Chichester. 
Turner, A. J. & Murphy, L. J. (1996) Biochem. Pharmacol. 51,91-102. 
Turner, A. J. & Tanzawa, K. (1997) FASEB J. 11,355-363. 
Valdenaire, 0., Rohrbacher, E., Mattei, M. -G. (1995) J. Biol. Chem. 270,29794- 
29798. 
Vane, J. R, Anggard, E. E. & Botting, R. M. (1990) New England J. Med. 323,27-36. 
Vijayaraghavan, J., Scicli, A. G., Carretero, O. A., Slaughter, C., Moomaw, C. & 
Hersh, L. B. (1990) J. Biol. Chem. 265,14150-14155. 
Wagner-Mann, C. E., Bowman, L. & Sturek, M. (1991) Am. J. Physiol. 260, C763- 
C770. 
Wagner-Mann, C. E. & Sturek, M. (1991) Am. J. Pharmacol. 260, C771-C777. 
Walsh, D. A., Mapp, P. I., Wharton, J., Polak, J. M. & Blake, D. R. (1993) Am. J. 
Pathol. 142,1610-1621. 
Warner, T. D., de Nucci, G. & Vane, J. R. (1989 a) Eur. J. Pharmacol. 159,325-326. 
Warner, T. D., Mitchell, J. A., de Nucci, G. & Vane, J. R. (1989 b) J. Cardiovasc. 
Pharmacol. 13, S85-S88. 
Warner, T. D., Budzik, G. P., Matsumoto, T., Mitchell, J. A., Forstermann, U. & 
Murad, F. (1992 a) Br. J. Pharmacol. 106,948-952. 
Warner, T. D., Budzik, G. P., Mitchell, J. A., Huang, Z. -J. & Murad, F. (1992 b) J. 
Cardiovasc. Pharmacol. 20, S19-S21. 
163 
Warner, T. D., Allcock, G. H., Corder, R. & Vane, J. R. (1993 a) Br. J. Pharmacol. 
110,777-782. 
Warner, T. D., Allcock, G. H., Mickley, E. J., Corder, R& Vane, J. R. (1993 b) J. 
Cardiovasc. Pharmacol. 22, S 117-S 120. 
Watanabe, K., Miyazaki, H., Kondoh, M., Masuda, Y., Kimura, S., Yanagisawa, M., 
Masaki, T. & Murakami, K. (1989) Biochem. Biophys. Res. Commun. 161, 
1252-1259. 
Watanabe, K., Tamaru, N. & Yoshida, M. (1991) Cell Biol. Int. Rep. 15,205-210. 
Watanabe, K. & Jaffe, E. A. (1993) Prostaglandins Leukot. Essent. Fatty Acids 49, 
955-958. 
Wenthold, R. J., Yokotani, N., Doi, K. & Wada, K. (1992) J. Biol. Chem. 267,501- 
507. 
Widdows, K. B., Kirkness, E. F. & Turner, A. J. (1987) FEBS Lett. 222,125-128. 
Wu-Wong, J. R., Budzik, G. P., Devine, E. M. & Opgenorth, T. J. (1990) Biochem. 
Biophys. Res. Commun. 171,1291-1296. 
Wu-Wong, J. R, Devine, E. M., Budzik, G. P. & Opgenorth, T. J. (1991) J. Cardiovasc. 
Pharmacol. 17,520-525. 
Wu-Wong, J. R., Chiou, W. J., Magnuson, S. R. & Opgenorth, T. J. (1995) J. 
Pharmacol. Exp. Therapeutics 274,499-507. 
Wu-Wong, J. R, Chiou, W. J., Magnuson, S. R., Bianchi, B. R & Lin, C. W. (1996) 
Biochim. Biophys. Acta 1311,155-163. 
Wypij, D. M., Nichols, J. S., Novak, P. J., Stacy, D. L., Berman, J. & Wiseman, J. S. 
(1992) Biochem. Pharmacol. 43,845-853. 
Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D. & Yanagisawa, M. 
(1994) Cell 78,473-485. 
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., 
Yazaki, Y., Goto, K. & Masaki, T. (1988) Nature 332,411-415. 
Yorimitsu, K., Moroi, K., Inagaki, N., Saito, T., Masuda, Y., Masaki, T., Seino, S. & 
Kimura, S. (1995) Biochem. Biophys. Res. Commun. 208,721-727. 
Yoshizumi, M., Kurihara, H., Morita, T., Yamashita, T., Oh-hashi, Y., Sugiyama, T., 
Takaku, F., Yanagisawa, M., Masaki, T. & Yazaki, Y. (1990) Biochem. 
Biophys Res. Commun. 166,324-329. 
